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Cardiovascular disease (CVD) is a complex combination of multiple conditions.  The 
majority of deaths within CVD include heart attacks and strokes caused by 
atherosclerotic disease.  The pathophysiological process for atherosclerotic disease 
occurs within the endothelial lining of the vessels of the body.  This prolonged 
process occurs when cholesterol deposits form irregularity in luminal flow resulting 
in decreased blood flow and ischaemia.  This unstable cholesterol plaque can rupture 
resulting in clot formation and artery occlusion.   
 
Within this thesis I aim to show background to the relevant pathophysiology of 
ischaemic heart disease (IHD) with the main emphasis on acute myocardial 
infarction (AMI), the history of its therapy to current therapy.  I will discuss the 
theorised role of stem cell therapy within animal models and previous clinical trials 
within regenerative medicine and AMI.  I will describe and discuss the method and 
the results of the REGENERATE-AMI trial (Clintrial.gov: NCT00765453), which will 
include the safety and efficiency of the therapy, and the possible cytokine mechanism 
by which this therapy may exert it effect.  Additionally I will describe the potential 
for assessing myocardial oedema using 3-slice T2-STIR short axis stack imaging post 
AMI compared to the conventional 10-slice T2-STIR technique to assess its feasibility 




I hope this thesis, which describes the rapid use of autologous bone marrow 
progenitor cells to salvage myocardium in patients with anterior AMI will help our 
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1.1. Cardiovascular Disease 
 
CVD is the leading cause of death in the developed world and is likely to remain so 
until at least 2030 (WHO). An estimated 17.3 million people died from CVD in 2008, 
representing 30% of all global deaths, with this predicted to increase to 25 million 
by 2030. Of these 17.3 million, 7.3 million were due to coronary artery disease 
(CAD). In middle-income countries these figures are more disproportionately 
affected with over 80% of deaths occurring due to CVD, with an equal distribution 
between sexes. Figure 1.1 (WHO 2011).  Therefore CVD has become the worlds 
leading health problem in terms of mortality and will remain the leading cause of 
global mortality for the foreseeable future.  
 
Within the UK there are over 150,000 deaths per year secondary to CVD, this mainly 
compromises of stroke and coronary artery disease (British Heart Foundation 2011).  
In 2004 the UK economy spent £29.1 billion on CVD of which £8.5 billion is spent on 
coronary artery disease.  This was mainly due to direct cost of health care (60% of 
total), and then followed by financial losses secondary to mortality and morbidity 





Figure 1.1. Mortality rates per 1000 from high income to low income countries adapted from 
the 2008 WHO statistics 
 
1.2. Pathophysiology of Cardiovascular Disease 
 
It is the formation of atheroma, lipid rich deposits, within the epicardial coronary 
arteries that cause CAD. The most common risk factors for atherosclerosis and their 
main pathobiological processes are shown on Table 1.1.  Previous autopsy studies 
have shown that atherosclerotic plaques develop slowly over many years and in 
patients who die without morphological evidence of catastrophic atherosclerosis 
there are still significant plaque formations (Solberg and Strong 1983).  The 
reduction in arterial diameter may lead to a slow but progressive increase in 
symptoms or an atheromatous plaque may rupture suddenly leading to thrombotic 
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occlusion of the coronary artery and the most notable manifestation of ischaemic 
heart disease (IHD), acute myocardial infarction (AMI) (Skyschally, Schulz et al. 
2008, Rognoni, Cavallino et al. 2014). 
 
Table 1.1. Risk Factors for IHD 
Modifiable risk factors Pathogenic Process 
Dietary (high in saturated fat and 
cholesterol) 
High blood cholesterol with increased oxidative 
stress 
Increased BMI Increased insulin resistance 
Decreased activity Poor perfusion with adverse lipid profile 
Smoking Increased oxidative stress 
Hypertension Increased oxidative stress and enhanced 
vasoconstriction 
Alcohol intake Increased oxidative stress 
Serum lipids Increased oxidative stress 
  
Related conditions Pathogenic Process 
Familial hypercholesterolemia Thrombogenesis 
Diabetes mellitus Increased oxidative stress and inflammatory 
process 
Renal impairment Increased oxidative stress 
  
Non-modifiable risk factors  
Age  
Male sex  
Family history of heart disease (genetics)  
Cultural identity  
Socioeconomic status  
  
 
1.2.1. Pathophysiology of Acute Myocardial Infarction 
 
There are around 175,000 AMI in the United Kingdom each year, with just over 60% 
affecting the male population (Townsend N 2012). AMI typically occurs when a 
plaque ruptures within a coronary artery leads to a sudden and total or near-total 
occlusion of that vessel.  The region affected by the occlusion occurs along the distal 
distribution of the occluded vessel resulting in myocardial infarction.  In the 1970s 
the concept of the ‘wavefront phenomenon’ was proposed by Reimer and Jennings 
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(Reimer and Jennings 1979). The wavefront phenomenon describes the increase of 
infarct size from the endocardium to the epicardium and is dependent on the 
duration of coronary obstruction and with increased severity of ischaemia (Figure 
1.2) 
Figure 1.2. Wavefront Phenomenon  
Cross section of a left ventricle showing the development of necrosis in an infarcted region 
 
The pathological process involved in the loss of myocardium after an ischaemic 
event results in migration of macrophages, monocytes, and neutrophils into the 
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infarcted area.  This initiates a neurohormonal activation and intracellular signaling 
that focuses the inflammatory response.  The 2 phases of myocardial remodeling 
post AMI are divided into early and late phases.  The early phase remodeling occurs 
within the first 72 hours after AMI, and involves the expansion of the infarcted area, 
that can results in ventricular rupture or aneurysm formation (Erlebacher, Weiss et 
al. 1984).  The late remodeling occurs after 72 hours and results in global LV 
dilatation and distortion.  These stresses exerted on the LV lead to progressive 
dilatation, the formation of scar along the infarcted border zone and decreased 
contractility (White, Norris et al. 1987).  
 
1.2.2. Acute myocardial mortality and management 
 
Treatment for AMI has evolved over the last 20 years from thrombolytic therapy to 
primary percutaneous coronary intervention (primary PCI), which is now the gold 
standard treatment for patients suffering an ST-elevation myocardial infarction 
(STEMI).  Nearly all cases of AMI are the result of a ruptured atherosclerotic plaque 
causing sudden occlusion of a coronary artery (Davies, Woolf et al. 1976).  
Reperfusion by primary PCI is a mechanical technique which restores coronary 
blood flow and includes the use of a guide wire with coronary ballooning or stenting.  
Multiple randomised controlled trials and meta-analyses have shown that primary 
PCI is superior in patients with STEMI compared to fibrinolysis (Keeley, Boura et al. 
2003).  In 2008 the final report of the National Infarct Angioplasty Project 
recommended the use of primary PCI within the UK as was feasible and cost effective 
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(Weaver, Simes et al. 1997).  In addition the use of thrombus extraction was widely 
used during primary PCI, however recent evidence has shown this not to be of 
clinical benefit (Sirker, Mamas et al. 2016).  The rate of primary PCI has risen to 374 
people per million in the UK in 2012 (BCIS 2014).  The current guidelines for 
primary PCI have been introduced to reduce myocardial damage from ischaemia and 
reduce the time from diagnosis to reperfusion (Brown 2014).  
 
The outcome of patients suffering from AMI has significantly improved since the 
introduction of primary PCI, however despite this coupled with optimal medical 
management there remains a significant risk of mortality at 30 days (7%) 
(Widimsky, Wijns et al. 2010). The increasing numbers of survivors post AMI, has 
resulted in an associated increase in the incidences of heart failure (HF) (15-20%) in 
patients who still develop significant myocardial damage (Velagaleti, Pencina et al. 
2008). Additionally to the damage caused by the period of ischaemia, reperfusion 
itself, although essential for myocardial salvage, actually results in further damage to 
cardiomyocytes that were alive at the time of reperfusion, so called reperfusion 
injury. Therefore although reperfusion with primary PCI is the gold standard for 
treating an occluded coronary vessel, reperfusion injury may account for up to 50% 
of the final infarct size (Yellon and Hausenloy 2007). 
 
The modern management of AMI has been built on large-scale trials over the past 
four decades, and the transition of these trials to clinical practice has been the 
leading cause for the decrease in mortality associated with AMI.  The current 
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combination of antithrombotic therapy with early reperfusion with primary PCI has 
been the mainstay of this therapy. The most commonly used anti-platelet medication 
in these patients is aspirin, the salicylate drug blocks the cyclooxygenase enzyme 
inhibiting the synthesis of thromboxane A2.  The initial benefit from aspirin seen in 
the first 24 hours following AMI was shown in the ISIS-2 trial where the combination 
of aspirin and streptokinase reduced five week vascular morality in comparison to 
single agent therapy (Group. 1988).  Current acute coronary syndrome (ACS) 
guidelines recommend a combination of duel anti-platelet medication of aspirin plus 
an additional P2Y12 receptor blocker.     Clopidogrel is a P2Y12 receptor blocker that 
has been shown in combination with aspirin in the STEMI population to significantly 
reduce cardiovascular death, myocardial infarction (MI), or stroke (Mehta, Yusuf et 
al. 2001).  More recent advances in P2Y12 receptor blocker such as Prasugrel and 
Ticagrelor have shown improvement in clinical outcomes in patients who suffer 
from ACS in comparison to the combination of aspirin and clopidogrel. Ticagrelor 
has a more rapid onset of action to that of clopidogrel, and differs from both 
prasugrel and clopidogrel by reversibly binding to the P2Y12 platelet receptor.  In the 
PLATO trial, patients treated with ticagrelor had lower rates of MI, stroke, or 
cardiovascular death compared to clopiodgrel (Husted, James et al. 2014) and it has 
now become the recommended antiplatelet therapy in addition to aspirin in patients 
who suffer with AMI. Additional anti-platelet medication used during primary PCI 
has been addressed with the use of glycoprotein IIb/IIIa inhibitors and bivalirudin.  
Due to the relatively limited antiplatelet potency of aspirin the addition of 
glycoprotein IIb/IIIa inhibitors in the context of high intracoronary (IC) thrombus 
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burden or inadequate P2Y12 antagonist loading is suggested in the guidelines 
(Carville, Harker et al. 2013, O'Gara, Kushner et al. 2013). An overview of current 
recommendation for antiplatelet medication during primary PCI is shown below on 
Table 1.2. 
 
Table 1.2. Clinical trials and recommendations for antiplatelet medication 
 
Recommendation Class/Level Trial 
IV or oral Aspirin I/B (Group. 1988) 
ADP-receptor blockers I/A  
    - Clopidogrel  I/C (Leon, Baim et al. 1998) 
    - Ticagrelor I/B (Wallentin, Becker et al. 2009) 
    - Prasugrel I/B (Montalescot, Wiviott et al. 2009) 
Routine use of GP IIb/IIIa IIb/B (De Luca, Suryapranata et al. 2005) 
    - Abciximab A (De Luca, Suryapranata et al. 2005) 
    - Eptifibatide B (Zeymer, Margenet et al. 2010) 
    - Tirofiban B (Valgimigli, Biondi-Zoccai et al. 2010) 
 
For medical therapy the level of evidence assigned is based on the type of clinical 
trial and the strength of evidence shown below on Table 1.3.  
 
Table 1.3. Classification and Level of Recommendations 
 
Class I Conditions for which there is evidence or general agreement that a given procedure 
or treatment is useful and effective. 
Class II Conditions for which there is conflicting evidence and/or a divergence of opinion 
about the usefulness/efficacy of a procedure or treatment. 
    - IIa. Weight of evidence/opinion is in favour of usefulness/efficacy 
    - IIb. Usefulness/efficacy is less well established by evidence/opinion 
Class III Conditions for which there is evidence and/or general agreement that the 
procedure/treatment is not useful/effective, and in some cases may be harmful 
Level A Data derived from multiple randomized clinical trials 
Level B Data derived from a single randomized trial, or non-randomized studies 




1.3. Heart Failure 
 
These advances in the management of AMI together with population ageing have 
contributed to a growing burden of HF. Although there have been significant 
improvement in the management of patients who suffer from an AMI with decreases 
in mortality, there remains a large proportion of patients who still suffer from 
significant HF and subsequent symptoms (Velagaleti, Pencina et al. 2008).  Despite 
the advances in both the acute and chronic setting, the prognosis for patients who 
are admitted to hospital with HF remains poor, with a 10-year survival of around 
10% (Mosterd, Cost et al. 2001).  Although primary PCI is now seen as the optimal 
therapy for a STEMI many studies have shown that the proportion of the patients 
that re-present with HF remains high (Bolognese, Neskovic et al. 2002).   Within the 
HORIZON-AMI trial of the 2,946 patients enrolled without a history of chronic heart 
failure (CHF) 5.2% patients developed symptomatic CHF at 2 year post STEMI (Kelly, 
Gershlick et al. 2011).  HF remains a major economic and public health issue, within 
the US it has been estimated that in 2010 that $39.2 billion of the total health care 
budget was devoted to HF with a similar proportional allocation within European 
countries (Lloyd-Jones, Adams et al. 2010).  On an individual patient basis, the 
diagnosis and treatment of HF has been associated with a cost of $8500 annually 
(Stewart, Jenkins et al. 2002).  The majority of the costs incurred for the treatment of 
HF occurs due to the hospitalisation of patients, and current therapy is aimed at the 
reduction of hospitalisation events.  The economic impact of HF therapy will increase 
over the coming decades due to the growing number of elderly patients and the 
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improving mortality rates for with HF. Current therapy for HF is aimed at both 
prognostic and symptomatic therapy and in this next section there is an overview of 
HF pathophysiology and for the reasoning of current therapies.   
 
1.3.1. Heart Failure Pathophysiology 
 
HF (Left ventricular systolic dysfunction) is when there is impairment of left 
ventricular (LV) contraction and therefore ejection of blood. The leading cause for 
decreased systolic function is due to loss of functioning myocardium secondary to 
ischaemic injury (Bourassa, Gurne et al. 1993).   The result of LV dysfunction leads to 
a decrease in cardiac output and therefore decreased global perfusion.  The LV 
dysfunction results in increased volumes of blood in the ventricles, increasing end 
systolic and end diastolic volumes and elevated left atrial pressures.  The increased 
left atrial pressure causes increased pressure in the pulmonary capillaries resulting 
in fluid leak producing pulmonary congestion and dyspnea. 
 
The symptoms of HF directly result from inadequate cardiac output and venous 
return.  Dyspnoea, cough and wheeze result from increased pressure in the 
pulmonary capillaries; fluid leak into the pulmonary alveoli decreases oxygenation 
and results in hypoxia and pulmonary oedema.  The decrease in venous return to the 
right ventricle causes lower limb oedema and ascites.  The result of decreased 




1.3.2. Heart Failure Conventional Treatment 
 
Current guidelines for the treatment of HF focus on both medical and lifestyle 
therapies (NICE 2010).  The current life style advice for the management of HF 
echoes current advice for cardiovascular risk factor modification.  Patients are 
encouraged to exercise, reduce weight as well as abstaining from smoking and 
alcohol use (Forouzanfar, Moran et al. 2012).   
 
Current medical therapy can be divided into pharmacological and device-based 
therapy.  The pharmacological management of HF aims to increase symptomatic 
relief as well as reducing the effects of the LV dysfunction and improve survival.  In 
patients with IHD maximal revascularisation either with coronary artery bypass 
grafting (CABG) or PCI is suggested.  
 
1.3.2.1. Heart Failure: Medical Therapy 
 
A large number of trials have shown the benefits of pharmacological therapy in 




1.3.2.1.1. Angiotensin-converting enzyme inhibitors 
 
Angiotensin-converting enzymes inhibitors (ACEi) have been shown to have benefit 
in the treatment of HF.  In the late 1980s the CONSeNSUS trial showed that enalapril 
resulted in a significant improvement in mortality in patients with congestive 
cardiac failure (Swedberg and Kjekshus 1988).  Subsequent meta-analysis have also 
shown that in HF patients ACEi treatment reduces the relative risk of mortality by 
over 23% (95% CI 67 to 88%; ARR 6.1%) and hospitalisation admissions reduced by 
35% (95% CI 26 to 43%; ARR 10.2%) (Garg and Yusuf 1995).  ACEi are now 
recommended in all patients who have significant LV systolic dysfunction (left 
ventricular ejection fraction (LVEF) < 40%) (Yancy, Jessup et al. 2013). Patients who 
are unable to tolerate ACEi due to well-documented side effects are suggested to 
start angiotensin receptor blockers (ARB).  However a side effect of both ACEi and 
ARB medications due to the effect on the renin-angiotensin-aldosterone system 




Beta-blockers have shown benefit in patients with significant LV systolic dysfunction 
in combination with an ACEi or ARB (CIBIS-II 1999, Hjalmarson, Goldstein et al. 
2000, Packer, Coats et al. 2001).  The majority of randomly controlled trials have 
shown a total mortality reduction seen with the use of B-blockers in chronic HF.  
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Previous analysis of the 4 major B-blockade trials (BEST, CIBIS-II, MERIT-HF and 
COPERNICUS) has shown an all cause mortality reduction by 23% (95% CI 8% to 
35%) (Domanski, Krause-Steinrauf et al. 2003).  B-blockers are suggested first line 




Diuretics are used in the majority of patients with HF to reduce fluid retention for 
symptomatic relief.  The most commonly used diuretic is a loop diuretic, frusemide 
that acts directly on the ascending loop of Henle.  Previous meta-analysis shown 
diuretics have a reduction on mortality and improvement in exercise capacity (Faris, 
Flather et al. 2002).  One of the largest issues regarding these trials is the relatively 
small number of patients recruited into them and the inconsistencies of the patient’s 
baseline therapy.  However although prognostic evidence supporting their use is 
limited, the symptomatic relief from diuretic therapy for the treatment of oedema 
and dyspnea is accepted.  Previous HF studies have shown that near 90% of patients 
were on at least 1 class of diuretic therapy for both the management of acute and 






Digoxin is a cardiac glycoside that is extracted from Digitalis lanta (Hollman 1996).  
Digoxin therapy does not have the mortality benefit seen in other medical therapies 
such as ACEi or Beta blockade.  However previous reviews have shown that digoxin 
therapy has a 64% improvement in symptoms (OR=0.31, 95% CI 0.21% to 0.43%) 
and a significant reduction in rates of hospitalisation (Hood, Dans et al. 2014).  
However, the Cochrane review relied heavily on the DIG study, which although a 
large randomised controlled study B-blockers or aldosterone antagonists could have 
influenced the beneficial effect on mortality (Group 1997). 
 
1.3.2.1.5. Aldosterone Antagonists 
 
Aldosterone antagonists in the addition to ACEi have been shown to reduce all cause 
mortality by 30% (RR 0.70, 95% CI 0.60% to 0.82%; p<0.001) (Pitt, Zannad et al. 
1999).  Patients who have suffered a recent AMI with significant LV impairment, 
were shown, in the EPHESUS study to have a 13% reduction in cardiovascular 
mortality and hospitalisation (95% CI 5% to 21%; p=0.002 ARR 3.3%; NNT=30) and 




1.3.2.1.6. Angiotensin Receptor-Neprilysin Inhibitors 
 
Recently newer therapies have emerged which show potential for the treatment of 
HF. Neprilysin is a neutral endopeptidase that degrades several endogenous 
vasoactive peptides (Rademaker, Charles et al. 1996) that inhibits the 
neurohormonal over activation, that contributes to vasoconstriction and remodelling 
(Kuhn 2004).  The publication of PARADIGM-HF has raised hope for the arrival of a 
new class of drug the angiotensin receptor-neprilysin inhibitors (ARNi).  The known 
benefits of both ACEi such as enalapril, which has shown to reduce mortality and the 
use of a neprilysin inhibitor, which increase levels of natriuretic peptide and 
bradykinin have created the niche for these drug (Swedberg and Kjekshus 1988, 
Cruden, Fox et al. 2004).  The PARADIGM-HF trials was able to demonstrate that the 
use of ARNi reduces the risk or morality and hospitalisations with heart failure 
compaired to monotherpay of enalapril (McMurray, Packer et al. 2014).  
 
1.3.2.2. Heart Failure: Device Therapy 
 
There have been significant advances in the development of device therapy for use in 
HF over the last 2 decades.  Approximately half of HF patients who die unexpectedly 




1.3.2.2.1. Implantable cardiac defibrillators 
 
The rationale for the use of implantable cardioverter-defibrillator (ICD) in HF is to 
prevent sudden cardiac death due to ventricular arrhythmias, which are responsible 
for up to 50% of deaths in HF patients.  Although pharmacological therapy can 
reduce mortality in patients with HF, there is a risk that some anti-arrhythmic drugs 
may increase the rates of dysthymias (Zipes, Camm et al. 2006).  ICD therapy has 
been shown to be of benefit in patients who have haemodynamic compromise with 
ventricular arrhythmias, or in patients with impaired LV systolic function who suffer 
from symptomatic HF and is the optimal pharmacological treatment or therapy 
(Bardy, Lee et al. 2005). 
 
1.3.2.2.2. Cardiac Resynchronisation Therapy  
 
The role of resynchronisation therapy in patients with HF is a challenging issue.  The 
initial outlay cost for the implantation of the device needs to be weighed against both 
the short and long term benefit (van Veldhuisen, Maass et al. 2009).  The effect of the 
long term use of CRT have been evaluated extensively in large scale trials and recent 
meta-analysis (Bradley, Bradley et al. 2003).  Two types of devices that have been 
studied have been CRT pacemakers or CRT-ICD devices.  The two main trials that 
were powered to assess the effect of CRT on all causes of mortality were CARE-HF 
and COMPANION (Bristow, Saxon et al. 2004, Cleland, Daubert et al. 2005).  These 
trials failed to demonstrate a superior CRT strategy, however, in CARE-HF the use of 
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CRT pacemakers showed a 36% reduction in all cause of death (Cleland, Daubert et 
al. 2006).  
 
1.3.2.3. Heart Failure: Transplantation 
 
Cardiac transplantation remains the optimal treatment choice in patients who are 
suffering from ESHF and remain symptomatic.  Although the prevalence of HF has 
increased over the past decade the number of cardiac transplantations have 
decreased, in the United States 2692 transplants occurred in 2009.  
 
1.3.2.3. Heart Failure: Ventricular Assist Devices 
 
The use of mechanical circulatory support for the treatment of severe heart failure 
has grown in the last decade (Lampropulos, Kim et al. 2014).  The development of 
reduced size and function has helped to improve both mortality and symptoms of 
heart failure (Ozalp, Bhagra et al. 2014).  The main aim of the ventricular assist 
device (VAD) is to provide a bridge-to-transplant until a suitable organ can be 
acquired.  The most recent guidelines for outpatient use of VADs have a level of 




1.3.2.5. Heart Failure: Future Therapies 
 
The use of stem cell therapy in chronic heart disease has been gaining momentum in 
the last decade.  The two main areas of interest has been within chronic IHD and 
dilated cardiomyopathy (DCM).  Although no large phase III trials have been 
performed in these fields to date multiple meta analyses have demonstrated the 
benefits of this therapy in chronic IHD (Fisher, Doree et al. 2013).  Within DCM only a 
single randomized controlled study has been published, the REGENERATE-DCM 
study was able to demonstrate the improvement in both LVEF and symptoms with 
stem cell therapy (Hamshere, Arnous et al. 2015).  Although not part of guidelines 
the use of stem cell therapy on compassionate grounds has become an option for 
these patients who have no other treatment options. 
 
1.3.2.6. Heart Failure: Current Guidelines 
 
Current guidelines both in Europe and USA suggest the initiation of ACEi or ARB with 
B-blockers in patients who have symptoms of HF as a Class 1 recommendation 




1.4 Need for new heart failure treatments 
 
AMI results in the loss of cardiomyocytes with the formation of fibrosis and scar 
tissue that results in decreased LV function and arrhythmic potential.  Despite the 
advances in ACS therapy there have been little progress in reducing cardiomyocyte 
loss other than the early mechanical intervention and newer pharmacological 
therapies.  The realisation of a novel therapy that could either regenerate or replace 
the damaged myocardium, and/or improve myocardial remodeling during the early 
phases of healing has been the main goal.  Potential therapies have been addressed 
including the use of pharmacological agents during primary PCI such as nitrite for 
the reduction of ischaemic reperfusion injury (Jones, Pellaton et al. 2015), the use of 
gene therapy for the targeting of specific pathways involved in the development of 
HF or biological agents such as stem cell therapy after AMI with their proposed role 
in regenerative medicine.  
 
1.5 Regenerative Medicine 
 
The Unitarian theory of haematopoiesis that stated that all cells develop from the 
same precursor cell, was first hypothesised by Alexander Maximow in the early part 
of the 20th century (Konstantinov 2000).  The discovery of stem cell phenotypes has 
yet to deliver their full therapeutic potential (Friedenstein, Chailakhjan et al. 1970).  
William Haseltine first coined the term regenerative medicine in the late 20th 
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century.  The introduction of cell-based therapy has become one of the most 
important fields in cardiovascular research in the last two decades. The transition of 
pre-clinical trials to the current boom in numbers of trials involving stem cells and 
progenitor cells aimed at repairing damaged myocardium has lead to the possibility 
of improving outcomes for these patients with reductions in the incidence of HF.   
 
1.6. The Heart and Regeneration 
 
The heart has historically been considered a terminally differentiated organ with no 
ability to self repair (Chien and Olson 2002). However recent studies (Liao, Pfister et 
al. 2007, Blum and Benvenisty 2008, Clifford, Fisher et al. 2012) have implied that 
there may be a background level of cellular renewal by engraftment and 
differentiation of primitive cells. Limited regeneration could occur through 
circulating primitive bone marrow mononuclear cells (BMNC) that could engraft in 
the heart in response to injury (Orlic, Kajstura et al. 2001) or from a resident cardiac 
stem-cell population (Oh, Bradfute et al. 2003). This reparative potential is not 
sufficient to respond to the significant myocardial damage caused by AMI but the 
discovery of this endogenous repair process has provided further rationale for the 
use of cell therapy based to amplify this natural process.  
 
The quintessential example of cardiac regeneration would be that of the Zebra fish.  
After approximately 20% surgical amputation of the total ventricular mass the Zebra 
fish is able to fully regenerate itself (Poss, Wilson et al. 2002). Further investigations 
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into the Zebra fish with gene mapping has shown that the regeneration of the 
myocardium is caused by pre-existing cardiomyocytes rather than undifferentiated 
progenitor cells that had been previously thought. The mammalian heart in 
comparison to that of the Zebra fish, is unable to regenerate itself (Porrello, 
Mahmoud et al. 2011).   
 
In the mammalian heart regeneration studies have shown that very early post 
partum, there is a degree of myocardial regeneration.  However after 7 days this 
ability for regeneration declines; this loss in regeneration may coincide with the 
reduction of the cell cycle activity (Porrello, Mahmoud et al. 2011). Again, gene 
mapping has shown that the regeneration is led by pre-existing cardiomyocytes, and 
this study demonstrates that there is a Zebra fish like regenerative mechanisms 
latent in mammalian hearts.  Therefore the aim of stem cell therapy use in the post 
AMI heart would be the repair of damaged myocardium with the subsequent 




Stem cells have two defined characteristics, the ability for unlimited self-renewal and 
the potential to differentiate into all different cell linages.  The most potent cell type 






Figure 1.3. Stem Cell Classification  
 
The zygote is the cell that results of the fusion of two haploid cells during fertilisation 
until the first cleavage, the further divisions of the zygote are therefore called an 
embryo.  The ability for multi cell differentiation of the zygote is termed totipotent.  
The developed embryo contains embryonic stem cells (ESCs) that are pluripotent as 
they have the ability to differentiate into three germinal layers and therefore are able 
to produce functional organisms.  Adult organisms have no ESCs, only adult stem 
cells (ASC) and progenitor cells.  Like ESCs, ASCs share the ability of self-renewal and 
production of cell linages, however ASCs have limited degree of daughter cells 





1.6.2. Stem Cell Types 
 
In theory the cell with the ability to form any new cell type and have unlimited 
replication ability would be ideal for cell-based therapy.  The myriad of cells that 
have the potential to be used in regenerative medicine is wide, and to date no leading 
cell type has emerged.   As seen in previous trials (Table 1.3) different stem cell types 
have been used giving rise to differing results, the most commonly used stem cells 
are discussed below. 
 
1.6.2.1. Embryonic Stem Cells 
 
As stated previously ESCs are able to generate multiple cell linages and undergo self 
renewal during early feotal development Therefore the use of ESCs would be an 
obvious choice for myocardial regeneration. In 1998, two papers reported the 
isolation of ESCs from human embryos was possible (Thomson, Itskovitz-Eldor et al. 
1998).  The technological advances of these early trials, lead to excitement in the 
field of regenerative medicine and the possible application into chronic diseases.  
The observed potential for the use of ESCs to transform into fully functionally 
cardiomyocytes in vitro (Kehat, Kenyagin-Karsenti et al. 2001) and successful use of 





There is however considerable development and ethical issues that need addressing 
before this promising technique is used in man.  The technical issues of selecting 
ESCs as they start to differentiate so they can be delivered to a certain tissue at the 
right time.  The transition of ESCs into specific cardiomyocytes would be the result of 
local host signaling, however due to the greater cell differentiation the result could 
be an abnormal amount of specialised cardiomyocytes such as Purkinje fibres 
resulting in possible arrhythmogenesis (Behfar, Hodgson et al. 2005).  A major issue 
lies with the risk of tumour formation where ESC transdifferentiate into non-
relevant cells or uncontrolled transdifferentiation, however this has been partly 
addressed by the pre-differentiation of ESC into cardiomyocytes phenotypes prior to 
implantation (Laflamme, Chen et al. 2007).   
 
The ethical and moral consideration for the use of ESCs is highly controversial and 
has been linked to the debate on human abortion due to the destruction of human 
embryos. The complex debate is divided between the belief that life begins at 
conception or that the embryo becomes a person at a later stage of development 
(Daley, Ahrlund Richter et al. 2007).    
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1.6.2.2. Skeletal myoblasts 
 
Skeletal myoblasts (SM) are derived from satellite cells, which are responsible for 
postnatal growth of skeletal muscle (Schultz 1996).  The first description of SM were 
reported in frogs (Mauro and Adams 1961) and over a decade later isolated in 
mammalian muscle (Schultz 1976).  The relative ease of extraction from muscle 
biopsies, expansion in vitro and skeletal muscles resistance to ischaemic conditions 
made skeletal stem cells the first assessed in pre-clinical and clinical trials 
(Chachques, Acar et al. 2004). 
 
Skeletal satellite cells were considered to be monopotent, with the ability to give rise 
to a few cell of the myogenic lineage.  By the end of the 20th Century evidence arose 
for the bi-directional differentiation potential between bone marrow and muscle 
(Ferrari, Cusella-De Angelis et al. 1998). Two studies have demonstrated bi-
directional placidity of muscle and bone marrow, and the repopulation of muscle 
cells from lethally irradiated mice.  These trials have demonstrated the ability for 
muscle derived cells to be able to repopulate major blood linages and muscle 
(Gussoni, Soneoka et al. 1999).  
 
Within animal studies initial trials showed promise with the limitation of post 
infarction LVEF deterioration and the improvement in scar tissue through the 
colonisation of fibrosis by skeletal muscle stem cells (Ghostine, Carrion et al. 2002). 
In more recent studies, the benefit was less imposed on the skeletal stem cell 
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infusion but the activation of cardiac stem cells (CSC) secondary to the secretion of 
growth factors (Pouly, Hagege et al. 2004). 
 
These encouraging preclinical results were quickly translated into clinical 
application.  The only patients who were considered as suitable for skeletal myoblast 
transplantation were patients who suffered from CHF due to the period of time for 
cell expansion.   The first application in man of skeletal myoblast by Menasche et al 
was on HF patients with significant LVEF impairment and poor exercise class as 
measured by the New York Heart Association (NYHA) functional class during CABG.  
In this trial a total of 800 x 106 cells, of which 65% were defined as myoblasts as 
CD56+ cells were injected in to the scarred region of the LV during CABG.  This 
intervention was associated with a significant improvement in NYHA class and LV 
function, however these findings are difficult to interpret due to concurrent 
revascularisation and no true control group (Menasche, Hagege et al. 2001).  Further 
small number trials resulted in improved LV function, LV remodeling and increased 
myoblast survival on histological examination in intramyocardial (IM) injections in 
patients (Steendijk, Smits et al. 2006) 
 
After these promising initial small-scale trials, larger randomised trials have been set 
up. The randomised, double blinded placebo controlled trial; Myoblast Autologous 
Grafting in Ischemic Cardiomyopathy (MAGIC) included patients with severely 
impaired LV function with an indication for CABG.  There was no significant 
difference between adverse advents or change in LV function, however there was a 
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significant decrease in LV end diastolic volume (LVEDV) and LV end systolic volume 
(LVESV) (Menasche, Alfieri et al. 2008).  Prior to this trial, the issue was raised 
regarding possible increased arrhythmias with the use of SM, this was addressed 
within MAGIC with patients fitted with ICDs. There was no significant difference 
between the burden of arrhythmias.  However further analysis showed that there 
was an earlier burden of arrhythmias in the skeletal myoblast group compared to the 
control group in the immediate post op period, with a more even distribution in the 
following 6 months.   
 
To date although the smaller non-randomised trials gave hope for the use of skeletal 
myoblast transplantation the larger trials have failed to fulfill this promise.   
 
1.6.2.3. Cardiac Stem Cells 
 
It has been traditionally regarded that cardiomyocytes were a terminally 
differentiated cell that react to any disease process by hypertrophy (Kelly, Alonso et 
al. 1995). However ongoing research in the last decade have shown the potential 
ability for cardiomyocyte regeneration and cell division in adult hearts post AMI or 
in HF (Beltrami, Urbanek et al. 2001).  In addition to this it has been found that the 
heart contains a large reservoir of stem cells, which are positive for a large number 




The thought of using CSC is an attractive option for cardiac regeneration, as their 
role is intended to repair the damaged heart.  However, CSC are difficult to harvest 
and isolate in comparison to BMNC At present the largest model for CSC is in large 
animal models post AMI, although CSC have been used in humans in chronic 
ischaemic cardiomyopathy (Lee, White et al. 2011).  In the CADUCEUS trial, a 
prospective randomised trial of 25 patients of whom 17 underwent endomyocardial 
biopsy and autologous stem cell expansion with IC infusion at 3 months post AMI.  
This trial showed the safety of cardiac stem cell infusion and also showed a 
significant reduction of scar size and increase in viable heart mass. However it failed 
to show significant improvement in LV function (Makkar, Smith et al. 2012).   
 
1.6.2.4. Bone Marrow Derived Stem Cells 
 
Bone marrow derived stem cells are the most common used cell type within 
regenerative medicine and heart disease. The first suggestion of their use came when 
in animal models it was demonstrated that circulating endothelial cells from bone 
marrow origin could contribute to neovascularisation (Takahashi, Kalka et al. 1999).  
Early preclinical animal models of wild type mice, showed that marked green 
fluorescent protein (GFP) positive bone marrow, contributed to cardiomyocytes and 
endothelial formation after an induced myocardial infarction (Jackson, Majka et al. 
2001).  There have been mixed results within animal models showing the 
differentiation of progenitor bone marrow derived cells to cardiomyocytes 
(Marchetti, Gimond et al. 2002, Min, Yang et al. 2002).  Adult bone marrow derived 
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stem cells include three populations of stem cells. These include hematopoietic stem 
cells (HSCs) that give rise to all blood lineages, mesenchymal stem cells (MSCs) that 
can differentiate into different cell lineages (Pittenger, Mackay et al. 1999, Kondo, 
Wagers et al. 2003) and endothelial progenitor cells (EPC). 
 
1.6.2.4.1. Endothelial Progenitor Cells 
 
Damage to the endothelium has been linked to atherosclerosis and hypertension, 
and it is the balance between injury and endothelial recovery that results in the 
reduction of cardiovascular events (Endemann and Schiffrin 2004).  Mature 
endothelial cells have limited capacity for regeneration therefore the focus has 
centered on circulating EPC and their role in maintenance of endothelial integrity 
and neovascularisation (Rafii and Lyden 2003). 
 
Bone marrow is a reservoir of specific stem and progenitor cells, including 
endothelial progenitor cells.  There is an increase in circulating endothelial 
progenitor cells following endothelial injury (Majka, Jackson et al. 2003).  
Endothelial progenitor cells and circulating endothelial progenitor cells express 
CD133+ phenotype, and cells that express CD133+VEGFR2+ can proliferate in vitro 
into endothelial cells (Peichev, Naiyer et al. 2000).  The recruitment of endothelial 
progenitor cells to regions of injury has been extensively studied (Zhang, Zhang et al. 
2002, Massa, Rosti et al. 2005).  Post AMI there is an increase in circulating 
endothelial progenitor cells that is mirrored by an increase in vascular endothelial 
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growth factor A (Rabbany, Heissig et al. 2003).   In pre-clinical animal models the 
infusion of endothelial progenitor cells has shown improvement in vascular supply 
and improvement in cardiac function (Kocher, Schuster et al. 2001).  The 
transplantation of endothelial progenitor cells has been show in multiple trials in 
both CABG patients and IC infusion (Hamano, Nishida et al. 2001, Assmus, Rolf et al. 
2010).  
 
1.6.2.4.2. Mesenchymal Stem Cells 
 
Friedenstein et al demonstrated that bone marrow cell population contained 
hematopoietic stem cells and a rare population of plastic-adherent stromal cells at a 
ratio of 1 in 10,000 nucleated cells (Friedenstein, Chailakhjan et al. 1970).  After 
these new plastic-adherent cells were expanded and the formation of round colonies 
of cells that resembled fibroblastic cells Friedenstein identified the importance of 
these cells in the control of the haematopoietic niche (Friedenstein, Chailakhyan et 
al. 1974).  These cells were initially referred to as stromal cells but have now 
commonly been known as mesenchymal stem cells (MSCs).  MSCs express CD29 and 
CD105 with the lack of expression of CD34 and CD45 surface markers (Dominici, Le 
Blanc et al. 2006).  
 
MSCs have been shown to differentiate into osteoblasts and adipocytes, with 
evidence that cartilage turnover was mediated by MSC differentiation (Caplan 1991). 
In the early 21st century both in-vivo and in-vitro studies have shown that MSCs can 
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transdifferentiate into cardiomyocytes (Xu, Zhang et al. 2004, Sato, Araki et al. 2005).  
The transition to large animal model studies has shown that MSC administration in 
ischaemic models have demonstrated the ability for MSCs to engraft and improve 
cardiac function (Shake, Gruber et al. 2002).  The use of cardiac magnetic resonance 
(CMR) imaging has further shown the regeneration of viable tissue with improved 
contractile function in a fibrotic region (Amado, Schuleri et al. 2006).  
 
The initial trials of MSCs have shown safety and improved left ventricular function 
following the IC infusion of MSCs after MI (Chen, Fang et al. 2004) however the range 





1.6.3. Proposed mechanism of action 
 
The potential mechanism of action of stem cell therapy remains hotly debated with a 
unified hypothesis yet to be agreed. Further information is emerging all the time 
from the large numbers of ongoing regenerative medicine clinical trials. The 4 most 









Figure 1.4. Proposed mechanism of action of cell therapy (Lovell and Mathur 2011) 
 
1.6.3.1. Paracrine Effect 
 
Recent research has provided supporting evidence that the introduction of aASC play 
an important role in the paracrine pathway.  It has been shown that the introduction 
of progenitor cells in the infarcted heart results in the secretion of a variety of 
cytokines, chemokines and growth factors that results in cardiac repair (Caplan and 
Dennis 2006).  
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Patients post AMI undergoing stem cell therapy have higher protein tissue 
concentrations of vascular endothelial growth factor (VEGF), hepatocyte growth 
factor (HGF) and insulin-like growth factor (IGF)-I (Nagaya, Kangawa et al. 2005).  
 
The increasing evidence shows that progenitor cells secrete growth factors, 
chemokine and cytokines that regulate their own cellular biology in an autocrine or 
paracrine manner with interaction with their surrounding environment (Majka, 
Janowska-Wieczorek et al. 2001).  It has been shown that the infusion of activated 
cells from bone marrow or mobilised peripherally from the blood results in secretion 
of these factors (Sahoo, Klychko et al. 2011), and therefore all stem cell types have 
the potential in regenerative medicine to exert a paracrine force.   
 
These paracrine factors may be able to inhibit apoptosis, stimulate 
neovascularisation and proliferation (Tse, Siu et al. 2007).  There are a wide range of 
factors secreted from progenitor cells, however the most important include VEGF, 
HGF, IGF-1 and necrosis factor alpha (NF-A).  It has also been shown that in times of 
hypoxic stress states there is an increase in several of these paracrine factors 
(Kinnaird, Stabile et al. 2004).  
 
It is believed that that secretion of paracrine factors varies with the stem cell types, 
and that paracrine factors have an important role in the regeneration of damaged 
tissue (Schweitzer, Johnstone et al. 2011).  BMNC expressing various growth factors, 
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chemokine and cytokines by enzyme linked immunosorbent assay have further 
supported this (Janowska-Wieczorek, Majka et al. 2001).  
 
The role of paracrine factors and their influence on their environment, their role in 
myocardial protection and neovascularisation have been extensively examined.  The 
immediate paracrine effect after stem cell infusion in an ischaemic environment is 
the release of molecules that improve cardiomyocyte survival.  It has been shown 
that the hypoxic MSCs can reduce necrosis in isolated cardiomyocytes that were 
exposed to low tension of oxygen (Gnecchi, He et al. 2005).  
 
There is therefore increasing evidence that paracrine mechanisms may be important 
in explaining how progenitor cells result in myocardial regeneration post AMI. Any 
future study assessing the use of stem cell therapy should measure levels of specific 
cytokines to investigate whether the effects of early IC infusion of BMNC in patients 
with AMI may be in part mediated by an increase in beneficial paracrine factors.  
 
1.6.3.1.1. Vascular endothelial growth factor  (VEGF) 
 
Vascular endothelial growth factor (VEGF) plays a role in the proliferation and 
recruitment of endothelial cells and ischaemic damage.  The expression of VEGF is up 
regulated during an AMI and studies have shown correlation between serum VEGF 
levels and size of infarction (Hojo, Ikeda et al. 2000).  Previous animal models have 
demonstrated the direct IM injection of stem cells results in localised enhancement 
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of VEGF levels in post infarction myocardium (Mathison, Gersch et al. 2012). In 
addition to this VEGF also mediates the phosphorylation of endothelial nitric-oxide 
synthase, which plays a major role in the regulation of angioblasts and endothelial 
cell proliferation (Gentile, Muise-Helmericks et al. 2013).  
 
1.6.3.1.2. Tumour necrosis factor–α 
 
Tumour necrosis factor–α (TNF-α) was originally recognised to exert 
antiproliferative and cytotoxic effects on tumours and was indicated in the role of 
septic shock (Tracey, Vlassara et al. 1989).  However recently TNF-α has been shown 
to have actions on the differentiation and proliferation of different cell types and is 
considered to play an integral part in the signal transduction cascade that regulates 
the inflammatory process (Vilcek and Lee 1991).  Multiple studies have shown that 
TNF-α has an effect on many cardiac pathologies ranging from viral myocarditis 
(Matsumori, Yamada et al. 1994) to the progression of chronic HF (Torre-Amione, 
Kapadia et al. 1996).  TNF-α has shown to be released from ischaemic myocardium 
and is involved in myocardial dysfunction (Nakano, Knowlton et al. 1998).  Within 
stem cell therapy, levels of TNF- α increase after an injection of stem cells in post 
AMI animal models (Takahashi, Li et al. 2006). We hypothesize that serum level of 
TNF- α after AMI will be increased in both groups of patients with a greater serum 
level seen in patients who have stem cell therapy that is maintained throughout 
follow up with greater levels in patients who had a significant improvement in LVEF 
from baseline to 12 months.   
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1.6.3.1.3. Interleukin 6  (IL-6) 
 
Interleukin 6 (IL-6) is a pleiotropic cytokine that has a wide range of cellular 
immune effects (Van Snick 1990).  IL-6 is pivotal in the mediation of the acute phase 
response and is produced in response to factors such as infection and IL-1 (Heinrich, 
Castell et al. 1990, Ng, Tan et al. 1994).  The evidence of serum IL-6 levels being 
raised has been shown in inflammatory conditions and its secretion from vascular 
endothelial and smooth muscle cells from arteries (Loppnow and Libby 1989, 
Papanicolaou, Wilder et al. 1998).  Further research has shown that IL-6 is increased 
in patients after AMI and this correlates with other inflammatory markers such as C 
reactive protein (Miyao, Yasue et al. 1993).  It is believed that IL-6 plays a role in the 
regulation of collagen formation in ventricular remodeling post AMI (Puhakka, 
Magga et al. 2003).  LV dysfunction and symptomatic HF are associated with 
increased serum levels of IL-6 however it is not known if levels of IL-6 play a 
detrimental effect of LV function after stem cell therapy.   
 
1.6.3.1.4. Granulocyte-colony stimulating factor 
 
Meta-analyses have shown that using BMNC after AMI in the last decade have shown 
a beneficial physiological response (Clifford, Fisher et al. 2012). However controlled 
trials using granulocyte-colony stimulation factor (G-CSF) post AMI have been 
inconclusive with conflicting results.  The use of subcutaneous G-CSF post AMI has 
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been shown to be safe (Ince, Petzsch et al. 2005).  The use of G-CSF has shown to 
promote the migration of progenitor cells and can also act directly promote 
cardiomyocytes survival in ischaemic conditions (Harada, Qin et al. 2005).  Meta 
analysis has shown that G-CSF therapy in patients with AMI is safe however has 
failed to show any overall benefit (Abdel-Latif, Bolli et al. 2008).  It is not known if 
intrinsic G-CSF has an effect on LV function post BMNC therapy delivered after AMI.  
 
1.6.3.1.5. Matrix metalloproteinases (MMP-9) 
 
Matrix metalloproteinases (MMPs) play a major pathophysiological regulation role 
within the extracellular matrix.  MMP are structurally related to endopepidases and 
are able to degrade components of the extracellular matrix.  The classification of 
MMP is in accordance to their substrate specificity.  The MMP family has a wide 
range of actions and have been shown to be involved in LV remodeling following AMI 
and are involved in the development of LV failure (Creemers, Cleutjens et al. 2001).  
As shown previously MMP-9 is unregulated post AMI and plays an important part in 





1.6.3.2. Cell Fusion 
 
There have been multiple pre-clinical trials looking at the natural process for stem 
cells fusing with several cell types after cell injury.  Cell fusion is a natural process 
throughout all stages of our lives, from the first cell fusion where a spermatozoa 
fuses with an ovum to infection and the immune response, cell fusion plays a pivotal 
role.  Cell fusion has been shown to have a role within tissue regeneration. In the last 
decade the discovery that BMNC can fuse with several cell types has promoted new 
ways that cell therapy can help in regeneration.   
 
The basic concept of cell fusion was first proposed by Schwann’s microscopic 
observations of pig embryos (Schwann 1839).  Most current work on cell fusion has 
been derived from study of fusion of viruses with cells (Hernandez, Hoffman et al. 
1996). In stem cell therapy, stem cells and a non-haematopoietic cell type fuse 
together forming a multi-nuclei cell.  These cells known as heterokaryon are a 
mixture of two cell type linages that result in the original stem cell type expressing 




Multiple trials have shown that progenitor cells have a role in neovascularisation in 
ischaemic tissue as well as in tumour tissue (Furuya, Nishiyama et al. 2005).  The 
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process of neovascularisation is essential to the development and differentiation of 
tissue throughout our life cycle from embryo development to wound repair.    
 
Trials have demonstrated that the use of BMNC has resulted in increased recovery of 
vascular supply to a region of tissue damage; this has been shown to improve the 




There is still debate regarding if cell fusion or cell transdifferentiation play a role in 
cardiomyocyte regeneration post AMI.  In essence transdifferentiation is the 
reprogramming of cell lineages into another type without reversion to a pluripotent 
cell.  Several studies have shown, using time-lapse microscopy, the colonisation of 
endothelial cells from ESC that could express certain cell antigens (Eilken, Nishikawa 
et al. 2009).   
 
Eglitis et al have proposed that ASCs could switch lineages, they were able to show 
that bone marrow from mice gave rise to neuronal astrocytes (Eglitis and Mezey 
1997).  Orlic et al showed that new cardiomyocytes cells were formed with the 
improvement in cardiac function after bone marrow derived stem cells were injected 
in to infarcted myocardium (Orlic, Kajstura et al. 2001), however since this early 
data, more recent studies have demonstrated conflicting results in regard to 
transdifferentiation of cells post implantation (Murry, Soonpaa et al. 2004). 
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1.6.4. Systems of delivery 
 
The major aim of stem cell delivery is to transfer a large enough quantity of cells into 
the area of damaged myocardium.   As seen in previous trials different methods of 
delivery has given rise to differing results, the most commonly used approaches to 
deliver stem cells are discussed below. 
 
1.6.4.1. Peripheral stimulation of progenitor cell release 
 
G-CSF, a hematopoietic cytokine produced by monocytes and endothelial cells is 
effective in stimulating the mobilisation of BMNC into the peripheral blood.  Animal 
studies have previously shown the beneficial effect of G-CSF mobilisation of stem 
cells on LVEF after an AMI (Kawamoto, Gwon et al. 2001, Minatoguchi, Takemura et 
al. 2004).  The mechanistic action of G-CSF on the infarcted myocardium is thought 
to prevent cardiac remodeling after AMI by inhibiting the apoptosis of cardiac 
myocytes (Harada, Qin et al. 2005). 
 
In human clinical trials, these beneficial pre-clinical effects have not been 
reproduced with meta-analyses of G-CSF use post AMI have failed to show 
improvement in LVEF (Zohlnhofer, Dibra et al. 2008).   
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1.6.4.2. Intravenous cell delivery 
 
The intravenous infusion of stem cell therapy has been used in some clinical trials. 
The risk of post primary PCI arrhythmias in patients post AMI remains high and the 
infusion of products directly into the myocardium is similarly high (Mattioli, Lonardi 
et al. 2012). The idea of intravenous infusion post primary PCI relies on the concept 
of stem cell homing to the region of myocardial injury, but as with peripheral 
stimulation the results have not been favorable (Price, Chou et al. 2006).   
 
1.6.4.3. Intracoronary delivery of cell therapy 
 
The majority of the trials within AMI patients use the IC infusion of stem cells for 
their mode of administration.  The most commonly used protocol of progenitor cell 
infusion was developed by Professor Zeiher et al (Schachinger, Erbs et al. 2006).  
This involved a 0.014-inch guide wire introduced into the infarcted artery and a 
0.5mm oversised “over-the-wire” balloon catheter positioned within the stented 
segment.  The balloon is inflated to low pressure-causing occlusion of the artery, and 
infusion of the stem cells occurs over three minute intervals with deflation for a 
further three minutes prior to the next occlusion and infusion in order to avoid 
extensive ischaemia (Figure 1.5).  It is thought that this method aims to allow for 
adhesion and potential transmigration of the infused cells thought the endothelium 
(Assmus, Schachinger et al. 2002).   
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In 2001 the first clinical use of unfractionated autologous mononuclear bone 
marrow stem cells were injected IC for the first time after AMI for poor LVEF in a 46-
year-old male  (Strauer, Brehm et al. 2001).  
 
Figure 1.5. Intracoronary Infusion  
 
1.6.4.4. Intramyocardial cell delivery 
 
As previously stated stem cells can be injected directly into the ventricular wall, 
although this is with the increased risk of ventricular arrhythmia post AMI.  The 
direct injection of stem cells during CABG or the transendocardial approach and IM 
electrophysiological mapping of scarred or damaged myocardium plus infusion of 
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stem cells with devices such as the NOGA™ device have been previously used 
(Banovic, Ostojic et al. 2011) (Figure 1.6).   
 
In July 2001 the first clinical use of CD133+ bone marrow derived stem cells were 
injected via the IM route in a 64-year-old patient with significantly impaired LVEF 
during CABG (Stamm, Westphal et al. 2003). 
 
 




1.6.4.5. Best delivery method 
 
Questions still remain regarding the optimum delivery method for stem cell therapy 
in patients post AMI, and to date there has been no consensus reached. Peripheral 
stimulation with G-CSF although an ideal low risk route has failed to show any 
benefit post AMI and therefore is not being tested in ongoing studies (Engelmann, 
Theiss et al. 2006).   
 
The issue with both invasive delivery routes is the potential for fatal risks to the 
patients undergoing the procedure.  Very few trials have used IM infusion of stem 
cells in patients after an AMI due to the proposed high risk of arrhythmia (Rodrigo, 
van Ramshorst et al. 2012).  The route of choice that has been used widely in 
previous trials has been the IC infusion of stem cells due to its safety and reduced 
risk of arrhythmias in comparison to IM. Table 1.3 shows the all the major stem cell 
trials in which IC infusion route was used. 
 
1.7. Research Trials into the use of Stem Cells and Acute Myocardial 
Infarction 
 
The transition from preclinical studies to human clinical trials has been rapid over 
the last decade.  There are currently over 100 actively recruiting clinical trials into 
heart disease being run worldwide as of December 2015. 
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1.7.1. Animal Models 
 
The method for inducing AMI in animal models is achieved in many ways.  The 
majority of preclinical trials aim to narrow or block the coronary artery that results 
in myocardial ischaemia this can be achieved by surgical ligation or drug 
intervention 
 
The initial work by Orlic et al studied the IM injection of lineage-negative (Lin-) bone 
marrow cells from transgenic mice after left anterior coronary artery ligation, Lin- c-
kit+ cells were injected in the contracting wall bordering the infarct.  They found that 
68% new cardiomyocytes were formed of the infarcted portion of the ventricle 
9 days post procedure (Orlic, Kajstura et al. 2001).  These findings suggested that an 
injection of hematopoietic stem cells generate de novo myocardium.  Further studies 
by Jackson et al. has shown that the infusion of highly enriched hematopoietic stem 
cells into the myocardium of ligated and reperfused lethally irradiated mice 
myocardium resulted in the demonstration of cardiomyogenic process at the borders 
of the infarcted region (Jackson, Majka et al. 2001). 
 
The evidence that human stem cells had the potential to regenerate the myocardium 
in rodents has further helped the transition to human clinical trials.  Kocher et al. 
showed that the infusion of human CD34+ stem cells into the infarcted myocardium 
of rats resulted in neovascularisation and the proliferation of preexisting of 
vasculature (Kocher, Schuster et al. 2001).   
 
 47 
1.6.7. Clinical Trials 
 
The first randomised control trial assessing cell therapy post AMI was TOPCARE-
AMI, published in October 2004 (Schachinger, Assmus et al. 2004).  The primary 
focus of the trial was to show the safety of IC cell infusion post AMI.  The 3-minute 
balloon inflation technique used for cell infusion was well tolerated and showed no 
procedural compilations (Schachinger, Erbs et al. 2006).  Secondary imaging end 
points showed improvement in LVEF from 51.6 ± 9.6% at baseline to 60.1 ± 8.6% at 
4 months in the cell therapy arm vs. 51.0 ± 10% at baseline to 53.5 ± 7.9% in the 
control arm (Assmus, Schachinger et al. 2002). The largest randomised controlled 
trial addressing cell therapy in AMI has been REPAIR-AMI, which looked at 204 
patients recruited from April 2004 to June 2005.  REPAIR-AMI showed a significant 
improvement in LVEF (5.5 ± 7.3%. vs. 3.0 ±6.5%, p=0.01) and mortality in the cell 
based therapy treated patients (Schachinger, Erbs et al. 2006).   
 
Contrary to these results a number of other clinical trials over the last decade have 
failed to replicate the results these early trials have shown.  The LEUVEN-AMI trial 
failed to show a significant change in LVEF after cell therapy although of note did 
show an improvement in infarct size (Janssens, Dubois et al. 2006), and further trials 
have pushed the timings of the cell therapy infusion beyond the standard 3-5 days 
post infarction.  In the TIME (Traverse, Henry et al. 2012) and LATE-TIME (Traverse, 
Henry et al. 2011) the time points were pushed to 1 week and 2-3 weeks post AMI 
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respectively, with both these trials failing to show improvement in LVEF with late 
infusions.   
 
Meta-analyses of all randomised controlled stem cell trials have identified 24 trials, 
with a total of 1,624 patients who received stem cell or placebo after successful 
primary PCI treating AMI.  These results have showed that progenitor cells treated 
patients had significant improvement in LV function at 6 months (2.23% (95% CI 
1.00 to 3.47); p<0.001) and at 12 months this trend continued in 11 studies (3.91% 
(95% CI 2.56 to 5.27); p<0.001) (Delewi, Andriessen et al. 2013).  A further Cochrane 
review of 33 randomised control trials showed stem cell therapy resulted in a 
significant improvement in LV ejection fraction of 3.75% at 1 year compared to 
patients treated with conventional therapy (Clifford, Fisher et al. 2012, Fisher, Doree 

















Janssens et al 
 
2005 MC-MNC 11-90 x 106 IC 1 day 
Increase scar size but no 
improvement in LVEF at 4 months 






BMNC 2.4 x108 
CPC 1.3 x107 
IC 3-7 days 
Improved LVFE and reduced infract 
size at 4–12 months 
(Assmus, Schachinger 




2012 BM-NMC 150x106 IC 3 + 7 days No difference in LVEF at 6 months 





2006 BMNC 2.4 x 108 IC 4 days 
Improved LVEF and reduced infarct 
size at 4 months 





2006 BMNC 8.7 x 108 IC 5-8 days No difference in LVEF at 6 months 
(Lunde, Solheim et al. 
2006) 
HEBE 2011 
BMNC 296 x 108 




3-8 days No difference in LVEF at 4 months 





2004 BMNC 24x109 IC 6 days 
Improved EF at 6 months, increased 
regional contractility 









No difference in LVEF at 4 months 





2011 BMNC 150x106  IC 2-3 weeks No difference at 6 months 




1.6.7.1. Limitations of current trials  
 
Despite the increasing clinical experience of stem cell therapy post AMI, there 
remain unanswered questions, these include optimal delivery time and route of 
administration of cells.  A key question that still needed to be assessed is whether 
any meaningful results can be achieved by the delivery of cell therapy within a 
normal clinical length of hospitalisation post AMI.   
 
1.6.7.1.1. Timing of stem cell transplantation  
 
The ideal timing for stem cell infusion in patients post AMI has been much 
debated.  The balancing of the proposed benefit against the risk of cell infusion 
has been a question that has been addressed in multiple trials.  To date as seen in 
Table 1.3 the trials have focused their time points 24 hours post primary PCI.  
The issue regarding the best time point for infusion is in part related to the 
underlying physiological process of myocardial healing. Within the first 24 hours 
after AMI the ischaemic cardiomyocytes undergo necrosis and cell swelling, by 
day 3-4 granulation tissue forms with new capillary formation. During the 
following weeks the granulation tissue migrates inwards toward the centre of the 
infarct maturing with the increase in connective tissue.  The proposed 
improvement in cardiac function post AMI with stem cell infusions will therefore 
be related to the stage of physiological healing process the myocardium is 




1.6.7.1.2. Preferred imaging modality for the assessment of intermediate 
end points 
 
Within regenerative medicine imaging of the heart is essential in the evaluation 
of cardiac repair.  For the majority of stem cell trials the measurable end points 
have included LVEF, infarct size and myocardial contractility.  Early trials have 
used LV angiography or echocardiography.  With the development of advanced 
cardiac imaging techniques such as CMR and Positron emission tomography–
computed tomography (PET CT) later trials have utilised these imaging 
techniques.  The benefit of the later techniques have included further 
quantification of myocardial damage and viability as well as better 
reproducibility.  
 
1.7. Research Trials into the use of Cardiac Magnetic Resonance 
Imaging in Acute Myocardial Infarction 
 
The use of magnetic resonance imaging (MRI) has been used within clinical 
medicine for over 20 years and has played an important role in the diagnosis and 
management in the fields of musculoskeletal medicine and neurology.  The 
improvements in the last decade in resolution and reduced scan timings have 
resulted in the ability to perform dynamic scans.  Since the first description of the 
behaviour of magnetic imaging after AMI in dogs the interest has grown within 




The ability for high reproducibility and accuracy of images including the function 
and tissue characterisation of the myocardial in multiple views has made CMR 
the gold standard in cardiac imaging post AMI.  However, the use of CMR should 
also be regarded as part of a multitude of imaging modalities within cardiology.  
The ability for a rapid scan in acute circumstances render the use of CMR difficult 
so methods such as transthoracic echocardiography will remain the method of 
choice in these cases for the coming years.  Another weakness of CMR is the 
inability to image certain cardiac patients with pacemakers and ICD, although 
some modern devices are CMR compatible, although they do produce image 
artefacts. 
 
As previously mentioned CMR has advanced to allow for detailed characterisation 
of cardiovascular structural and functional phenotypes of HF.  This versatility and 
power of CMR has been able to address key issues in the evaluation of new novel 
therapy within many CVD.  
 
1.7.1. Cardiac Imaging: Angiographic Area at Risk and Myocardial 
Salvage 
 
CMR has become the gold standard in the quantification of ventricular volumes, 
function and tissue characterisation (Lorenz, Walker et al. 1999).  Myocardial 
oedema can be one of the early manifestations of ischaemia and can occur 
without irreversible myocardial damage.  Myocardial oedema has recently been 
used to quantify the area at risk (AAR) after AMI. The size of the AAR plays a 
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major determination in the final infarct size (Reimer and Jennings 1979).  T2 
short tau inversion recovery (T2-STIR) imaging is very sensitive in myocardial 
AAR after AMI (Aletras, Tilak et al. 2006).  In combination with delayed 
gadolinium enhancement it can differentiate between irreversible and reversible 
damage after reperfusion to measure myocardial salvage index (MSI) (Friedrich, 
Abdel-Aty et al. 2008). 
 
1.7.2. Cardiac Imaging: Stem Cell Trials 
 
The assessment of LV function is an important factor in patients’ management 
and outcomes (White, Norris et al. 1987). Within cardiac phase II trials several 
diagnostic methods have been used to evaluate LV function these include 2-
dimensional echocardiography, left ventriculography, cardiac computed 
tomography and CMR imaging.    
 
Each of these techniques have been used within cardiovascular stem cell research 
although each technique does have its benefits and limitations.  
Echocardiography is often used in acute trials as it offers fast inexpensive 
functional imaging of the LV, however due to the need to have optimal acoustic 
windows, the quality is dependent on the operator skills and patients chest wall 
anatomy.  Early acute trials used left ventriculography after PCI was performed; 
this method is an invasive imaging technique (see chapter 2.7.3.4.1) however this 
method does have the drawbacks that include 2D image acquisition that suffers 
the same LV geometrical assumptions that echocardiography provides.  Cardiac 
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CT had been shown to be reliably accurate in assessing the coronary arteries, as 
well as that of LV function (Budoff, Dowe et al. 2008, Wu, Tadamura et al. 2008). 
CMR is now considered to be the method of choice for the assessment of global 
and regional LV function (Bellenger, Burgess et al. 2000). In addition to volume 
measurement, CMR is able to give structural assessment that these other images 
techniques are unable to provide such as infarct size and AAR.   
 
All of the early cardiovascular stem cells trials have used LV function as its 
surrogate primary end point marker.  The range of imaging sequences that CMR 
provides has given further ability to assess the effect of regenerative medicine. 
 
The majority of trials to date have used only a single imaging technique to assess 
the end points, however it would be beneficial when designing a future study to 
include several different imaging modalities to help answer which is the best 
imaging modality to be used in cardiac regenerative medicine; in addition to 




1.7.3. REGENERATE-AMI Trial 
 
The REGENERATE-AMI is the first trial of autologous bone marrow derived cells 
delivered to patients less than 24 hours after presentation with AMI.  This trial 
will demonstrate whether such early delivery is achievable and safe as well as 
completing the time course for cell administration that has previously been 
investigated (Hamshere, Choudhury et al. 2014).  This time point is the closest to 
that used in the preclinical models, which demonstrated a significant benefit in 
restoration of cardiac function.  In addition patients underwent CMR, TTE and LV 
angiography to help provide further mechanistic information using the latest 
advanced imaging techniques.  
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The administration of autologous bone marrow derived progenitor cells (in 
addition to standard medical therapy) within 24 hours of primary PCI for 
anterior AMI leads to improvement in LVEF compared to standard medical 




1). To demonstrate that the use of the IC infusion of autologous bone marrow 
derived progenitor cells within 24 hours of primary PCI following an anterior 
AMI is safe and feasible. 
 
2). To demonstrate whether the administration of autologous bone marrow 
derived progenitor cells (in addition to standard medical therapy) leads to 
improvement in LVEF. 
 
3). To assess whether the mechanisms underlying changes in LV function, 
dimension and scar burden in patients treated with early IC infusion of BMNC is 
related to changes in circulating cytokines.  
 
4). To assess the feasibility of 3 slice T2-STIR short axis stack imaging for 
assessing myocardial oedema and the correlation to AAR compared to other 









2.1. Study Design 
 
The design of the REGENERATE-AMI trial followed the early small clinical trials 
that had translated the seminal work of Orlic et al in 2001 that showed the 
therapeutic benefit of allogeneic bone marrow derived cells in a mouse model of 
AMI (Orlic, Kajstura et al. 2001).  The time point used in the REGENERATE-AMI 
trial was the closest used to Orlic et al, in addition the inclusion of only anterior 
AMIs targeted the patient population most likely to benefit from therapy 
(Richardson, Bertaso et al. 2013) 
 
The study performed employed a double-blind, randomised, multi-centre, 
placebo controlled trial to determine if the early use of IC infusion of BMNC 
improved LVEF after an anterior AMI (REGENERATE-AMI). The REGENERATE-
AMI trial was designed to establish for the first time whether the early infusion of 
BMNC (within 24 hours of primary PCI) is safe, beneficial and feasible when used 
as an adjunct to current ‘gold standard’ therapy for an anterior AMI.  The 
recruiting centres that participated were The London Chest Hospital (London, 
UK), Royal Free Hospital (London, UK), Heart Hospital (London, UK), Centre 
Hospitalier Universitaire Vaudois (Lausanne, Switerzland) and Rigshospitalet 




2.2. Ethics and Trial Registration 
 
The REGENERATE-AMI trial was performed in accordance with the Declaration of 
Helsinki (1993) and the principles of the International Conference of 
Harmonization– Good Clinical Practice (ICH-GCP) guidelines, and was approved 
by a local ethics committee (NRES Committee London West London: 
07/Q0603/76).  The trial was registered with a public registry 
http://clincialtrials.gov (NCT00765453).  The trial protocol design was published 
in 2014 (Hamshere, Choudhury et al. 2014).  
 
2.2.1. Patient selection 
 
Consecutive patients presenting to each of the recruiting centres were 
approached up to 18 hours post successful primary PCI for an anterior AMI.  
Patients who attend the recruiting centres out of normal working hours (outside 
weekday 9am to 5pm and weekends) were approached in normal working hours 
if within the 18 hour time period.  Potentially eligible patients were identified by 
the trial teams at each of the recruiting centres and were approached either prior 
to successful primary PCI or afterwards on the ward.  They had the trial explained 
to them and were given a summary patient information sheet (PIS) (APPENDIX I) 
and a full version PIS (APPENDIX II), after which patients were left to read the 
PIS.  If patients agreed to participate, they were asked to provide written consent 
(APPENDIX III).  In addition to this patients were consented for viral blood 
screening (APPENDIX IV) in accordance to the research protocol.  In addition to 
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written consent for the trial patients provided written consent for bone marrow 
aspiration (BMA) and infusion procedure. 
 
2.2.2. Inclusion and Exclusion criteria 
 
2.2.2.1. Inclusion criteria: 
 
 Patients aged between 18 to 80 years 
 Acute anterior myocardial infarction (ST elevation in at least 2 contiguous 
anterior leads ≥ 0.2 mV) and treated with acute primary PCI with stent 
implantation within 24 hours after symptom onset 
 Acute primary PCI / stent implantation has been successful (residual 
stenosis visually < 30% and TIMI flow ≥ 2) 
 At the time of inclusion patient no longer requires i.v. catecholamines or 
mechanical hemodynamic support (aortic balloon pump) 
 Significant regional wall motion abnormality on LV angiogram in left 
anterior descending (LAD) territory at the time of acute primary PCI 




2.2.2.2. Exclusion criteria: 
 
 Regional wall motion abnormality not consistent with culprit vessel 
 Need to revascularise additional vessels, outside the infarct artery as a 
planned procedure (these vessels can be treated at baseline) 
 Arteriovenous malformations or aneurysms 
 Active infection, or fever or diarrhoea within last 4 weeks 
 Chronic inflammatory disease 
 Known human immunodeficiency virus (HIV) infection or active hepatitis 
 Neoplastic disease without documented remission within the past 5 years 
 Cerebrovascular insult within 3 months 
 Impaired renal function (creatinine > 200mmol) at the time of cell 
therapy 
 Significant liver disease (GGT > 2x upper limit) or spontaneous 
INR > 1,5) 
 Anemia (haemoglobin < 8.5 mg/dl) 
 Platelet count < 100.000/µl 
 Hypersplenism 
 Known allergy or intolerance to clopidogrel, heparin or abciximab 
 History of bleeding disorder 
 Gastrointestinal bleeding within 3 months 
 Major surgical procedure or trauma within 2 months 




 Mental retardation leading to inability to obtain informed consent 
 Previously performed stem / progenitor cell therapy 
 Participation in another clinical trial within the last 30 days 
 
2.2.3. Data collection and Statistical analysis 
 
To calculate the target sample size for the trial, an absolute increase in ejection 
fraction of 6% compared to baseline as measured by CMR were considered 
significant and consistent with previous studies that used advanced imaging to 
measure end-points (Wollert, Meyer et al. 2004). The published standard 
deviation for these observations is approximately 8% and in keeping with what 
has been observed by Janssens et al (Janssens, Dubois et al. 2006).  For a 
statistical power of 90% and a probability of a Type I error of 0.05 using a two-
sided t-test, with an estimated 25% drop-out at 1 year we will recruit a total of 
100 patients in this study.  Previous trials have shown a 2% improvement in 
patients who underwent primary PCI alone (Petronio, Rovai et al. 2003).  
Therefore using this information we will perform a post hoc analysis to compare 
the two groups, which will have 80% power to detect a 4% difference.   
The analysis of the data was based on the intention to treat principle.  Baseline 
demographic and clinical variables are summarised for each randomised arm of 
the study. Continuous variables will be presented as mean (SD) or median (IQR). 




The statistical comparisons within the treatment arms with respect to the 
primary endpoint will be performed using the independent-samples t-test as the 
principal analytic tool.  Further statistical comparison between treatment arms 
with respect to the primary endpoint, will be performed using the analysis of 
covariance (ANCOVA), including LVEF values at 12 months as dependent 
variables, the associated baseline values and the factor treatment as independent 
variables. Estimates of the treatment effect are presented together with the 95% 
confidence interval. Comparisons will be between the stem cell-treated and 
placebo control-treated group for the primary and secondary outcomes.  
Estimates of the treatment effects will be presented together with 95% 
confidence intervals.  All p-values are 2-sided (Surder, Schwitter et al. 2010). 
 
For clinical outcomes such as the incidence of MACE (predefined clinical 
scenarios; death, myocardial infarction, readmission for HF or 
revascularisation), Kaplan-Meier curves displaying the pattern of events over the 
6 and 12-month follow-up period are drawn.  Statistical significance and 95% 
confidence intervals are calculated using Cox's proportional hazards model. All 
statistical analyses were performed using SPSS version 19 (IBM Corp. Armonk, 
NY, USA) and graphs produced using Graphpad Prism version 5.0 (GraphPad 




Patients who consented for the REGENERATE-AMI trial were randomised using 
dedicated trial software IHD CLINICAL™ (Bishops Stortford, UK).  IHD CLINICAL™ 
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is a web-based password secured and encrypted data management system that 
has been designed specifically for clinical trials.  All members of the 
REGENERATE-AMI trial teams at each recruiting centre had an individual 
password and any change was recorded.  After registering patients on IHD 
CLNICAL, patients would undergo a 1:1 block randomisation allocation to receive 
either the IC infusion of autologous BMNC or the IC infusion of placebo. The 
placebo infusate had a colour characteristic similar to the IC stem cell suspension 
making them indistinguishable from each other. All study personnel and patients 
were blinded to treatment allocation until the study had been completed and 
analyses performed.  
 
2.3. Primary Percutaneous Coronary Intervention (PCI) 
 
The PCI procedure was performed as per operator preference with no restriction 
of procedural route or interventional technique (pre-dilatation or direct 
stenting).  Bystander PCI was allowed at time of index event, however staged PCI 
procedure at a later date was not permitted.  
 
2.3.1. LV ventriculography 
 
LV ventriculography was performed after primary PCI in the 30-degree right 
anterior oblique (RAO) position and recorded at a minimum of 15-30 frames per 
second.  Contrast was injected through a standard pigtail catheter over 10 
seconds, with at least 2 well opacified sinus beats that were not post-premature 
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beats.  All LV ventriculograms had simultaneous electrocardiogram (ECG) 
recording during injection as well as pressure measurement within the aorta and 
LV prior and after contrast administration. 
 
2.4. Bone marrow aspiration and Processing 
 
2.4.1. Bone Marrow Aspiration 
 
All patients who were randomised into the REGENERATE-AMI trial underwent a 
BMA procedure.  A fully trained member of the research team performed this 
BMA.  The patient was placed on their side and landmarks for the posterior 
superior iliac spine were assessed.  This region was then cleaned (in accordance 
with the recruiting centres local policy on antibacterial skin preparation) and 
draped with a sterile drape.  Local anaesthetic was administered from the 
epidermis to the posterior superior iliac spine.  A heparinised BMA needle was 
used to aspirate 100mls of bone marrow into 20 luer-lock syringes and placed 
into a sterile specimen bag for transport to the recruiting centres local stem cell 






Figure 2.1. Sterile trolley prepared for bone marrow aspiration 
A – Sterile swabs, B – Chlorhexidine, C – Sterile transfer bags, D – 10mls of 1% Lidocaine in sterile 
syringe, E – Sterile IV bungs, F – Bone marrow Jamshidi needle, G – Sterile drape, H – 10mls luer-
lock syringe with 1 ml of 1:1000 heparin, I – Sterile gauze 
 
Figure 2.2. Bone marrow aspiration procedure 
A – Sterile and covered patient, B – Inserted BMA needle with attached aspiration syringe  




The procedure of bone marrow processing was carried out in the recruiting 
centres cell culture laboratory using a standardised protocol. The three London 
based recruiting centres (The London Chest Hospital, Royal Free Hospital, Heart 
Hospital) used the same stem cell laboratory (Stem Cell Laboratory, Barts Health 
NHS Trust and Blizard Institute). The bone marrow processing method was based 
on previous work by Schächinger et al (Schachinger, Assmus et al. 2004) to GCP 
standard. 
 
2.4.3. Intracoronary Stem Cell preparation 
 
Progenitor cell infusate preparation was performed in a laminar flow cabinet. 
100mls of bone marrow was mixed in a transfer bag using sterile luer locks 
syringes connected to the bags coupling site.  The 100mls of bone marrow was 
diluted by adding 100mls of 0.9% saline via the cleaned coupling site and mixed 
thoroughly.  A platelet transfer set was connected to the coupling site, a 3 way tap 
connected to the end of the platelet transfer set and 1.5mls of bone marrow 
harvest was aspirated from the transfer bag.  This 1.5 mls of bone marrow 
harvest was then transferred equally into 1x2ml cryovial and two ‘Bact Alert’ 
culture bottles.  Patient identified 50ml conical tubes were placed into a sterile 
tube rack with their lids removed and 15mls of Ficoll solution was placed in each 
conical tube.  The harvest was drawn into a 50ml syringe that was placed at the 
end of the platelet transfer set with a 200μm filter.  The harvest was placed on 
top of the Ficoll solution so no mixing occurred in the 50ml conical tubes (Figure 
2.3).  To ensure all the bone marrow aspirate was utilised the bag and filter were 
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washed with 0.9% saline and placed onto the bone aspiration sample in the 50ml 
conical tube.  Once all bone marrow has been layered onto the Ficoll, the lids 
were tightly screwed onto the tube and placed in a centrifuge at 1900rpm for 30 
minutes.   
 
During centrifugation the laminar flow cabinet was cleaned and a further 4-8 
conical tubes were labeled.  On removal of the centrifuged conical tubes the small 
band of mononuclear cells (Figure 2.3) were transferred to the empty 50ml tubes, 
with the remainder of the liquid discarded.  The new 50ml conical tubes 
containing mononuclear cells were centrifuged at 2500rpm for 10 minutes, after 
which the supernatant was discarded.  To the 50ml conical tubes 5ml of re-
suspend was added and all 50ml conical tubes solutions were combined to a 
single tube.  This single conical tube was centrifuged for 2500rpm for 10 minutes 
after which the supernatant was discarded.  The tube was then filled up to 25ml 
with re-suspend and repeat centrifugation at 2500rpm for 10 minutes with 
supernatant discarding at the end.  The reconstitute was then passed through a 
BD Falcon Cell trainer 100μm and rinsed with 1ml of 0.9% saline.  Samples were 
sent as before for analysis and sterility checking, the remainder of the cell 
suspension was made up to 10mls with 0.9% saline and placed in a sterile labeled 
luer-lock syringe (infusate). 
 
Placebo was created by the combination of serum and 0.9% saline in a sterile 
labeled luer-lock syringe.  The colour of the placebo was such so it matched the 




Figure 2.3. Density Gradient Separation 
 
2.5. Intracoronary infusion 
 
Patients underwent the IC infusion of either BMNC or placebo within 24 hours of 
primary PCI, ideally within 6-8 hours when possible.  The processed infusate was 
returned to the recruiting centres catheterisation laboratory in a sterile sealed 
specimen bag.  The infusion procedure was based on a protocol used in previous 
positive clinical trials (Schachinger, Erbs et al. 2006).  
 
Patients underwent the reinfusion procedure from either the radial or femoral 
access route, a bolus of body weight adjusted dose of heparin was given so that 
the ACT remained < 200 throughout the procedure. A guide catheter was used to 
intubate the left main coronary ostium and diagnostic pictures were acquired, 
with estimation of coronary blood flow and the integrity of the treated vessel 
documented and assessed.  A 0.014-inch guide wire was passed to the distal part 
of the left anterior descending artery and a 10mm “over-the-wire” balloon was 
placed within the stented segment of the left anterior descending artery.  The 
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“over-the-wire” balloon’s diameter was ±0.5 mm the size of the implanted stent, 
so to achieve complete occlusion of the vessel at nominal pressure; with 
angiographic occlusion assessed prior to infusion.  A total of 10ml of the infusate 
was infused in three portions (each 3.3ml) during three minutes occlusion time 
for each portion.  After each infusion the “over-the-wire” balloon was deflated for 
three further minutes, prior to the next occlusion in order to avoid extensive 
ischaemia. This method has been used in previous trials with the aim to allow for 
adhesion and potential transmigration of the infused cells thought the 
endothelium (Assmus, Schachinger et al. 2002). 
 
Patients returned to the ward after the infusion underwent standard ward based 
care including cardiac monitoring for a minimum of 24 hours post procedure.  
Any complications during or after the IC infusion were documented.  The 
patients’ clinical care was carried out by the clinical team with length of stay and 




2.6. Study Endpoints 
 
2.6.1. Primary Endpoint 
 
The primary efficacy endpoint was change in global LVEF assessed by advanced 
cardiac imaging (in patients who were clinically unable to undergo CMR cardiac 
CT was performed as an alternative) at 12 months compared to baseline.  The 
choice of change in global LV function was decided as to allow comparison 
previous studies (Mills and Rao 2007, Surder, Schwitter et al. 2010). 
 
2.6.2. Secondary Endpoints 
 
2.6.2.1. Secondary Imaging Endpoint 
 
Additional advanced cardiac imaging related secondary endpoints were change in 
left ventricular volumes, myocardial salvage and infarct size at 3 months and 1 
year.  LV ventriculography secondary endpoint was change in global LVEF at 6 
months.  Echocardiographical secondary endpoint was change in LVEF as 
calculated by Simpson’s rule and change in wall motion scoring at 3 days, 6 




2.6.2.2. Secondary Safety Endpoint 
 
Safety endpoints included the acute safety and tolerability of IC stem cell infusion 
following AMI (haemodyamics and in-patient major adverse events (MACE) 
occurring after stem cell infusion, including Death {independent of cause and 
sudden death}, myocardial infarction {Q-wave and Non-Q-wave}, vascular 
complications, bleeding, and any ventricular rhythm disturbance during 
infusion).  Additional safety endpoints included assessment of MACE at 3 months, 
6 months and 12 months. 
 
2.6.2.3. Secondary Clinical Endpoint 
 
Clinical secondary endpoints included change in HF status as measured by NYHA 
(Table 2.1), angina symptoms as measured by Canadian Cardiovascular Society 
(CCS) (Table 2.1), evidence of HF (defined as physical signs of pulmonary 
crackles/rales, peripheral oedema, jugular venous distension, S3 gallop, 
radiological evidence of pulmonary oedema), number of HF admissions and 
changes in medications. 
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Table 2.1. New York Heart Association and Canadian Cardiovascular Society classification 
and functional status 
 
2.7. Data Collection 
 
2.7.1. Blood sampling 
 
All patients underwent routine clinical blood tests prior to primary PCI.  These 
bloods included routine full blood count, renal function, clotting, glucose, liver 
function, creatine kinase (CK), serum cholesterol levels, and troponin T. The 
attending clinical team responded to abnormal routine blood results at baseline.  
Consented patients had further blood test at the time of BMA for virology testing 
(HIV, Hepatitis B and C, HTLV and Syphilis).  At the London Chest recruiting 
centre only, additional blood was taken in a citrate bottle, EDTA bottle, and 2 
serum bottles. These were left to stand for 10 minutes after which they were 
spun in a centrifuge at 1000g for 10 minutes.  The serum was then pipetted into 
patient unique identifier number and time stamped cryovials.  Three 500ul 
samples from the citrate, EDTA and 500ul from the serum sample were stored in 
a -80oC freezer, the final serum tube sample was sent to a central reference 
NYHA Class Functional Capacity 
I No limitation of everyday physical activity 
II Slight limitation of everyday physical activity 
III Marked limitation of everyday physical activity 
IV Unable to carry out any physical activity / bedbound 
  
  
CCS Class Functional Capacity 
I Angina only on strenuous or prolonged activity 
II Slight limitation with angina during vigorous activity 
III Moderate limitation with symptoms on everyday physical activity 
IV Severe limitation with angina on limited physical activity or at rest 
 
 74 
laboratory for analysis for N-terminal of the prohormone brain natriuretic 
peptide (NT-proBNP) within UK sites.   
 
2.7.2. Quality of life questionnaires 
 
To assess patient quality of life, patients were given an EQ5D, MacNew health 
questionnaire and SF36 questionnaire during their admission (Brazier, Roberts 
et al. 2004, Hofer, Lim et al. 2004). This standardised questionnaire was a health 
outcome measurement tool and will be used throughout follow up.  
 
2.7.3. Advanced Cardiac Imaging  
 
2.7.3.1. Cardiac MR (CMR) 
 
CMR is the gold standard for the assessment of LV volumes and tissue 
characterisation (Lorenz, Walker et al. 1999, Schelbert, Hsu et al. 2010).  CMR 
imaging was performed on a 1·5 Tesla (T) scanner with a cardiac 32-channel 
phased array coil. Each examination used cine-CMR for ventricular volumes and 
function, and delayed enhancement (DE)-CMR for infarct size assessment and 
evaluation of microvascular obstruction (MVO). Myocardial oedema was assessed 
at all time points using 3 slice T2-weighted triple inversion turbo spin echo STIR 
imaging. The CMR scan protocol commenced with acquisition of a stack of 
localizer images in the transaxial plane with a half-fourier acquisition single-shot 
turbo spin echo (HASTE) sequence during free breathing.  From these images, a 
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vertical long-axis (VLA) cine image was obtained using a balanced SSFP sequence 
with breath-holding in end-expiration.  Five single steady-state free precession 
(SSFP) short-axis (SAX) scout images were acquired from the VLA image, 
covering the base to mid-ventricle. Breath-hold SSFP cine images in 2-, 3- and 4-
chamber views were piloted from the short-axis scout and VLA images. Finally, 
the 4-chamber and 2-chamber cine images at end-diastole were used to plan a 
stack of short-axis SSFP cine images. Contiguous short-axis slices were then 
acquired at 10mm intervals (7mm slice thickness, 3mm gap) from base to apex, 
ensuring complete ventricular coverage. For cine imaging, 25 frames or phases 
were acquired per cardiac cycle with an approximate temporal resolution of 30-
40ms. Images were routinely obtained with retrospective electrocardiographic 
gating, to allow the entire cardiac cycle to be acquired; typical sequence 
parameters for the SSFP cines were TE 1.6ms, TR 3.2 ms, in plane pixel size 2.1 x 
1.3mm, and flip angle 60°. 
 
T2 STIR imaging occurred prior in injection of gadolinium with a short repetition 
time of 1800-2200ms and an inversion time of 120-130ras. The inversion time 
was used to null any fat signal, and breath-hold 4- and 2-chamber STIR views as 
well as 3 slice short-axis STIR images were acquired.  Gadolinium enhanced 
imaging was performed by a peripheral injection of gadolinium (0.2 mmol/kg of 
body weight).  A three-dimensional inversion-recovery T1-weighted sequence 
was used with a repetition time of 3.5 to 4.2 ms, an echo time of 1.2 ms, flip angle 
of 15° and patient image dependent inversion time of 200 to 300ms.  For early 
gadolinium enhancement patients had images taken within the first 5 minutes of 
injection, for delayed gadolinium enhancement images were acquired at 15 to 20 
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minutes post infusion.  Both early and delayed enhanced sequences included 2-, 
3- and 4-chamber views as well as a 10-slice short axis stack.  
 
Images were anonymised, batched and analyzed in blinded fashion by two 
experienced operators (Dr Stephen Hamshere and Dr Danielle Longchamp). LV 
volumes and LVEF were calculated by manually drawing endocardial and 
epicardial contours of the SAX cine (Figure 2.4). Scar (infarct size) and oedema 
(AAR) volumes were calculated by manually drawing endocardial and epicardial 
contours followed by semi-automated selection of normal remote myocardium 
per slice (Figure 2.5). Myocardial oedema was described as >2SD in signal 
intensity from remote normal myocardium. Infarct and AAR endocardial surface 
area (ESA) was calculated as the percentage of the endocardial enhancement 
against the total endocardial area. Where cases of discordance were found 
between operators, a independent blinded review by a level III accredited CMR 
reader was performed (Dr Mark Westwood).  Analysis was performed using a 
dedicated software system (CVI42, Circle Cardiovascular Imaging Inc, Calgary, 
Alberta, Canada). Interobserver variability was calculated.  CVI42 is a 
commercially available software that has been widely used and validated for the 
assessment of LV volumes (Childs, Ma et al. 2011), infarct size and myocardial 





Figure 2.4. LV function analysis in short axis images using long axis views as a cross-reference 





Figure 2.5. Screenshot of left ventricular scar and oedema analysis 
A = without computer generated borders showing myocardial scar and myocardial oedema 
B = Left view screen shows myocardial scar assessment; right view screen shown myocardial oedema assessment 
Green contour – epicardial contour, Red contour – endocardial contour, Grey contour – excluded myocardium, Blue contour – Normal myocardium, Pink 
contour – abnormal myocardium, + – blue zone shows area of myocardial oedema, Φ – gold zone shown area of myocardial scar
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2.7.3.1.1. Myocardial salvage index 
 
When assessing the efficacy of a reperfusion treatment strategy, it is essential to 
express myocardial infarct size as a percentage of the AAR. In this study, the AAR 
was quantified using both coronary angiography (modified Bypass Angioplasty 
Revascularisation Investigation (BARI) (Rippel, Ghanbari et al.) (Alderman and 
Stadius, 1992) and the modified Alberta Provincial Project for Outcome 
Assessment in Coronary Heart Disease jeopardy score (APPROACH) (Ortiz-Perez 
et al., 2007) and the acute (2 day) CMR scan (Myocardial oedema-T2 imaging). 
Myocardial infarct size as previously described. MSI was calculated as the ratio of 
the CMR determined infarct size and the AAR (Bøtker, Kaltoft et al. 2012). 
 
2.7.3.2. Cardiac CT 
 
A small number of patients who were unable to tolerate, or had a 
contraindication to CMR underwent Cardiac CT imaging.  Studies were performed 
on an ECG-gated 64-slice spiral CT (Sensation 64, Siemens, Forchheim, Germany) 
scanner.  Cardiac CT has provided accurate and reproducible assessment of both 
LV and RV volumes in comparison to CMR (Maffei, Messalli et al. 2012), and is a 
reliable alternative in patients who are unable to under CMR imaging. 
 
Intravenous B-Blockers were used in patients to achieve optimal pulse rate prior 
to initiation of the scan, all patients were on cardiac monitors during 
administration.  All scans were performed in the craniocaudal direction.  An 
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initial scouting x-ray (topogram) was performed to ensure correct alignment of 
the patient for the remainder of the scan.  The scan was initiated when contrast 
arrives within the ascending aorta, this can be performed manually after test 
bolus or using an automated CT triggering once the Hounsfield unit crosses a 
threshold in a set region of the aorta.  A total of 50 – 100 mls of contrast was used 
for the scan with a duration of 10 – 15 minutes for the scan.  Reconstruction 
algorithms were used to convert the raw data into interpretable images, which 
were then analyzed on specialist software.  The data was reconstructed 
throughout the cardiac cycle and cine movie images are collected in 10 phases 
along the cardiac cycle and 10 levels.  Analysis of LV volumes and function was 
performed using dedicated PC-based software Siemens (Forchheim, Germany) to 
calculate epicardial and endocardial borders in both systole and diastole 
(Keenan, Pugliese et al. 2014) (Figure 2.6 and Figure 2.7) by two experienced 
operators (Dr Stephen Hamshere and Dr Tawfiq Choudhury).  Where cases of 
discordance were found between operators, a independent blinded review by a 
third operatorr was performed (Dr Ceri Davies).  The Cardiac CT scans were 




Figure2.6. Screenshot of analysis method left ventricular ejection fraction on cardiac CT 






Figure 2.7. Screenshot of left ventricular ejection fraction on cardiac CT  
B = Manual epicaedial (Red contour) and endocardial (Green contor), * RV pacing lead 





The imaging modality of echocardiography was chosen due to the availability 
directly after an AMI and the ease of getting repeated measurements.  Patients 
underwent standard views as defined by the British Society of Echocardiography 
(Wharton, Steeds et al. 2012).  These images were parasternal long axis (PLAX), 
parasternal short axis (PSAX), apical four chamber (A4C), apical two chamber 
(A2C), apical five chamber (A5C) and apical three chamber (A3C) (Wharton, 
Steeds et al. 2012).  Echocardiograms were performed 3 days, 6 and 12 months 
after primary PCI. The scans were anonymised, batched and analysed by an 
experienced operator (Dr Stephen Hamshere and Dr Denis Pellerin).  LVEF was 
calculated using the Simpson’s Biplane method and regional wall was assessed 
using wall motion index.  
 
2.7.3.4. Angiographic analysis 
 
2.7.3.4.1. LV ventriculography 
 
LV ventriculograms were performed prior to consent and directly after primary 
PCI and at 6 months.  All images were analysed using a dedicated system (CMS 
version 6.0, Medis, Leiden, Netherlands) by tracing the endocardial border 






Figure 2.8. Quantative Left Ventricular Analysis: Centreline method  
A: Admission Left ventriculograms with diastolic and systolic endocardial mapping and centerline 
motion indexing 




2.7.3.4.2. Angiographic risk scores (Area at risk) 
 
Patients underwent coronary angiography prior and after primary PCI.  All 
angiograms were reviewed by 2 experienced blinded observers and were 
assessed for the angiographic AAR using both the modified BARI and modified 
APPROACH jeopardy scoring systems.  (Figure 2.9 and Figure 2.10). 
 
 
Figure 2.9. The modified- Alberta Provincial Project for Outcome Assessment in Coronary 











Figure 2.10. Diagram to show the BARI angiographic myocardial risk score (Alderman and 
Stadius 1992) 
 
2.8. Patient discharge 
 
Patients’ clinical care was under their attending clinical physician, their medical 
therapy was optimised as far as possible prior to discharge. All patients were on 
duel antiplatelet therapy for a minimum of 1 year, life long statin therapy if 





Patient follow up is shown in Table 2.2. 
Table 2.2. Follow up investigations and measurements timeline 
 
2.9.1. 3 month follow up 
 
At 3 months follow up patients underwent a CMR and routine blood testing 
 







Screening x      
Physical 
examination x  x  x x 
Consent x x     
Raindomisation x      
Bloods x  x x x x 
ECG x x x  x x 
primary PCI x      
Echocardiogram  x x  x x 
BMA  x     
Reinfusion  x     
QoL Assessment   x  x x 
Advanced 
Cardiac Imaging   x x  x 
Left 
Ventriculogram  x   x  
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2.9.2. 6 month follow up 
 
At 6 months follow up patients underwent clinical examinations, repeat 
echocardiogram, routine bloods including NT-proBNP, left ventriculography and 
quality of life questionnaires.  
 
2.9.3. 12 months follow up 
 
At 12 months follow up patients underwent clinical examinations, CMR imaging, 
echocardiogram, quality of life questionnaire and routine bloods including NT-
proBNP. 
 
2.10. Chemokine analysis methods 
 
Patients who were admitted to the London Chest Hospital who were enrolled in 
the REGENERATE-AMI trial consented to have additional blood tests taken at 
baseline, 3, 6 and 12 months.  Patients who were recruited at other centres were 
not entered into the analysis.   
 
2.10.1 Blood collection and storage 
 
Peripheral blood samples were taken using the BD Vacutainer® system, blood 
samples were taken in EDTA tubes, serum and heparinised containers in 
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accordance to the manufactures specifications.  All patients from the London 
Chest Hospital had bloods taken at baseline (directly after primary PCI and 
consenting for the trial and prior to stem cell infusion), patients were asked to 
consent for additional bloods at 3, 6 and 12 months.   Blood samples were 
centrifuged for 10 minutes at 3000 revolutions per minute at room temperature.  
The serum was aliquated and placed in labeled cryovials and stored at -80°C until 
analysis. 
 
2.10.2. Serum defrosting 
 
Samples were transferred for analysis in -80°C transport container.  Samples 
were removed from the -80°C containers and were allowed to acclimatize to 
room temperature for 10 minutes.  Each cryovial was placed in a 30-37°C sterile 
water bath, a constant thermostatic temperature measurement was maintained 
to reduce the risk of excessive temperature fluctuations and possible degradation 
of the samples.  The cryovials were regularly gently shaken until completely 
thawed then removed to analyze.   
 
2.10.3. Preparation of samples for FlowCytomix analysis 
 
25μl of each standard, blank assay buffer solution and defrosted serum were 
transferred into the flow cytometry tubes, 25μl of bead mixture and 50μl of 
biotin-conjugate-mix was added to these samples and incubated for 2 hours at 
room temperature.  After incubation the mixture was washed twice with 1ml of 
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buffer.  50μl of Streptavidin-Phycoerythrin solution was added to the samples 
with a further hour of incubation at room temperature followed by two washes 
and the addition of 400μl assay buffer was added to each tube.  
 
For the analysis of MMP-9 the serum samples had to be diluted 1:1250 with milli-
Q water. The processed samples were analyzed using a BD LSR Fortessa Cell 
Analyser ("BD LSRFortessa | Cell Analyzer | BD Biosciences, 2014).  
 
2.10.4. FlowCytomix System 
 
The serum cytokine concentrations were assessed using FlowCytomix kits 
(Bender Medsystems Inc. Austria), the FlowCytomix kit allows for multiple 
measurements of multiple cytokines.  Flow cytometry is an effective technique 
that allows for the identification and analysis of various cytokines using specific 
fluorescence-labeled antibodies.   
 
Within the FlowCytomix system a single file of cells pass through a hydrodynamic 
layer with a laser beam focused on this region.  The fluorescence that is emitted is 
focused using a lens system and converted to electrical pulses that is translated 
into digital data.  
 
The FlowCytomix system is a fluorescent bead immunoassay system where beads 
are coated with antibodies reacting to a specific analyte.  The beads are incubated 
with the analyzing sample serum and then biotin-conjugated second antibody is 
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added. The beads are internally dyed with the addition of Streptavidin-
Phycoerythrin (PE), which binds to the biotin conjugate, emitting fluorescent 
signals. Within the FlowCytomix there are two size of beads that makes it 
possible to distinguish 20 sets of single fluorescence channels and the 





Figure 2.11. Schematic of Flow Cytometry 
Fluorochromes employed to detect target proteins emit fluorescence when excited by a laser with 
the correspondent excitation wavelength. Each stained particle or cell is detected individually and 
the data analysed through sensors called photo multiplying tubes (PMTs) detecting fluorescent 
light filtered at a specific wavelength. PMTs are able to convert the energy into an electronic 
signal. As each fluorescing cell passes the laser beam a pulse of voltage, described as an event. 
Each event is displayed digitally. 
 
 93 
Light from the laser results in a scattered patterned after coming in contact with 
the beads.  Light that is scattered in a forward direction generates a forward 
scatter (FSC) parameter whilst light that is scattered elsewhere generates a side 
scatter (SSC) parameter.  Each particle has a unique combination of FSC and SSC 
therefore allowing identification of multiple particles.   
Figure 2.12.  Flowcytomix Flow Cytometry 
The antibody bead population was gated according to the FSC/SSC and the variable signal from 
the 700nm excitation probe (R670/14-A). This allows differentiation between MCP-1 and VEGF 
(B). The amount of cytokines for numerous data-points vary in the amount of reporter 
fluoresecence PE. This allows standard curves to be generated from the median fluorescence 
intensity of the standards. Test sample MFI values are then read off the standard curves. 
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Analysis was performed by Dr Stephen Hamshere and a BMedSci student Mr 
Salem Shawaf, supervised by Dr Daniel Jones PhD. The detection limit of the assay 
and inter-assay and intra-assay coefficients are shown below (Table 2.3).  
 
Table 2.3. Flowcytomix assay detection limit and inter- and intra assay coefficient of 
variance 







IL-6 7.2pg/ml <10% <10% 
TNF-α 3.2pg/ml 8.9% 12.0% 
VEGF 7.9g/ml 4.3% 6.2% 
G-CSF 6.35pg/ml 7.6% 8.1% 














As discussed in chapter 1, despite the advances in the acute management of AMI 
with the introduction of primary PCI centres, 30-day mortality is still estimated at 
approximately 7% despite optimal medical management (Widimsky, Wijns et al. 
2010).  Although prompt PCI results in decreased ischaemic injury it also can 
result in further damage associated with ischaemia-reperfusion injury, which can 
account for at least 50% of final infarct size (Yellon and Hausenloy 2007, Jones, 
Andiapen et al. 2013).  The final infarcted myocardium undergoes a process of 
remodeling that is characterised by LV cavity dilation, dysfunction and 
subsequent HF (Pfeffer and Braunwald 1990).   
 
The optimal time for the delivery of progenitor cells has been a topic of debate 
and remains unknown.  The first trials used time points different to the first 
animal studies to reduce the risk of harm to the patients and increase the change 
of survival of the transplanted progenitor cells.  The timeline for the infusion can 
now be placed and future clinical trials can compare the unanswered early and 






Figure 3.1.  Cell delivery timeline of selected randomised control trials of bone marrow 
derived cell therapy in acute myocardial infarction (Choudhury 2014) 
The relationship between time to delivery of progenitor cells after AMI and the change in LVEF 
and infarct size.  
Green text donates trials with positive improvements in cardiac function whilst red text reflects 
trials in which the results did not reach statistical significance. 
 (ND-Not done/reported; ns-not significant; BMMC - Bone marrow-derived mononuclear cells: F-
manual Ficoll cell preparation, A-Automated cell preparation of BMMC; *-18-months follow-up)  
 
REGENERATE AMI was designed to test whether following primary angioplasty 
early infusion of autologous bone marrow derived cells is safe and would lead to 






3.2.1. General characteristics of Study population 
 
Between 19th March 2008 and 5th March 2013, 984 patients were screened after 
hospitilisation for AMI at 5 recruiting centres (The London Chest Hospital 
(London, UK), Royal Free Hospital (London, UK), Heart Hospital (London, UK), 
Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland) and 
Rigshospitalet (Copenhagen, Denmark)).  840 patients were evaluated and 
excluded for the following reasons: culprit vessels that were not the LAD 
(n=506), normal LV function (n=78), delayed presentation (n=59), intubated 
patients or on inotropes (n=61), Age < 18 or > 80 (n=49), Left ventriculography 
not performed (n=39), not suitable for IC infusion (n=28), participating in other 
trials (n=20).  This left 144 suitable patients, of which 44 patients declined to 
participate in the study.  The data is thus presented for the 100 patients (45 in 
control group and 55 in BMNC group, Figure 3.2).  
 
The mean age for the total population was 56.50 ± 10.51 months and 87% were 
male.  Patients who were randomised to BMNC had a longer ischaemia time than 
those who received placebo, however it was not significant (233.0 ± 38.15 vs 
193.0 ± 26.52 minutes, p=0.2257).  All baseline characteristics were similar 
between the treatment groups (Table 3.1).  The two study groups were similar 





Figure 3.2. Consort Diagram for REGENERATE AMI 
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Table 3.1. Baseline characteristics of the study population 
 
Data are presented as No. (%) unless otherwise specified. BMI - body mass index, G-CSF - 
granulocyte-colony stimulating factor, ACE - angiotensin-converting enzyme inhibitor, ARB - 
Angiotensin receptor blocker, BM – bone marrow 
 Control BMNC  
 (n=45) (n = 55) p-value 
Age (yr), mean ± SEM 56.67 ± 1.60 56.36 ± 1.41 0.8868 
Sex (M/F), (No.) 41/4 46/9  
Ethnicity (Caucasian) (No. (%)) 36 (80%) 47 (85.5%)  
    
Medical History prior to infarct:    
Hypertension (No. (%)) 12 (26.7%) 24 (43.6%)  
Hypercholesterolemia (No. (%)) 10 (22.2%) 19 (34.5%)  
Diabetes mellitus (No. (%)) 4 (8.8%) 6 (10.9%)  
Active smoker (No. (%)) 24 (53.3%) 27 (49.0%)  
Previous MI (No. (%)) 1 (2.2%) 1 (1.8%)  
Previous PCI (No. (%)) 0 (0%) 1 (1.8%)  
Family history (No. (%)) 13 (28.8%) 17 (30.9%)  
    
Medical Therapy prior to primary PCI:    
Aspirin (No. (%)) 45 (100%) 55 (100%)  
Clopidogrel (No. (%)) 39 (86.7%) 50 (90.9%)  
Prasugrel (No. (%)) 4 (8.9%) 3 (5.5%)  
Ticagrelor (No. (%)) 2 (4.4%) 2 (3.6%)  
Heparin (No. (%)) 40 (88.9%) 50 (90.9%)  
Bivalirudin (No. (%)) 5 (11.1%) 5 (9.1%)  
GP iib/iiia inhibitors (No. (%)) 33 (73%) 44 (80%)  
DES Stent used (No. (%)) 32 (71%) 36 (65%)  
Concomitant PCI performed (No. (%)) 1 (2.2%) 3 (5.5%)  
    
Baseline Observations:    
Blood Pressure (Diastolic/Systolic), mean 138.6 / 85.64 138.0 / 83.91  
Pulse (bpm), mean ± SEM 84.45 ± 4.68 80.25 ± 3.14  
BMI (kg/m2), mean ± SEM 27.11 ± 0.68 26.69 ± 0.42 0.5801 
CCS > 1 (No. (%)) 1 (2.2%) 5 (9.1%)  
NYHA > I (No. (%)) 3 (6.7%) 4 (7.3%)  
    
Timings:    
Chest Pain to primary PCI (min), median (IQR) 193.0 (145.5 – 320.5) 233 (155.0 – 348) 0.2257 
Door to primary PCI time (min), median (IQR) 36.0 (26.0 – 55.5) 40.0 (32.0 – 58.0) 0.2243 
primary PCI to BM aspiration time (min), median (IQR) 230.0 (112.0 – 966.0) 172.0 (105.0 – 976.0) 0.6060 
primary PCI to reinfusion (min), median (IQR) 583.0 (458.0 – 1276) 532.0 (403.0 – 1312) 0.4090 
BM aspiration to infusion (min), median (IQR) 313.0 (287.0 – 374.0) 323.0 (290.0 – 370.0) 0.7414 





3.3.1. Bone Marrow Aspiration 
 
All patients underwent successful BMA. The most common symptom experienced 
by patients during the procedures was bone pain at site of aspiration, with no 
patient experiencing more than mild pain and did not require any sedation or 
opiates.  There were three events within the control (bone marrow site bleeding 
n=2 and bone marrow site infection n=1) compared to two events in the BMNC 
(bone marrow site infection n=2) (Table 3.2).  Both bone marrow site bleeding 
events required compression bandaging to the puncture site and did not require 
blood transfusion, all site infections required short course of oral antibiotics.   
 
3.3.2. Stem cell infusion 
 
Two patients in the control group did not undergo the reinfusion procedure.  
There was a total of 23 events that occurred during the reinfusion procedure.  
There was no significant difference seen between groups in events including 
arrhythmias, bleeding, no reflow and repeat PCI (Table 3.2).  
 
There were three events within the trial of infusion-induced arrhythmias (control 
n=1 and BMNC n=2), two patients had non-sustained ventricular tachycardia not 
requiring cardioversion or antiarrhythmic agents and one patient had second-
 
 102 
degree atrioventricular block during balloon inflation that resolved after balloon 
deflation.  All 10 episodes of ST change occurred during coronary artery balloon 
occlusion, which resolved after balloon deflation.  Ischeamic pre-conditioning 
was seen during the three occlusions with improvement in ST changes over time.  
Two patients underwent PCI during infusion, this was not related to balloon 
inflation but distal stent dissection seen on initial angiogram prior to infusion. 
 
Table 3.2. Bone marrow aspiration complications and re-infusion complications across the 

















          
Values are No. (%) 
 
 Control BMNC 
 (n=45) (n = 55) 
   
Events During Bone Marrow Aspiration:   
Bone Marrow Bleeding  2 (4.4 %) 0 (0 %) 
Bone Marrow Infection  1 (2.2 %) 2 (3.6 %) 
   
Events During Intracoronary Infusion:    
Infusion Arrhythmia 1 (2.2 %) 2 (3.6 %) 
Infusion Bleeding/Heamatoma  3 (6.7 %) 3 (5.5 %) 
Infusion no-reflow 2 (4.4 %) 0 (0 %) 
Infusion PCI  1 (2.2 %) 1 (1.8 %) 
Infusion ST Changes with CP 2 (4.4 %) 2 (3.6 %) 
Infusion ST Changes without CP 4 (8.9 %) 2 (3.6 %) 
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3.3.3. Renal function and cardiac markers 
 
Blood analysis for Creatine, Troponin T and Creatine Kinase (CK) were performed 
on admission, discharge, 6 months and 12 month months for each patient.  At 
baseline both the groups had similar concentrations (Table 3.3).   
 







Values are mean (95% CI) 
 
Creatine concentrations significantly increased in the BMNC from admission to 
12 months by 8.52 umol/L from 77.56 ± 16.55 umol/L at admission to 86.06 ± 
21.58 umol/L at 12 months (p<0.0001), that was not seen in the control (3.67%, 
95% CI, -0.8117 to 8.145%; p=0.1057).  CK peaked at admission and decreased 
significantly over time (-455.6IU/L, 95% CI, -772.8 to -139.0IU/L; p=0.0058) in 
the BMNC and (-340.0IU/L, 95% CI, -639.0 to -40.95IU/L; p=0.0273) the control.  
 
Troponin T concentrations significantly increased from admission to discharge in 
both groups (Figure 3.3).  There was a significant increase in troponin T in the 
BMNC group during admission from 282.1 ± 319.2ng/L at baseline to 2165 ± 
1933ng/L at discharge (p=0.0020) and within the control from 1193 ± 2477ng/L 
 Control 
n = 45 
BMNC 
n = 55 
p-value 
 
    
Creatine (umol/L) 82.16 (76.62 – 87.69) 78.72 (74.28 – 83.17) 0.3276 
    
Creatine Kinase (IU/L) 788.2 (360.5 – 1216) 565.1 (291.1 – 838.3) 0.3566 
    
Troponin (ng/L) 1283 (463.7 – 2103) 647.9 (227.2 – 1069) 0.1390 
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at baseline to 2709 ± 2091ng/L at discharge (p=0.0082).  The change in Troponin 
did not differ between both groups at any time point.  
Figure 3.3. Change in Troponin T concentrations from admission to discharge 





3.3.4. Major Adverse Cardiac Events 
 
12 months after MI, 15.4% of patients in the control suffered MACE compared to 
15.9% of patients in the BMNC (p=0.9481) (Figure 3.4). 
 
 
Figure 3.4. Kaplan Meier curves showing cumulative probability of major adverse cardiac 





3.4. Left Ventricular Ejection Fraction assessed by advanced 
imaging (Primary Endpoint)  
 
Baseline scans were performed at discharge on day 3-4 after primary PCI, and of 
the 100 patients recruited, 93 patients underwent advanced cardiac imaging at 3 
months and 91 completed the primary endpoint for advanced cardiac imaging at 
12 months (n=51 in BMNC group and n=41 in control group). Ninety-six patients 
underwent CMR assessment and two underwent CT assessment of cardiac 
function, due to the small number of patients who underwent CT assessment all 
cardiac function data was pooled and analysed. 
 
Baseline measurement of LVEF did not differ significantly between the treatment 
groups (Table 3.4).   
 
Global LVEF increased in the BMNC by 5.06% from 47.51 ± 9.18% at baseline to 
52.57 ± 10.45% at 12 months (p<0.0001) and in the control by 2.82% from 49.15 
± 9.59% at baseline to 51.96 ± 9.13% at 12 months (p=0.0019) (Figure 3.5). 
There was a greater trend for improvement seen in the BMNC group compared to 
control at 12 months, with the mean improvement of 5.06 ± 7.27% in the BMNC 
versus 2.89 ± 5.05% in the control (2.17%; 95% CI, -0.576 to 4.91; p=0.1200) 






Figure 3.5. Change in LVEF between groups and change in LVEF from baseline to 12 months 
assessed by advanced cardiac imaging  
Panel A: Box and whisker plot (median and range) in change in LVEF at 12 months between 
groups in the REGENERATE AMI trial (primary end-point). Panel B and C: Dot plots showing LVEF 




Further assessment of change in Global LVEF was assessed at 3 months.  There 
was a greater trend for improvement seen in the BMNC group compared to 
control at 3 months.  The mean improvement in the BMNC group was 5.71 ± 
12.50% versus 1.59 ± 10.30% in the control (4.13 %; 95% CI, -0.528 to 8.79; 
p=0.0816) (Table 3.4 & Figure 3.6).   
 
Table 3.4. LVEF data by advanced cardiac imaging for study population 
 
Values are mean (95% CI).  
 Control BMNC  
3 months paired samples (n = 40) (n= 53) 
Between 
Group 
12 months paired samples (n = 41) (n= 51) P value 
 
Primary Endpoint  
   
Baseline LVEF (%) 49.15 (46.12 – 52.17) 47.51 (44.93 – 50.10) 0.5553 
3 months LVEF (%) 49.90 (46.90 – 46.90) 53.26 (50.38 – 56.15)  
12 months LVEF (%) 51.96 (49.08 – 54.84) 52.57 (49.63 – 55.51)  
    
In group p value (3 months) 0.3358 0.0048  
In group p value (12 months) 0.0019 <0.0001  
ANOVA of LVEF (p value) 0.3490 0.0094  
    
Difference in LVEF (%)    
3 months 1.588 (-1.707 – 4.882) 5.717 (2.645 – 8.789) 0.0816 
12 months 2.888 (1.141 – 4.634) 5.056 (3.011 – 7.101) 0.1200 




Figure 3.6. Change in LVEF at 3 months and 12 months 
Box and whisker (median and range) of change in LVEF at 3 months and 12 months. BMNC 
administration did not result in a significant improvement in LVEF as measured by advanced 
cardiac imaging compared to placebo administration at 3 and 12 months.   
 
Analysis of serial changes in LVEF over time was performed by repeated-
measures ANOVA.  Global LVEF increased statistically significantly between time 
points (p = 0.0094).  This trend was not seen in the control across the 1-year time 





Figure 3.7. Assessment of LVEF function over time 
LVEF assessment was performed at baseline, 3 and 12 months after IC delivery of either BMNC or 
placebo in all patients.  Each line representing the difference between baseline, 3 months and 12 
month LVEF- values are shown for each patient in the control in panel A and BMNC in panel B.  




3.5. Effects of Bone Marrow Progenitor cells on Geometry 
 
3.5.1. LV volumes  
 
LVESV, LVEDV and LVSV were assessed at baseline, 3 months and 12 months.  
There was no evidence of a difference seen between treatment groups in LVESV, 
LVEDV or LVSV at baseline, 3 months or 12 months.   
 
There was trend for greater improvement in LV volumes in the BMNC group 
compared to control.  There was a trend for an increase in LVEDV in both groups 
with greater improvement in BMNC group (3.65mls; 95% CI, -8.60 to 15.89; 
p=0.5556).  There was a greater trend for increase in LVEDV from baseline to 12 
months in the BMNC group 9.92mls (155.2 ± 32.05mls to 164.2 ± 41.19mls; 
p=0.0.0561) and in the control by 7.27mls (159.5 ± 33.41mls to 164.8 ± 35.64mls; 
p=0.1553).   There was similar decrease in LVESV in both groups with no 
significant difference between the 2 treatment groups (5.53mls; 95% CI, -2.066 to 
13.12; p=0·1516) There was a significant increase in LVSV from baseline to 12 
months in both groups, in the BMNC the LVSV increased by 11.61mls (73.39 ± 
17.01mls to 85.0 ± 20.41mls; p<0.0001) and in the control by 7.27mls (78.32 ± 
23.20mls to 85.59 ± 22.11mls; p=0.0015), with no significant difference between 




Table 3.5a. LV dimensions by advanced cardiac imaging for study population 
 
Values are mean (95% CI). LVEF - left ventricular ejection fraction, LVEDV - left ventricular end 







 Control BMNC  
3 months paired samples (n = 40) (n= 53) 
Between 
Group 
12 months paired samples (n = 41) (n= 51) p value 
    
LV End diastolic volume    
Baseline LVEDV (mls) 159.5 (148.9 – 170.0) 155.2 (146.2 – 164.2) 0.4430 
3 months LVEDV (mls) 166.7 (149.9 – 170.2) 162.6 (151.3 – 173.9)  
12 months LVEDV (mls) 164.8 (153.6 – 176.1) 164.2 (152.6 – 175.7)  
    
In group p value (3 months) 0.1477 0.1987  
In group p value (12 months) 0.1553 0.0561  
    
Difference in LVEDV (mls)    
3 months 6.625 (-2.447 – 15.70) 7.076 (-2.341 – 16.49) 0.9487 
12 months 5.275 (-2.440 – 12.99) 8.922 (-0.2431 – 18.09) 0.5556 
    
LV End systolic volume    
Baseline LVESV (mls) 80.67 (73.33 – 88.01) 82.49 (75.26 – 89.72) 0.9271 
3 months LVESV (mls) 84.33 (75.03 – 89.22) 78.19 (69.28 – 87.09)  
12 months LVESV (mls) 79.23 (71.18 – 87.28) 79.98 (70.47 – 89.49)  
    
In group p value (3 months) 0.5799 0.4360  
In group p value (12 months) 0.5994 0.4764  
    
Difference in LVESV (mls)    
3 months 2.200 (-5.773 – 10.17) -4.508 (-12.73 – 3.710) 0.2753 
12 months -1.550 (-7.182 – 4.082) -2.510 (-9.535 – 4.516) 0.8372 
    
LV Stroke Volume    
Baseline LVSV (mls) 78.32 (70.99 – 85.64) 73.39 (68.61 – 78.18) 0.2660 
3 months LVSV (mls) 81.33 (74.56 – 88.09) 84.89 (79.47 – 90.31)  
12 months LVSV (mls) 85.59 (78.61 – 92.56) 85.00 (79.26 – 90.74)  
    
In group p value (3 months) 0.2369 0.0007  
In group p value (12 months) 0.0015 <0.0001  
    
Difference in LVSV (mls)    
3 months 3.838 (-2.624 – 10.30) 11.48 (6.303 – 16.65) 0.0688 
12 months 7.275 (2.839 – 11.71) 12.80 (6.951 – 18.66) 0.1516 
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Table 3.5b. BSi LV dimensions by advanced cardiac imaging for study population 
 
 
Values are mean (95% CI). LVEDVi – indexed left ventricular end diastolic volume, LVESVi – 
indexed left ventricular end systolic volume, LVSVi – indexed left ventricular stroke volume 
 
 Control BMNC  
3 months paired samples (n = 40) (n= 53) 
Between 
Group 
12 months paired samples (n = 41) (n= 51) p value 
    
LVEDVi     
Baseline LVEDVi 82.56 (77.42 – 87.69) 80.04 (76.01 – 84.07) 0.4328 
3 months LVEDVi  86.87 (80.46 – 93.27) 84.59 (79.37 – 89.81)  
12 months LVEDVi 84.85 (79.52 – 90.18) 85.06 (79.60 – 90.53)  
    
In group p value (3 months) 0.0972 0.1950  
In group p value (12 months) 0.1978 0.0375  
    
Difference in LVEDVi    
3 months 3.87 (-0.736 – 8.477) 3.850 (-2.034 – 9.733) 0.9958 
12 months 2.582 (-1.403 – 6.586) 4.718 (0.283 – 9.152) 0.4831 
    
LVESVi    
Baseline LVESVi 42.35 (38.23 – 46.27) 42.32 (38.98 – 45.69) 0.9789 
3 months LVESVi 44.06 (38.80 – 49.31) 40.49 (36.20 – 44.78)  
12 months LVESVi 40.90 (36.71 – 45.09) 41.31 (36.68 – 45.93)  
    
In group p value (3 months) 0.5151 0.4140  
In group p value (12 months) 0.5357 0.4418  
    
Difference in LVESVi    
3 months 1.327 (-2.759 – 5.413) -2.098 (-7.211 – 3.015) 0.3192 
12 months -0.884 (-3.742 – 1.975) -1.327 (-4.766 – 2.111) 0.8469 
    
LVSVi    
Baseline LVSVi 40.30 (37.19 – 43.42) 37.72 (35.42 – 40.01) 0.1730 
3 months LVSVi 42.81 (39.53 – 46.09) 44.10 (41.39 – 46.81)  
12 months LVSVi 43.95 (40.79 – 47.11) 42.75 (40.75 – 46.77)  
    
In group p value (3 months) 0.1109 0.0006  
In group p value (12 months) 0.0099 <0.0001  
    
Difference in LVSVi    
3 months 2.544 (-0.610 – 5.698) 5.948 (2.677 – 9.218) 0.1448 
12 months 3.466 (0.879 – 6.053) 6.045 (3.539 – 8.551) 0.1563 
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3.5.2. Infarct Size 
 
Measurement of infarct size was performed 2-3 days post IC infusion of BMNC or 
placebo.  At baseline infarct size was significantly reduced in the BMNC compared 
to the control (-4.44%; 95% CI, -8.35 to -0.53; p=0·0264) (Figure 3.8).    
 
Figure 3.8. Infarct size assessment by CMR 
Panel A - Box and whisker (median and range) of baseline infarct size (%), *p<0.005 using 
unpaired t-test.  Panel B + C - Box and whisker (median and range) of infarct size (%) at baseline, 
3 and 12 months after delivery of either intra-coronary placebo (panel B) or BMNC (panel C). 





Infarct size decreased significantly in both groups over time. In the BMNC infarct 
size decreased by 4.68% (14.72 ± 7.69 to 10.07 ± 10.13; p=0.0003) with a 
greatest decrease seen in the control of 8.91% (20.14 ± 10.57% to 11.38 ± 9.14%; 
p<0.0001) (Table 3.6).  At 12 months there were similar infarct sizes in both 
groups (-0.69%; 95% CI, -4.89 to -3.50; p=0·7428). 
 
Table 3.6. Infarct size for study population 
 









12 months paired samples (n = 37) (n= 45) P value 
    
LV Infarct Size (%)    
Baseline IS (%) 20.14 (16.61 – 23.66) 14.72 (12.43 – 17.00) 0.0264 
3 months IS (%) 13.37 (10.16 – 16.58) 10.42 (7.736 – 13.10)  
12 months IS (%) 11.38 (8.33 – 14.43) 10.07 (7.057 – 13.07)  
    
In group p value (3 months) 0.0004 0.0006  
In group p value (12 months) <0.0001 0.0003  
    
Difference in Infarct size (%)    
3 months -6.611 (-9.995 – -3.227) -4.835 (-6.985 – -2.685) 0.3531 
12 months -8.910 (-12.07 – -5.755) -4.681 (-7.057 – -2.305) 0.0301 
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3.5.3. Area at Risk 
 
Measurement of AAR was assessed by STIR imaging technique by CMR at 
baseline, 3 and 12 months. AAR was greatest at baseline (34.34±14.06% in the 
control versus 32.80±9.634 in the BMNC) with significant reductions over time at 
3 months (4.10±5.69% in the control versus 4.42±7.17% in the BMNC) with the 
lowest values at 12 months (1.09±3.50% in the control versus 0.27±1.03% in the 
BMNC) (Figure 3.9).  
 
 
Figure 3.9. Area at risk assessment by CMR 
Dot plots showing AAR measured at baseline, 3 and 12 months after delivery of either intra-
coronary BMNC or placebo in all patients reaching primary end point.  Each line representing the 
difference between baseline to 3 months to 12 month, AAR- values are shown for each patient in 
the control in panel A and BMNC in panel B.  ***p<0.0001 using paired t-test.  
 
There was no significant difference between the 2 treatment groups at both 3 
months (3.57%; 95% CI, -2.215 to 9.357; p=0·2231) and 12 months (0.66%; 95% 
CI, -5.406 to 6.723; p=0.8292. 
 
 117 
3.5.4. Myocardial Salvage index 
 
Acute myocardial salvage was calculated as by (Baseline AAR – Baseline Infarct 
Size) / Baseline AAR.  There was a significantly greater myocardial salvage index 
seen in the BMNC compared to the control at baseline (0.1; 95% CI, 0·0008 to 
0.2025; p=0·0483) (Figure 3.10).    
 
Figure 3.10. Assessment of myocardial salvage index on CMR 
The mean index as assessed by CMR was significantly larger in the BMNC group compared to the 
control (P=0.0483). Significance evaluated using unpaired t test and data shown as mean ± SEM 
 
At 12 months myocardial salvage was calculated by:  
(Baseline AAR – 12 month Infarct Size) / Baseline AAR 
The trend that was seen at baseline was not present at 12 months (-0.074; 95% 
CI, -0.1813 to 0.034; p=0.1784)  
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3.5.5. Sub-analysis of BMNC based on baseline ejection fraction 
 
Based on previous studies a sub analysis of patients within the BMNC group with 
a LVEF < 45% was performed to assess if the improvement in LVEF was greater 
than patients who had a baseline LVEF > 45% (Dill, Schachinger et al. 2009).  
Both sub-groups showed improvement in LVEF at 12 months with the greatest 
increase seen in the subgroups of LVEF < 45%.  There was a mean improvement 
of 6.62 ± 8.31% in the subgroup with LVEF less than 45% versus 3.79 ± 6.71% in 
the BMNC subgroup with LVEF greater than 45% (p=0.1853) (Figure 3.11). 
 
Figure 3.11. Sub-analysis of BMNC with LVEF less or greater than 45% at baseline 
Box and whisker (median and range) of change in LVEF at 12 months between sub-group 
analysis, Patients with a lower LVEF at baseline after BMNC administration did not results in a 
significant improvement in LVEF as measured by advanced cardiac imaging compared to patients 
who LVEF was greater than 45% 
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3.5.6. Microvascular Obstruction  
 
MVO was assessed was performed in 68 baseline studies.  There was a 
significantly lower number of patients with MVO in the BMNC group 36.8% vs. 
60.6% in the control arm.  However there is no difference in the amount of MVO 
between the two groups (Table 3.7). 
 















 (n = 33) (n= 38) 
(between 
group) 
    
MVO     
MVO Present (n) 20 14 0.0456 
MVO (g) 1.0 (0.0–5.0) 0.0 (0.0–2.0) 0.0721 
MVO (% of LV mass) 2.2 (0.0-7.3) 0.0 (0.0–3.0) 0.0777 
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4.5.6. Transthoracic Echocardiography 
 
Echocardiography was performed on all patients after PCI prior to stem cell 
infusion, discharge, 6 months and 12 months as per protocol.  At admission all of 
the 100 patients recruited underwent echocardiography, 98 patients at 
discharge, 89 patient at 6 months and 93 patients underwent echocardiography 
at 12 months (n=52 in BMNC group and n=41 in control group).   
 
3.5.6.1. Left Ventricular Ejection Fraction by Echocardiography 
 
Global LVEF at admission did not differ significantly between groups (-2.03%; 
95% CI, -5.687 to 1.622; p=0·2724) (Table 3.7).  In the BMNC the LVEF increased 
significantly at 6 months by 1.90% (47.26 ± 9.01% to 49.16 ± 8.74%; p=0.0308) 
and at 12 months by 3.077% (47.98 ± 9.30% to 51.06 ± 9.82%; p=0.0088).  There 
was a significant improvement in LVEF seen at 12 months in the control by 
1.90% (50.41  ± 9.63% to 52.32 ± 9.09%; p=0.0167), which was not seen at 6 





Figure 3.12. LVEF at baseline, 6 months and 12 months assessed by echocardiography 
Dot plots showing LVEF measured at baseline, 6 months and 12 months after delivery of either IC 
BMNC or placebo in all patients.  Each line representing the difference between the 3 time points.  
Values are shown for each patient in the control in panel A and BMNC in panel B.    












6 months paired samples (n = 39) (n=50) 
Between 
Group 
12 months paired samples (n = 41) (n=52) P value 
    
Admission LVEF (%) 48.78 (45.92 – 51.63) 46.75 (44.34 – 29.75) 0.2724 
Discharge LVEF (%) 50.41 (47.38 – 52.45) 46.98 (45/39 – 50.57)  
6 months LVEF (%) 50.56 (47.37 – 53.75) 49.16 (46.67 – 51.65)  
12 months LVEF (%) 52.32 (49.45 – 55.19) 51.06 (48.33 – 53.79)  
    
In group p value (6 months) 0.5214 0.0308  
In group p value (12 months) 0.0167 0.0088  
    
Difference from baseline 
LVEF (%) 
   
6 months 0.41 (-0.87 – 1.69) 1.90 (0.18 – 3.62) 0.1863 
12 months 1.90 (0.35 – 3.44) 3.08 (0.81 – 5.35) 0.4176 
    
    
Admission WMSI (%) 13.42 (10.76 – 16.09) 14.39 (12.32 – 16.46) 0.5604 
Discharge WMSI (%) 12.20 (10.59 – 15.80) 15.63 (13.44 – 17.81)  
6 months WMSI (%) 13.31 (10.39 – 16.22) 15.14 (12.60 – 17.68)  
12 months WMSI (%) 12.29 (9.27 – 15.32) 12.82 (10.38 – 15.27)  
    
In group p value (6 months) 0.9704 0.1703  
In group p value (12 months) 0.3024 0.0002  
    
Difference from baseline 
WMSI (%) 
   
6 months 0.51 (-1.31 – 1.41) -0.78 (-1.97 – 0.41) 0.3561 
12 months -0.85 (-2.56 – 0.86) -2.79 (-4.11 – -1.47) 0.0696 
    
Values are mean (95% CI). LVEF - left ventricular ejection fraction, WMSI – Wall score motion 
index 
 
There was no evidence of difference in LVEF between the BMNC and Controls at 
both 6 and 12 months.  There was trend for improvement in both groups with the 
greatest improvement seen in the BMNC group of 1.90 ± 6.04% in the BMNC 
versus 0.41 ± 3.96% in the control at 6 months (p=0.1863), and 3.08 ± 8.15% in 





Figure 3.13. Change in LVEF between group at 6 months and 12 months 
Bar graph (mean and SEM) of change in LVEF at 6 months and 12 months between groups.  
 
3.5.6.2. Wall Motion Score Index 
 
WMSI was assessed in all patients and did not differ significantly between groups 
on admission or baseline (Table 3.7).  In the BMNC WMSI decreased significantly 
at 12 months by -2.80% (15.63 ± 7.77% to 12.82 ± 8.69%; p=0.0002), no 
significant changes in WMSI was seen in the control (Figure 3.14).  The change in 
WMSI over time between groups was at the border of conventional statistical 






Figure 3.14. WMSI at admission, baseline, 6 months and 12 months assessed by 
echocardiography 
Bar graph (mean and SEM) showing WMSI measured on admission, discharge, 6 months and 12 
months after delivery of either IC BMNC or placebo in all patients in the control in panel A and 




Figure 3.15. Change in WMSI between group at 6 months and 12 months 






3.5.7. Quantitative Left Ventriculography  
 
Quantitative Left Ventriculography (QLV) was performed on all patients at 
baseline after PCI as per protocol and at 6 months.  Of the 100 patients recruited, 
87 patients undertook 6-month angiography with QLV (n=48 in BMNC and n=39 
in control). There was no difference in baseline LVEF between the treatment 
groups.  Global LVEF increased significantly in the BMNC by 7.12% from 49.23 ± 
11.12% at baseline to 56.35 ± 14.92% at 6 months (p=0.0007) and by 5.00% 
from 52.41 ± 10.29% at baseline to 57.42 ± 12.14% at 6 months (p=0.0121) in 
the control (Figure 3.14). There was a trend for a greater improvement in global 
LVEF in the BMNC group compared to the control at 6 months (2.12%, 95% CI, -
3.401 to 7.632; p=0.4478).  
 
 
Figure 3.14. LVEF at baseline and 12 months assessed by quantitative left ventriculography 
Box and whisker (median and range) showing LVEF measured at baseline and 12 months after 





3.5.8. Comparison of imaging modalities 
 
There was a weak correlation between LVEF assessed by QLV and CMR 
(r=0.4598, p<0.0001) and between QLV and echocardiography (r=0.3480, 
p<0.0001). Echocardiography showed a strong correlation with CMR (r=0.8597, 
p<0.0001) (Figure 3.17).  
 
Figure 3.17. LVEF association between echocardiography and CMR and LV Angiography 
There was a significant positive correlation between echocardiography LVEF measurements and 
CMR (r=0.8597) as shown in panel A. Panel B depicts the weak association between CMR and LV 
angiography (r=0.4598).  
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3.6. Effects of Bone Marrow Progenitor cells on the patient 
 
3.6.1. Change in NYHA and CCS 
 
Change in NYHA and CCS classification in each group of the trial is shown in 
(Figure 3.18).   Baseline NYHA and CCS classification did not differ between 
groups and there was no significant change in either groups NYHA or CCS 
classification over time.  
 
Figure 3.18. Changes in NYHA functional class and CCS Class  
Change in CCS functional class in patients in both groups at 6 months (panel A) and 12 months 
(panel C), Change in NYHA functional class in patients in both groups at 6 months (panel B) and 
12 months (panel D) 
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3.6.2. Change in Quality of Life 
 
Patients undertook quality of life assessment using EQ5D, McNew and SF6 
questionnaire at Baseline, 6 months and 12 months within UK based centres.  At 
baseline there was no significant difference between both groups, and this 
pattern was at mirrored at 6 and 12 month follow up in both groups and 
assessment tool used.  Full assessment for quality of life assessment is shown in 
(Table 3.8 and 3.9). 
 
Table 3.9. Mean scores and mean changes in EQ5D among the patient population 
 
 
Values are mean (95% CI). VAS – Visual analogue scale
 Control BMNC  
6 months paired samples (n = 25) (n = 37) 
Between 
Group 
12 months paired samples (n = 28) (n = 37) p-value 
 
EQ5D  
   
Index Score – Baseline 0.65 (0.52 – 0.79) 0.66 (0.53 – 0.79) 0.4611 
Index Score – 6 months 0.78 (0.66 – 0.91) 0.73 (0.61 – 0.85)  
Index Score – 12 months 0.76 (0.63 – 0.89) 0.79 (0.71 – 0.87)  
    
In group p value (6 months) 0.0298 0.1149  
In group p value (12 months) 0.1735 0.0397  
    
Difference in Index Score    
6 months 0.11 (0.01 – 0.21) 0.10 (-0.03 – 0.23) 0.9167 
12 months 0.10 (-0.05 – 0.25) 0.13 (0.01 – 0.26) 0.7484 
    
VAS – Baseline 59.35 (48.11 – 70.59) 66.50 (58.95 – 74.05) 0.6793 
VAS – 6 months 64.95 (53.95 – 76.42) 71.76 (62.68 – 80.83)  
VAS – 12 months 71.59 (63.51 – 80.40) 73.76 (66.06 – 81.47)  
    
In group p value (6 months) 0.1854 0.0070  
In group p value (12 months) 0.0325 0.0459  
    
Difference in VAS    
6 months 9.42 (-4.95 – 23.79) 9.00 (2.660 – 15.34) 0.9502 
12 months 12.61 (1.15 – 24.07) 7.27 (0.14 – 14.39) 0.3941 




Table 3.10. Mean scores and mean changes in SF36 and MacNew questionnaires among the 
patient population 
Values are mean (95% CI). VAS – Visual analogue scale 
 Control BMNC  
6 months paired samples (n = 25) (n = 37) 
Between 
Group 
12 months paired samples (n = 28) (n = 37) p-value 
    
SF36®     
Physical – Baseline 38.13 (33.30 – 42.95) 38.68 (33.73 – 43.63) 0.6997 
Physical – 6 months 44.84 (39.46 – 50.22) 40.29 (35.71 – 44.87)  
Physical – 12 months 44.17 (38.98 – 49.36) 41.69 (36.75 – 46.64)  
    
In group p value (6 months) 0.0144 0.2356  
In group p value (12 months) 0.0124 0.2535  
    
Difference in Physical    
6 months 6.34 (1.38 – 11.31) 2.88 (-1.96 – 7.72) 0.3279 
12 months 6.03 (1.42 – 10.66) 3.02 (-2.25 – 8.29) 0.4039 
    
Mental – Baseline 47.14 (41.85 – 52.43) 44.13 (44.36 – 53.90) 0.6221 
Mental – 6 months 48.85 (42.53 – 54.16) 49.10 (44.64 – 53.56)  
Mental – 12 months 53.08 (49.10 – 57.07) 52.10 (47.86 – 56.33)  
    
In group p value (6 months) 0.6031 0.6021  
In group p value (12 months) 0.0060 0.2689  
    
Difference in Mental    
6 months 1.30 (-3.80 – 6.41) -1.26 (-6.10 – 3.59) 0.4724 
12 months 5.95 (1.85 – 10.04) 2.96 (-2.39 – 8.33) 0.4019 
    
MacNew    
Mean Score – Baseline 4.74 (4.18 – 5.29) 5.36 (4.77 – 5.75) 0.3738 
Mean Score – 6 months 5.51 (4.91 – 6.10) 5.31 (4.84 – 5.78)  
Mean Score – 12 months 5.69 (5.24 – 6.14) 5.53 (5.10 – 5.97)  
    
In group p value (6 months) 0.0155 0.7768  
In group p value (12 months) 0.0017 0.2838  
    
Difference in Mean Score    
6 months 0.59 (0.12 – 1.06) 0.06 (-0.38 – 0.50) 0.1081 
12 months 0.96 (0.39 – 1.53) -0.24 (-0.24 – 0.78) 0.0723 





Blood analysis for NT-proBNP was performed on samples at baseline, 6 months 
and 12 month months for each patient.  At baseline both the BMNC and Controls 
had similar concentrations.  There was a significant decrease in the levels of NT-
proBNP in the BMNC over time from 1304 ± 1069pg/ml at baseline to 514.2 ± 
1024pg/ml at 6 months (p=0.0028) to 337.6 ± 615.2pg/ml at 12 months 
(p=0.0010) and in the Control from 894.6 ± 994.7pg/ml at baseline to 262.6 ± 
225.6 pg/ml at 6 months (p=0.0036) to 214.3 ± 140.9pg/ml at 12 months 
(p=0.0005) (Figure 3.19). 
 
 
Figure 3.19. NT-proBNP and treatment group 
Bar chart (Mean and SEM) Panel A: control, Panel B: BMNC. * =P<0.05, **=P<0.01, *** =P<0.001  
 
At 12 months there was no significant difference between NT-proBNP 
concentrations (337.6 ± 615.2pg/ml in the BMNC versus 209.1 ± 141.9pg/ml in 




3.8. Cell Type 
 
The total number of mononuclear cell count in the pre processing bone marrow 
aspirate was 185x109 (IQR: 127-238.5) with a total of 40.6 (18.5-84.2) at the end 
of processing.  The mean cell viability at the end of processing was 97.6%.  There 
was no difference between groups of the baseline bone marrow aspirate and end 
product (Table 3.11). 
 
Table 3.11. Characteristics of BMNC and cell treatment 
 
 
Colony forming unit granulocyte-macrophage progenitor (CFU-GM) assessment 
was performed in a small number of patients (n=29). CFU-GM was performed 
prior and at the completion of cell preparation with no difference between either 
group (Table 3.12). 
 Control BMNC p-value 
 (n = 40) (n = 51) 
(between 
group) 
    
    
CD34 Total    
Pre-processing (x106) 3.7 (1.78-5.90) 3.46 (1.55-6.09) 0.8083 
% Recovery post-processing 52.5 (36.5-61.1) 46.0(33.9-60.5) 0.4557 
Reinfused (x106) - 1.32 (0.64-2.55) - 
    
    
MNC Total x109    
Pre-processing (x109) 207 (123.5-278.0) 184.8 (127.8-213.3) 0.1710 
% Recovery post-processing 17.11 (7.72-32.96) 12.54 (6.97-32.99) 0.6497 
Reinfused (x109) - 31.5 (18.0-71.0) - 
    
    
EPC Total x102    
Pre-processing (x102) 60.0 (25.0-140) 57.43 (24.4-226.3) 0.6369 
% Recovery post-processing 14.9(8.4-23.7) 29.16 (6.1-54.6) 0.1638 
Reinfused (x102) - 25.4 (2.56-79.54) - 
    
    
Viability (%) 98 (97-99) 98 (97-98) 0.2495 




Table 3.12. CFU-GM assessment 
 
 
3.8.1. Catheter biocompatibility  
 
Prior to the set up of the REGENERATE-AMI study infusions assessment were 
performed on a standard commercially available OTW balloon (Medtronic). No 
difference in the cell viability in any of the 10 samples assessed using a rapid 
infusion technique (within 10 seconds) or a prolonged infusion technique (over 3 
minutes) were seen.  The results for all 10 samples are shown below in table 3.13.  
This data set the standard infusion technique and catheter used for the 
REGENERATE-AMI study across all sites. 
 
 Control BMNC p-value 
 (n = 11) (n = 18) 
(between 
group) 
    
Prior to Cell Processing    
CFU-GM (x105) 9.4±11.6 4.7±5.4 0.1418 
    
Completion of Cell Processing    
CFU-GM (x104) 20.5±25.3 24.3±31.5 0.7351 
    
 Pre MNC (ul) Post MNC (ul) Pre viability (%) Post viability (%) 
 Fast Slow Fast Slow Fast Slow Fast Slow 
         
Sample 1 477.76 477.6 306.78 152.8 66.3 88.3 80.7 82.4 
Sample 2 450.72 450.72 176 186.66 70.5 70.5 91.3 88.9 
Sample 3 278.85 278.85 176.24 129.62 69.1 69.1 87.5 84.6 
Sample 4 442.19 442.19 205.08 161.22 68.9 68.9 89.5 84.2 
Sample 5 256.07 256.07 458.85 384.78 73.9 73.9 93.3 91.9 
Sample 6 984 984 769.64 757.4 75.3 75.3 72.9 73.3 
Sample 7 935.31 935.31 1027.1 648.62 74.6 74.6 76.3 75.3 
Sample 8 821.85 821.85 773.47 718.04 77.8 77.8 71 73.5 
Sample 9 984.15 984.15 1198.56 755.53 81.4 81.4 71.4 71.8 
Sample 10 938.98 938.98 1004.5 835.42 75 75 77 76.6 





1. Intra-coronary BMNC infusion appears safe in the short term in patients 
who have undergone primary PCI for AMI with 24 hours 
2. BMA can be performed safely in patients who have been anti-coagulated 
post primary PCI for AMI 
3. In the trial population, BMNC infusion was associated with an 
improvement in LVEF at 12 months compared to placebo as assessed by 
advanced cardiac imaging however the improvement was smaller than 
expected 
4. BMNC infusion was associated with a reduction in infarct size and 
improved myocardial salvage as assessed by cardiac enzymes (CK or 
Troponin T) or CMR imaging  
5. There was an association between baseline LVEF level and effect of BMNC 








Changes in Cytokine and Growth 






Paracrine factors within the heart play an important role in the re-modelling that 
occurs after AMI. The cytokine hypothesis holds that the progression to HF is due 
to a cytokine cascade that exacerbates an indirect haemodynamic or a direct toxic 
effect on the heart.  The role of cytokines in BMNC therapy has previously been 
seen in both animal and human studies (Deten, Volz et al. 2002, Nian, Lee et al. 
2004).  Cytokines, which are small molecules that are secreted by cells during 
times of stress play a role in apoptosis, differentiation and proliferation.  
Evidence has shown that the transplantation of progenitor cells decrease the 
release of inflammatory cytokines in response to stresses (Maltais, Tremblay et 
al. 2010).  Additionally there is strong evidence to show that using BMNC can 
produce and secrete a wide range of cytokines and growth factors that can 
promote angiogenesis and reduce apoptosis in ischaemic conditions (Yoon, 
Wecker et al. 2005).  This chapter investigates the changes in certain cytokine 
and growth factors after the early IC infusion of BMNC in patients who were part 
of REGENERATE-AMI, and to assess if these paracrine factors mediate the results 
seen.  
 
For this sub-study the following cytokines were selected due to either their 
previous links as possible adjunctive targets or associations with BMNC therapy 
or the use of exogenous cytokine therapy in other REGENERATE trial (Hamshere, 
Arnous et al. 2015).  IL-6, TNF-α and VGEF has been widely assessed in both AMI 
setting and the within cell therapy, therefore a comparison with these trials 
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would be possible.  The exogenous use of G-CSF was once trialled for patients 
post AMI however as previous stated in this thesis no significant benefit was 
observed, the rationale behind selecting G-CSF was to assess if endogenous G-CSF 
played any significant role in conjunction with cell therapy.  MMP plays an 
important spectrum in cardiovascular disease from AMI to heart failure and 
remodeling.  With the progression of heart failure MMP levels increase, therefore 







Of the 67 patients who were recruited at the London Chest Hospital to the 
REGENERATE-AMI trial, 64 patients (64% of total study) had bloods taken at 
baseline prior to BMA and re-infusion procedure.  In addition to the baseline 
bloods, samples were taken at 3 months (n= 15, 23.4% of sub-study population), 
6 months (n= 28, 43.8%) and 12 months (n= 36 (56.3%) (Figure 4.1).  Baseline 
data is presented for the 64 patients in Table 4.1.  Baseline blood samples were 
taken prior to BMA and any additional therapy other than standard management 
























Table 4.1. Baseline characteristics 
 Control Group BMNC Group 
 (n=28) (n=36) 
Age (yr), mean ± SEM 56.54 ± 2.21 54.64 ± 1.66 
Sex (M/F), (No.) 27/1 30/6 
Ethnicity (Caucasian) 22 (78.6%) 28 (77.8%) 
BMI, mean ± SEM 26.19 ± 0.76 26.58 ± 0.54 
   
Medical History prior to infarct:   
Hypertension 8 (28.6%) 17 (47.2%) 
Hypercholesterolemia 5 (17.9%) 13 (36.1%) 
Diabetes mellitus 3 (10.7%) 3 (8.3%) 
Active smoker 13 (46.4%) 16 (44.4%) 
Previous MI 0 (0%) 1 (2.7%) 
Previous PCI  0 (0%) 1 (2.7%) 
Family history 8 (28.6%) 17 (30.9%) 
   
Timings:   
Chest Pain to PCI (min), median (IQR) 225.0 (144.8 – 324.5) 227.0 (151.3 – 379.5) 
Door to PCI time (min), median (IQR) 34.5 (25.5 – 54.5) 33.25 (33.3 – 57.8) 
PCI to reinfusion (min), median (IQR) 942.5 (468.5 – 1385) 589.0 (410 – 1370) 
BM aspiration to infusion (min), median (IQR) 306.5 (285.5 – 357.0) 327.0 (280.8 – 373.5) 
   
Baseline LVEF (%), mean ± SEM 47.71 ± 1.68 47.30 ± 1.66 
Baseline Infarct size (%), mean ± SEM 20.79 ± 2.02 14.91 ± 8.43 
Baseline AAR (%), mean ± SEM 35.04 ± 2.56 32.69 ± 2.08 
   
Sample number   
Baseline (No.) 28 36 
Paired 15 (54.5%) 21 (58.3%) 
Triplicate samples 9 (32.1%) 18 (50%) 
   
Data are presented as No. (%) unless otherwise specified 
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4.2.1. Baseline cytokine  
 
The BMNC and control group were similar with respect to baseline plasma 
concentrations of VEGF, IL-6, TNF-α and G-CSF.  There was a significant 
difference in the baseline MMP-9 concentrations between the control group 
155.2 ± 13.79ng/ml and the BMNC group 68.71 ± 9.02ng/ml  (Table 4.2).  
 
Table 4.2. Baseline Cytokine concentrations 
 Control BMNC  
 (n = 28) (n= 36) p value 
    
Baseline VEGF (pg/ml) 884.3 ± 109.3 746.2 ± 71.01 0.2756 
Baseline IL-6 (pg/ml) 232.4 ± 50.33 264.9 ± 86.28 0.7635 
Baseline TNF-α (pg/ml) 26.45 ± 8.05 25.37 ± 6.16 0.8527 
Baseline G-CSF (pg/ml) 38.85 ± 16.51 35.27 ± 11.05 0.8527 
Baseline MMP-9 (ng/ml) 155.2 ± 13.79 68.71 ± 9.02 <0.0001 
    
    Values expressed as Mean and SEM). Statistical comparisons performed using unpaired t-test. 
 
4.2.1.1. VEGF concentrations over time points post primary PCI 
 
In all patients the plasma level of VEGF was highest at baseline 806.6 ± 62.36 
pg/ml with a significant change over time with the lowest levels seen at 3 months 
compared to baseline (259.4 ± 63.55 pg/ml versus 806.6 ± 62.36 pg/ml, 
p=0.0004).  Levels at 12 months were similar to but not back to baseline levels 








Figure 4.2 VEGF concentration change over time post primary PCI.  
Bar charts of VEGF concentration measured at baseline, 3 months 6 months and 12 months after 
primary PCI.  VEGF concentration assessed over time in all patients is shown.  Data expressed as 
mean ± SEM. * denotes significance with p<0.05, ** denotes significance with p<0.01 and *** 





No difference was seen in VEGF concentration when splitting patients in BMNC 
and control group after primary PCI (p=0.3115) (Figure 4.3). 
Figure 4.3. VEGF concentration over time by treatment group after primary PCI 
VEGF concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays VEGF concentration count over time showing BMNC treated vs control. VEGF 
concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 
Statistical comparison performed using two-way repeated measures ANOVA. 
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4.2.1.2. IL-6 concentrations over time points post primary PCI 
 
There is a decrease seen in IL-6 concentrations over time in all patients however 
this does not reach conventional statistical significance.  Levels of IL-6 were 
highest at baseline (250.7 ± 52.97 pg/ml) with the lowest levels seen at 6 months 
although this did not reach significance (95.95 ± 13.17 pg/ml versus 250.7 ± 
52.97 pg/ml, p=0.0716) (Figure 4.4). 
 
 
Figure 4.4. IL-6 concentration change over time post primary PCI 
Bar charts of IL-6 concentration measured at baseline, 3 months 6 months and 12 months after 
primary PCI.  IL-6 concentration assessed over time in all patients is shown.  Data expressed as 
mean ± SEM.  * denotes significance with p<0.05, ** denotes significance with p<0.01 and *** 
denotes significance p<0.001 using 1-way ANOVA with Bonferroni’s multiple comparison test. 
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No difference was seen in IL-6 concentration when splitting patients in BMNC 
and control group after primary PCI (p=0.1028) (Figure 4.5). 
 
 
Figure 4.5. IL-6 concentration over time by treatment group after primary PCI 
IL-6 concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays IL-6 concentration count over time showing BMNC treated vs control. IL-6 
concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 
Statistical comparison performed using two-way repeated measures ANOVA. 
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4.2.1.3. TNF-α concentrations over time points post primary PCI 
 
TNF-α appeared to increase at 3 months with a near significant trend for an 
increase in TNF-α from baseline over time however this did not reach 
conventional statistical significance (p=0.0585). Level of TNF-α was lowest at 
baseline (25.84 ± 4.90 pg/ml) with the peak level seen at 3 months (27.09 ± 
11.39 pg/ml versus 25.84 ± 4.90pg/ml, p=0.0790) (Figure 4.6).   
 
 
Figure 4.6. TNF-α concentration change over time post primary PCI 
Bar charts of TNF-α concentration measured at baseline, 3 months 6 months and 12 months after 
primary PCI.  TNF-α concentration assessed over time in all patients is shown.  Data expressed as 
mean ± SEM.  
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No difference was seen in TNF-α concentration when splitting patients in BMNC 
and control group after primary PCI (p=0.8822) (Figure 4.7). 
 
 
Figure 4.7. TNF-α concentration over time by treatment group after primary PCI 
TNF-α concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays TNF-α concentration count over time showing BMNC treated vs control. TNF-a 
concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 





4.2.1.4. Changes in G-CSF concentrations over time after primary PCI 
 
No difference was seen in plasma G-CSF concentrations over time in all patients 
(p=0.1273).  Level of G-CSF was lowest at baseline (36.84 ± 9.45 pg/ml) with the 
highest level seen at 12 months compared to baseline although this did not reach 
significance (91.25 ± 32.52 pg/ml versus 36.84 ± 9.45 pg/ml, p=0.0666) (Figure 
4.8).  
 
Figure 4.8. G-CSF concentration change over time post primary PCI 
Bar charts of G-CSF concentration measured at baseline, 3 months 6 months and 12 months after 
primary PCI.  G-CSF concentration assessed over time in all patients is shown.  Data expressed as 




No difference was seen in G-CSF concentration when dividing patients in BMNC 
and control group after primary PCI (p=0.8822) (Figure 4.9). 
 
 
Figure 4.9. G-CSF concentration over time by treatment group after primary PCI 
G-CSF concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays G-CSF concentration count over time showing BMNC treated vs control. G-CSF 
concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 
Statistical comparison performed using two-way repeated measures ANOVA. 
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4.2.1.5. Change in MMP-9 concentrations over time after primary PCI 
 
In all patients the plasma level of MMP-9 was highest at baseline (106.5 ± 9.50 
ng/ml) with a significant change over time with lowest level seen at 3 months 
compared to baseline (12.28 ± 7.20 ng/ml versus 106.5 ± 9.50 ng/ml, p=0.0003).  
Levels at 12 months were similar to baseline levels (101.6 ± 15.28 ng/ml versus 
106.5 ± 9.50 ng/ml) (Figure 4.10). 
 
Figure 4.10. MMP-9 concentration change over time post primary PCI 
Bar charts of MMP-9 concentration measured at baseline, 3 months 6 months and 12 months after 
primary PCI.  MMP-9 concentration assessed over time in all patients is shown.  Data expressed as 






There was a significance difference seen in MMP-9 concentration when splitting 
patients in BMNC and control group after primary PCI (p=0.0003) (Figure 4.11). 
 
 
Figure 4.11. MMP-9 concentration over time by treatment group after primary PCI 
MMP-9 concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays MMP-9 concentration count over time showing BMNC treated vs control. MMP-9 
concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 





4.2.2. Relationship between cytokines and infarct size  
 
Baseline imaging was performed on patients at day 3 after primary PCI.  Analysis 
demonstrated that both baseline G-CSF and TNF-α concentrations showed a weak 
association with infarct size (Figure 4.12).  No correlations were observed with 
MMP-9, IL-6 or VEGF (Table 4.3). 
 
Table 4.3. Correlation matrix of cytokine concentrations to LVEF and change in cytokine 




(correlation coefficient/ p value) 
VEGF  0.2136 / 0.0927 
IL-6  0.3650 / 0.0033 ** 
TNF-α  0.2628 / 0.0853 
G-CSF  0.3162 / 0.0116 ** 






Figure 4.12. Associations between cytokine concentration and infarct size on CMR at 
baseline 
There was a significant positive association between TNF-α concentration and LGE assessed 
infarct size on CMR at baseline, as shown in panel A. Panel B depicts a similar positive association 
between G-CSF concentration and LGE assessed infarct size on CMR at baseline 
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4.2.3 Relationship between cytokine concentration and Left 
Ventricular Ejection Fraction  
 
There was a weak but significant relationship seen between combined IL-6 
concentrations and all time point LVEF (Figure 4.13). 
 
Figure 4.13. Associations between IL-6 concentration and LVEF on CMR at baseline 
There was a significant weak negative association between VEGF concentration and LVEF 




No relationship was observed in the remainder of the cytokine concentration and 
LVEF or in all the changes in cytokine concentration or change in LVEF over time 
(Table 4.4).   
 
Table 4.4. Correlation matrix of cytokine concentrations to LVEF and change in cytokine 
concentration and change in LVEF over time 
Cytokine 
LVEF 
(correlation coefficient/ p value) 
Change in LVEF 
(correlation coefficient/ p value) 
VEGF  0.0600 / 0.5358 -0.1627 / 0.3505 
IL-6  -0.2564 / 0.0074** -0.2294 / 0.1850 
TNF-α  -0.0923 / 0.3419 0.0317 / 08565 
G-CSF  -0.1076 / 0.2676 -0.0232 / 0.8949 







4.2.3.1. Correlation between change in cytokine concentration and area at 
risk  
 
As previously described cytokine concentration changed over time in the total 
population.  There was a strong negative correlation between change in VEGF 
concentration at 1 year and change in AAR at 1 year (Figure 4.14).  No 
correlations were observed with IL-6, TNF-α, G-CSF and MMP-9 (Table 4.5). 
 
Figure 4.14. Associations between VEGF concentration and area at risk size on CMR at 
baseline 
There was a significant positive association between VEGF concentration and myocardial oedema 




Table 4.5. Correlation matrix of change in cytokine concentrations at 1 year and change in 
AAR at 1 year 
Cytokine 
Infarct Size 
(correlation coefficient/ p value) 
VEGF  -0.3674 / 0.0420 
IL-6  0.2304 / 0.2125 
TNF-α  0.1909 / 0.3035 
G-CSF  0.2008 / 0.2789 




4.2.4. Relationship between cytokine concentration and NT-
ProBNP 
 
Matched NT-proBNP samples were correlated with corresponding cytokine 
concentrations of the combination time point (baseline, 3 months, 6 months and 
12 months).  Analysis demonstrated that TNF-α was directly associated with NT-
proBNP whilst MMP-9 demonstrated a negative association with NT-proBNP 
(Figure 4.15). 
Figure 4.15. Associations between cytokine concentration and NT-proBNP 
There was a significant positive association between TNF-α concentration and NT-proBNP, as 
shown in panel A. Panel B depicts a negative association between MMP-9 concentration and NT-
proBNP concentrations  
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4.2.5. Cytokine concentration in BMNC responders 
 
In order to test whether the cytokine concentration were related to changes in 
LVEF assessment of the BMNC group responders was performed.   The median 
improvement of LVEF in all patients was 6% at 12 months.  In those patient who 
received BMNC therapy 20 patients were deemed improvers with an LVEF 
improvement ≥ 6% and 16 as non-improvers (≤ 6%).  There was no significant 




4.2.5.1. Change in VEGF concentrations over time in improvers vs non 
improvers 
 
There was no significant difference seen in VEGF concentration when dividing 
patients into improvers and non-improvers (p=0.5644) (Figure 4.16). 
Figure 4.16. VEGF concentration over time by improvers and non-improvers 
VEGF concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays VEGF concentration count over time showing Improvers vs Non-improvers. VEGF 
concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 
Statistical comparison performed using two-way repeated measures ANOVA. 
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4.2.5.2. Change in IL-6 concentrations over time in improvers vs non 
improvers 
 
There was no significant difference seen in IL-6 concentration when dividing 
patients into improvers and non-improvers (p=0.7538) (Figure 4.17). 
 
Figure 4.17. IL-6 concentration over time by improvers and non-improvers 
IL-6 concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays IL-6 concentration count over time showing Improvers vs Non-improvers. IL-6 
concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 
Statistical comparison performed using two-way repeated measures ANOVA. 
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4.2.5.3. Change in TNF-α concentrations over time in improvers vs non 
improvers 
 
There was no significant difference seen in TNF-α concentration when dividing 
patients into improvers and non-improvers (p=0.7538) (Figure 4.18). 
 
Figure 4.18. TNF-α concentration over time by improvers and non-improvers 
TNF-α concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays TNF-α concentration count over time showing Improvers vs Non-improvers. TNF-
α concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 
Statistical comparison performed using two-way repeated measures ANOVA. 
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4.2.5.4. Change in G-CSF concentrations over time in improvers vs non 
improvers 
 
There was no significant difference seen in G-CSF concentration when splitting 
patients into improvers and non-improvers (Figure 4.19). 
Figure 4.19. G-CSF concentration over time by improvers and non-improvers 
G-CSF concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays G-CSF concentration count over time showing Improvers vs Non-improvers. G-
CSF concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 
Statistical comparison performed using two-way repeated measures ANOVA. 
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4.2.5.5. Change in MMP-9 concentrations over time in improvers vs non 
improvers 
 
There was no significant difference seen in MMP-9 concentration when splitting 
patients into improvers and non-improvers (p=0.7538) (Figure 4.20). 
Figure 4.20.  MMP-9 concentration over time by improvers and non-improvers 
MMP-9 concentration measured at baseline, 3 months 6 months and 12 months after primary PCI.  
Figure displays MMP-9 concentration count over time showing Improvers vs Non-improvers. 
MMP-9 concentration assessed over time in all patients is shown.  Data expressed as mean ± SEM. 





One year after AMI all acute changes seen on T2-STIR imaging had resolved.  As 
stated in the previous chapter there was a significant reduction in the mean scar 
burden on follow up in the BMNC group with a significant mean over 
improvement in LVEF over time.  Patients who were deemed non-improvers 
showed a negative correlation between changes in VEGF concentrations and 
changes in LVEF at 1 year (r=-0.5656, p=0.0224) that was not seen in improvers 
(r=0.2583, p=0.2857) (Figure 4.21). In addition in the non-improvers there was a 
significant positive correlation between changes in TNF-α concentrations and 
changes in infarct size over follow up (r=0.6344, p=0.011) which again was not 
seen in the LVEF improvers (r=0.0989, p=0.7057) (Figure 4.21). 
 
Within the LVEF improvers sub-group there was a significant negative 
relationship between changes in IL-6 concentrations and changes in LVEF at 1 
year (r=-0.4727, p=0.0410) that was not seen in the non-improvers group 





Figure 4.21.  Association between change in cytokine and CMR assessed changes in infarct 
time and LVEF change  
There was a significant negative correlation between change in LVEF assessed by CMR and 
change in VEGF concentration (r=-0.5656) in the non-improvers, as shown in panel A. Panel B 
depicts a positive association between change in TNF-α and change in infarct size as measured by 
CMR (r=0.6344). Panel C depicts a negative correlation in LVEF assessed by CMR and change in 
IL-6 concentration (r=-0.4727) in the improvers. Associations determined using Pearson’s 





1. In the whole cohort serum cytokine concentrations changed after primary 
PCI and by 12 months had returned to near baseline. Significant time 
related changes were seen in VEGF concentrations and near significant 
changes seen in TNF-α concentrations   
 
2. MMP-9 concentrations were significantly higher at baseline and over time 
observed in the BMNC group compared to control   
 
3. Significant relationships was seen in both baseline serum concentrations 
of TNF-α and G-CSF with CMR assessed infarct size  
 
4. A significant positive correlation was observed between baseline IL-6 
concentrations and LVEF measured by CMR 
 
5. A significant relationship was observed between change in VEGF 
concentrations and change in AAR over follow up 
 
6. Serum NT-proBNP showed a significant relationship with both serum 
TNF-α and MMP-9 concentrations 
 
7. In a sub study of LVEF improvers vs. non-improvers there was a 
significant negative relationship observed between change in IL-6 




8. In non-improvers there was a significant negative correlation observed 
between change in VEGF concentrations and LVEF and changes in TNF-α 
concentrations and infarct size 
 
9. No significant changes were observed between BMNC group and control 
between VEGF, IL-6, TNF-α and G-CSF cytokine concentrations over all 
time points 
 
10. No significant changes were observed over all assessed cytokines and the 







Use of Cardiac MRI in assessing 







CMR has become the gold standard in the quantification of ventricular volumes, 
function and tissue characterisation (Lorenz, Walker et al. 1999).  It is now well 
established for the assessment of the myocardial AAR defined as ‘the ischaemic 
myocardium during coronary artery occlusion i.e. the region that will be subject 
to infarction if the blood flow is not restored’ after an AMI, using T2-weighted 
imaging to assess the myocardial oedema occurring in the ischaemic 
myocardium.  
 
The quantification of the AAR is crucial in assessing the efficacy of reperfusion 
therapy and novel cardioprotective agents. Currently methods for assessing the 
AAR require coverage of the whole left ventricle with 10-12 myocardial slices 
acquired usually with a breath hold per acquisition. This can lengthen the CMR 
scan for patients early after a myocardial infarction and therefore techniques that 
shorten examination times are advantageous to improve patients’ compliance 
and to reduce the risk for patients with AMI. Additionally despite advancements 
in semi-automated software, the analysis of the slices still requires contour 
detection and manual readjustments of multiple slices throughout the cardiac 
cavity remains a tedious process.  
 
Thus the aim of this chapter is to assess the feasibility of 3-slice T2-STIR imaging 
for the assessment of the AAR following AMI and to compare 3-slice STIR imaging 
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to conventional 10-slice STIR imaging, the ESA method and angiographic AAR 
scores.    
 
5.2. Study Design 
 
Data was collected from patients who had undergone primary PCI for STEMI 
within 24 hours of symptoms onset.  CMR scans were obtained from three clinical 
trials having the same time point of imaging performed at day 3.  These trials 
were REGENERATE- AMI (NCT00765453), NITRITE-AMI (NCT01584453) and 
myocardial oedema in acute myocardial infarction (NCT00987259).  Patient 
within the NITRITE-AMI study underwent IC infusion of nitire or placebo during 
primary PCI whilst patient within the myocardial oedema in acute myocardial 
infarction study only underwent primary PCI.  CMR protocol for patients in the 
REGENERATE-AMI has previously been described in Chapter 2.7.3.1.   Patients in 
the NITRITE-AMI and myocardial oedema in acute myocardial infarction 
underwent standard CMR imaging with conventional 10-slice STIR imaging.  
Angiographic risk assessment has previously been described in Chapter 2.7.3.4.2 
and was calculated on all patients.  
 
5.2.1. Statistical analysis 
 
Baseline demographics and continuous variables are summarised for 3 slice and 
10 slice groups. Continuous variables are presented as means ± SD and 
categorical variables are presented as percentages. 95% confidence intervals (CI) 
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are given.  Intra-observer variability and correlation between the methods were 
calculated using the coefficient of intra-class correlation.  All p-values are 2-sided 
and a value <0.05 was considered to indicate statistical significance. Data plotting 
used in analyzing the agreement between the different methods was made with 
Bland-Altman analysis. All statistical analyses were performed using SPSS version 
19 (IBM Corp. Armonk, NY, USA) and graphs produced using Graphpad Prism 




5.3.1. General characteristics and Study population 
 
167 patients presenting with AMI undergoing primary PCI at a single cardiac 
intervention centre were included in the analysis. The mean ages of patient was 
56.2 ± 10·18 years and 88% were male.  Clinical, CMR and angiographic 
characteristics of the population are shown in Table 5.1. Patients underwent 
either 3 slice (n=82) or 10 slice (n=85) T2-weighted STIR imaging for AAR 
assessment as previously described. These 2 groups (3 slice and 10 slice) were 
similar with regards to age, sex, LVEF and medical therapy, with the only 
difference between the 2 groups being a difference in culprit vessel treated with a 
greater number of LAD occlusions in the 3 slice group (p<0.0001). CMR was 
performed at a median of 3 days (range: 2-3 days) after primary PCI. In all cases, 




Table 5.1. Baseline characteristics of the study population. 
 
 3 slice  10 slice   
 (n=82)  (n=85)  P value 
Age (yr) 56.95 ± 10.49  55.93 ± 11.35  0.6202 
Sex (M/F) 71/11  75/12  0.3037 
BMI (kg/m2) 27.04 ± 3.79  27.44 ± 3.87  0.5277 
Ethnicity (Caucasian)  66 (80%)  71(83.5%)  0.6113 
      
Medical History:      
Hypertension  30 (36.5%)  28 (32.9 %)  0.6235 
Hypercholesterolemia  24 (29.3%)  31 (26.4 %)  0.3251 
Diabetes mellitus  10 (12.2%)  9 (11.6 %)  0.5766 
Active smoker  42 (51.2%)  47 (55.3 %)  0.6004 
Previous MI  1 (1.2%)  2 (2.4 %)  0.5841 
Previous PCI  1 (1.2%)  3 (3.5 %)  0.3320 
Family history  25 (30.5%)  19 (22.4 %)  0.2354 
      
Culprit Vessel:     <0.0001 
LAD (No. (%)) 82 (100%)  23 (27%)   
LCx (No. (%)) 0 (0%)  11 (13%)   
RCA  (No. (%)) 0 (0%)  51 (60%)   
      
Timings:      
Chest Pain to PCI (min) 194.5 ± 25.42  201.0 ± 32.16  0.8459 
      
 
Data presented as No. (%) unless otherwise specified. BMI - body mass index, LAD – left anterior 
descending artery, LCx – left circumflex artery, RCA – right coronary artery, PCI – percutaneous 




5.3.2. Comparison of 3-slice AAR size and 10-slice AAR size 
 
 The 10-Slice AAR group underwent both 10-slice and 3-slice analysis to directly 
compare the 2 techniques. When assessing the 3-slice acquisition in the 10-slice 
cohort, all scans had the same level basal, mid and apical slice assessed. Within 
the 10-slice AAR group the AAR ranged from 11.5 to 46.8% (mean 27.89 ± 7.33) 
and the 3-slice AAR assessment of the same patients showed an AAR range from 
10.0 to 52.0% (mean 27.86 ± 8.26).  There were strong correlations between 3-
slice AAR and 10-slice AAR in this patient group (r=0.9224, p<0.0001) (Figure 
5.1).  
 
Figure 5.1. Association between 3 Slice AAR and 10 Slice AAR. Data presented shows the 
relationship between 3-slice STIR area at risk and 10-slice STIR area at risk assessed by 
CMR on sub group 10-slice STIR group 
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5.3.3. Comparison of CMR assessed AAR size and angiographic risk 
 
The CMR assessed AAR in the 3-slice group ranged from 8 to 56% of the LV 
myocardium.  Angiographic AAR was assessed for all patients, with the BARI risk 
score ranging from 21.0 to 47.4% (mean 35.32 ± 8.99) and the APPROACH 
angiographic risk score ranging from 27.5 to 47.8% (mean 37.6 ± 7.6%) of the LV 
myocardium with good correlation between the 2 scores (r=0.8639 p<0.0001).   
 
Oedema ESA was assessed for all patients, with the oedema ESA ranging from 2 
to 59% (mean 31.47 ± 11.60%).  The intraclass correlation coefficients between 
the angiographic and CMR methods of 3-slice and 10-slice STIR imaging 
techniques for the assessment of myocardial oedema were performed (Table 5.2). 
There was significant correlation between 3-slice AAR and oedema EAS 
(r=0.9126, p<0.0001), in addition there was significant correlation between the 
3-slice AAR and both the BARI angiographic risk score (r=0.3049, p =0.01) and 





Figure 5.2. Association between angiographic risk score and 3-slice STIR AAR.  
Data presented shows a significant positive correlation between 3-slice STIR AAR assessed by 
CMR at 3 days and BARI angiographic risk at baseline (r=0.3049) as shown in panel A. Panel B 
depicts a similar association between the 3-slice STIR AAR assessed by CMR and APPROACH 




Table 5.2. Intraclass Correlation Coefficients Between Angiographic and Cardiovascular 
Magnetic Resonance Methods of 3-slice and 10-slice STIR imaging techniques.  
3 Slice Assessment T2 STIR APPROACH BARI 
Infarct ESA 0.50 (0.30 – 0.66) *** 0.22 (-0.02 – 0.43) 0.16 (-0.07 – 0.37) 
Oedema ESA 0.91 (0.86 – 0.95) *** 0.16 (-0.06 – 0.38) 0.26 (0.02 – 0.47) * 
Infarct % 0.47 (0.26 – 0.64) *** 0.16 (-0.06 – 0.37) 0.16 (-0.07 – 0.37) 
BARI 0.30 (0.07 – 0.51) * 0.86 (0.80 – 0.91) ***  
APPROACH 0.25 (0.01 – 0.46) *   
 
10 Slice Assessment T2 STIR APPROACH BARI 
Infarct ESA 0.64 (0.50 – 0.75) *** 0.44 (0.25 – 0.60) *** 0.28 (0.07 – 0.47) ** 
Oedema ESA 0.89 (0.84 – 0.93) *** 0.40 (0.20 – 0.56) *** 0.17 (-0.05 – 0.37) 
Infarct % 0.73 (0.61 – 0.82) *** 0.50 (0.32 – 0.64) *** 0.33 (0.13 – 0.51) ** 
BARI 0.27 (0.06 – 0.46) *** 0.85 (0.78 – 0.90) ***  
APPROACH 0.46 (0.27 – 0.61) ***   
 
Data presented as intraclass correlation coefficients (confidence interval). p value <0.05 = *, <0.01 
= **, <0.001 = ***. APPROACH, Alberta Provincial Project for Outcome Assessment in Coronary 
Heart Disease; BARI, Bypass Angioplasty Revascularisation Investigation Myocardial Jeopardy 
Index; ESA, endocardial surface area; STIR, T2-short tau inversion recovery; LAD, left anterior 
descending artery  
 
Within the 10-slice AAR group the CMR assessed AAR ranged from 11.5 to 46.80, 
the BARI angiographic risk score ranged from 10.5% to 47.4% (mean 26.56 ± 
10.11), and the APPROACH angiographic risk score ranged from 6.5% to 47.8% 
(mean 29.24 ± 8.95%) of the LV myocardium. There was good correlation 
between the 2 angiographic risk scores (r=0.8544, p<0.0001). There was a 
significant correlation between the 10-slice AAR and both the BARI angiographic 
risk score (r=0.2702, p=0.0124) and the APPROACH angiographic risk score 
(r=0.4568, p<0.0001) (Figure 5.3). 
 
To correct for the higher number of LAD infarcts in the 3-slice group a sub-group 
analysis of just patients within the 10-slice AAR group where the culprit vessel 
was the LAD showed only a significant correlation between 10-slice AAR and 




Figure 5.3. Association between angiographic risk score and 10-slice STIR AAR. 
Data presented as a significant positive correlation between 10-slice STIR AAR assessed by CMR 
and BARI angiographic risk at baseline (r=0.2702) as shown in panel A. Panel B depicts a similar 
association between the 3-slice STIR AAR assessed by CMR and APPROACH angiographic risk 




Figure 5.4. Association between angiographic risk score and sub-study LAD 10-slice STIR 
AAR. 
Data presented shows a significant positive correlation between the sub-study LAD 10-slice STIR 
AAR assessed by CMR and APPROACH angiographic risk score (r=0. 4247) as shown in panel B, 
that was not present between sub-study LAD STIR AAR and BARI score, panel A.   
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5.3.4. Comparison Between Infarct size and myocardial AAR Scores 
 
Infarct size (assessed by LGE) ranged from 1% to 44% of the LV myocardium 
(mean 18.02 ± 8.82%).  There was a significant correlation between infarct size 
and 3-slice AAR (r=0.4722, p<0.0001) and infarct size and 10-slice AAR 
(r=0.7324, p<0.0001) (Figure 5.5).  
 
Infarct size assessed by ESA ranged from 0 to 45% (mean 17.25 ± 9.75%).  There 
was significant correlation between infarct size ESA and 10-slice AAR (r=0.4155, 
p<0.0001) and 3 slice AAR (r=0.4722, p<0.0001).  Infarct size assessed by ESA in 
the 3 slice AAR ranged from 1 to 57% (mean 17.28 ± 10.01%).  For 10 slice AAR 
group infarct ESA ranged from 0 to 45% (mean 17.25 ± 9.75).  There was 





Figure 5.5. Association between infarct size and AAR.   
Data presented as panel A shows a significant positive correlation between 3-slice STIR AAR 
assessed by CMR and infarct size assessed by CMR at baseline (r=0.4722) as shown in panel A. 
Panel B depicts a similar association between the 10-slice STIR AAR and infarct size assessed by 
CMR at baseline (r=0. 7324).   
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5.3.5. Timing for acquisition and analysis of 3-slice versus 10-slice 
area at risk 
 
The time taken for the acquisition of the T2-STIR sequences was assessed from 
the initiation of the scan to the start of the next imaging sequence.  The 3-slice 
group had a median acquisition time of 100 seconds (range: 65-171 seconds) and 
the 10-slice group had a median acquisition time of 355 seconds (range: 275-603 
seconds), with a significant difference seen between the two groups (p<0.0001) 
(Figure 5.6)   
 
For analysis the 3-slice group had a median time of 42.74 seconds (IQR: 36.04-
55.17 seconds) and 10-slice group had a median time of 137.1 seconds (IQR: 133-
143.5 seconds), with again a significant difference seen between the two groups 
(p<0.0001) (Figure 5.6).  The inter-observer timing variability correlated well 
between analysers; 3-slice r=0.9580 p<0.0001, 10-slice r=0.9288 p<0.0001).  
 
Figure 5.6. Acquisition and Analysis timings.  
Data presented shows a significant decrease in acquisition time for the 3-slice AAR group 
compared to the 10-slice AAR group in Panel A.  Panel B shows a significant decrease in analysis 
time for the 3-slice AAR group compared to the 10-slice AAR group. *** indicates p value < 0.001. 
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5.3.6. Comparison of 3-slice and 10-slice AAR technique. 
 
The comparison of the different correlation coefficients were compared using 2-
tail Fisher’s z-transformation statistical analysis. The analysis revealed that there 
was no significant difference in correlation between 3-slice STIR group and the 
10-slice STIR group in regards to BARI angiographic risk score 
(z=0.23, p=0.8181), APPROACH angiographic risk score (z=-1.42, p=0.1556).  
Within the subgroup analysis patients there was no significant difference in 
correlation between 3-slice STIR group and the 10-slice STIR LAD culprit only 
group in regards to BARI angiographic risk score Within the subgroup analysis 
patients there was no significant difference in correlation between 3-slice STIR 
group and the 10-slice STIR LAD culprit only group in regards to BARI 
angiographic risk score (z=1.07, p=0.2846), APPROACH angiographic risk score 
(z=-0.58, p=0.5619).  However there the 10-slice STIR assessment correlated 
better with infarct size percentage compared to the 3-slice STIR (z=-
2.53, p=0.0.0114) (Table 5.3). 
Table 5.3. Correlation of groups and Angiographic risk score. 
3-Slice 10-Slice 
10-Slice STIR  
(LAD culprit only) 
   
BARI Angiographic Risk 0.8181 - 
   
APPROACH Angiographic Score 0.9045 0.4533 
   
Infarct Size 0.0114 0.1802 
   
 
Data presented shows a Fisher’s z-transformation of 3 slice STIR against 10-Slice STIR and LAD 
sub-study. APPROACH, Alberta Provincial Project for Outcome Assessment in Coronary Heart 
Disease; BARI, Bypass Angioplasty Revascularization Investigation Myocardial Jeopardy Index; 
ESA, endocardial surface area; STIR, T2-short tau inversion recovery; LAD, left anterior 
descending artery  
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5.3.7. Intra-observer and Inter-observer variability of 3-Slice STIR 
imaging 
 
3-slice STIR imaging showed a low inter-observer variability. For the Bland-
Altman plot, the 95% limits of agreement (−5.3%, 3.6%) contained 95.1% 
(78/82) of the difference scores.  The mean bias of the measurements between 
observers was 0.08%, and the maximum and minimum difference was 8.0% and -
7.0% respectively (Figure 5.7). 
 
Figure 5.7. Linear regression and Bland-Altman plot for the interobserver variably for 3-
slice group.  
Data presented shows a significant positive correlation between the observer A and observer B 




The 10-slice STIR imaging showed low inter-observer variability. For the Bland-
Altman plot, the 95% limits of agreement (−4.68%, 4.04%) contained 94.1% 
(80/85) of the difference scores.  The mean bias of the measurements between 
observers was -0.32%, and the maximum and minimum difference was 5.0% and 
-5.6% respectively (Figure 5.8). 
 
Figure 5.8. Linear regression and Bland-Altman plot for the interobserver variably for 10-
slice group.  
Data presented shows a significant positive correlation between the observer A and observer B 






1. The 3-slice AAR technique correlates well with the traditional 10-12 Slice 
AAR method 
2. The 3-Slice AAR technique correlates well with angiographic AAR 
quantification methods (BARI and APPROACH)  
3. The 3-slice AAR technique significantly reduces the acquisition time and 
hence leads to increased efficiency a CMR department and decreases 
patient exposure to the scan  
4. The 3-slice AAR technique requires less time for analysis compared to the 
standard 10-slice method.  In both the clinical and research setting this 
protocol could result in quicker analysis times without the loss of clinical 
information  
5. The 3-slice AAR technique only images levels within the LV unlike the 10-
12 slice AAR technique which can on occasion not image the LV.  This 
reduced imaging technique stops any risk of a sequence not including the 
LV and wasting valuable time for both the patients and clinicians  













This thesis examined the use of BMNC as a strategy to improve myocardial 
function after successful primary PCI applied within the standard length of 
hospital stay post AMI.  Even with advances in the treatment of AMI a significant 
number of patients are left with substantial left ventricular impairment, HF and 
its associated morbidity and mortality.  Few therapies have the ability to 
regenerate damaged myocardium or improve myocardial function after AMI and 
therefore BMNC are an appealing proposition.  
 
The novel strategy of using the bodies own cells to regenerate the heart early 
post AMI is a key aim of regenerative medicine in CVD.  Since early preclinical 
models demonstrated the potential benefit of early stem cell therapy after AMI 
the translation to trials in man have been rapid however all of these clinical trials 
have performed stem cell infusions over 24 hours post-coronary reperfusion with 
successful primary PCI (Table 1.3). 
 
This thesis suggests that the intra-coronary infusion of BMNC is safe and 
tolerable in patients who have undergone infusion within 24 hours post 
successful primary PCI for AMI.  Furthermore in patients who received BMNC 
within 24 hours of primary PCI it may improve myocardial salvage, and decrease 




This thesis also assesses the potential paracrine effect associated with BMNC 
infusion and the relationship to the improvements seen following AMI. The data 
presented proposes that BMNC infusion may have a direct effect on circulating 
cytokines that results in these beneficial effects.  Additionally, this thesis assesses 
the potential role of a novel CMR imaging sequence (3-slice T2-STIR) for the 
assessment of the AAR following AMI compared to the standard 10-slice T2-STIR 
imaging approach. This sequence appears to correlate well with standard 
techniques with the added benefit of shorter acquisition and analysis times.   
 
Three key aims were set out by this thesis, which will be discussed in detail 
during this discussion. 
 
6.2. To assess whether the intracoronary infusion of autologous 
bone marrow derived progenitor cells within 24 hours of 
primary PCI following an anterior AMI is safe and feasible 
 
A major concern regarding the early infusion of BMNC after AMI is the risk of 
bleeding complications and arrhythmias.  Within the first 24 hours post AMI it is 
well established that patients are at a greater risk of developing cardiac 
arrhythmias, be it related to reperfusion or scar related mechanism(Manolis 
2014).   The early infusion of BMNC may potentiate these events with previous 
clinical trials in humans illustrating the safety and feasibility of IC stem cell 




Performing BMA within 24 hours of primary PCI has the possibility of resulting in 
complications, such as bleeding secondary to anticoagulation and infection.  
Documented complications associated with BMA or bone marrow trephine have 
been well reported by the British Society for Haematology in the annual survey of 
biopsy-associated morbidity and mortality.  It is usually a relatively safe 
procedure, with only 2 reported mortalities and serious adverse events in a study 
of 55,000 patients (<0.05% of procedures) (Bain 2003).   
 
This thesis demonstrates that BMA performed within 24 hours of primary PCI 
was not associated with any significant serious events with only minor 
complications reported. There were a small number of patients who had 
complications during aspiration, with 5 non-critical events in total reported. This 
low number of events would reflect a similarity with patients who undergo BMA 
suffering from haematological disorders (Malempati, Joshi et al. 2009).   
 
6.2.1. No adverse events were demonstrated with the re-infusion 
procedure 
 
The IC infusion procedures appeared safe and were not associated with any 
adverse effects in patients within the whole trial population.  The placebo or 
BMNC infusion procedure occurred after a median of 564.5 minutes following 
AMI and were in general well tolerated without major complications related to 
the reinfusion procedure.  However one patient in both groups had intra-infusion 
PCI performed due to distal stent dissection prior to infusion, with a small 
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number of patients suffering chest pain with ECG changes.  Importantly there was 
no evidence of further myocardial damage occurred during the IC infusion 
procedure as no significant changes in Troponin or CK were seen in either group.  
 
The low number of adverse events reported in this thesis is reflected by previous 
studies in this field.  The early studies such as BOOST and REPAIR AMI failed to 
fully describe events during BMA and stem cell infusion (Wollert, Meyer et al. 
2004, Schachinger, Erbs et al. 2006).  The trial with the most descriptive event 
profile was ASTAMI (Beitnes, Hopp et al. 2009), which reflects well with my 
results.  In ASTAMI 1 patient had a significant complication with contaminated 
infusate requiring IV antibiotics.  Of particular note is the number of patients who 
complained of chest pain or had ECG changes during coronary balloon occlusion.   
In ASTAMI 72% of patients had chest pain and 77% of patient had ST changes 
during the stem cell infusion procedure.  Our data showed that only a small 
number of patients developed chest pain (4%) or ECG changes (6%) during the 
re-infusion procedure. The potential explanation for this substantial difference 
between the two trials is the time between MI and stem cell infusion.  Within the 
ASTAMI trial the infusion time point was around 6 days in comparison to under 1 
day in this thesis.  This difference seen in ischaemic changes during coronary 
occlusion could possibly be due to the shorter interval after primary PCI and 
BMNC infusion due to post ischaemic conditioning (Vinten-Johansen, Yellon et al. 
2005).  This low rate of complications compares well to other published studies 
and shows that BMA and BMNC infusion in the early time-period post primary 
PCI is safe and better tolerated compared to later coronary re-infusion 




6.2.2. The reinfusion of BMNC is logistically feasible following 
primary PCI 
 
During the running of the trial, logistical issues with respect to the time from 
BMA to BMNC infusion not previously described in other trials were encountered. 
All recruiting centres were run within busy cardiovascular interventional units 
treating patients with AMI.  Although in some cases the infusate was ready within 
the appropriate time-period there were delays due to the availability of 
angiography laboratories. Within this thesis the median time from aspiration to 
reinfusion was 372 minutes, however the longest time from aspiration to infusion 
was 713 minutes and this delay was due to unavailability of a free angiography 
laboratory.  There were six patients who had a delayed BMNC infusion due to lab 
unavailability if these patients were removed from analysis the median time from 
aspiration to reinfusion was 314 minutes.  Previously described trials such as 
BOOST and ASTAMI had a planned aspiration and infusion time making time 
delays less likely. 
 
Although BMNC infusion is feasible in the acute phase there are relative 
drawbacks.  The biggest issue with the early time point is the difficulty in 
planning for the procedures.  Throughout medical practice planned elective 
therapies have a much lower event rate than those undergoing emergency 
therapies (Tottrup, Erichsen et al. 2012).  The possible risk of complications due 
to unplanned or rapid turnaround after primary PCI could in theory result in 
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increased events, however this did not occur.  The lack of difference between the 
event profile between the acute and the delayed time point trials, could suggest 
that the skillset within the recruiting centers and the safety profile of the infused 
agent counteracts the possibility for acute complications.   
 
6.2.3. The lack of adverse events seen with BMNC therapy  
 
This thesis was successful in demonstrating that the use of BMNC in the acute 
phase was both safe and feasible.  When assessing the risk of MACE after BMNC 
therapy in patients who had undergone primary PCI for an AMI this thesis failed 
to demonstrate any difference.  Within the 1-year follow up there were similar 
event profiles of 15.4% of patients in the control and 15.9% of patients in the 
BMNC arm suffering from a MACE.  The possible reasons for the similar event 
profile are probably multifactorial.  One of the main reasons is that this trial was 
only powered to demonstrate an imaging end-point, the numbers required to 
assess a difference in MACE are much larger than the numbers assessed here.  In 
addition there was a wide range of baseline LVEF in this thesis from 25% to 68% 
meaning that patients with higher LVEF are at a lower risk of MACE (Wang, Xie et 
al. 2011).   
 
To date no study has been able to demonstrate any difference in MACE due to the 
low numbers.  Previous positive meta analysis in regards to LVEF changes have 
failed to demonstrate change in clinical outcomes such as MACE (Clifford, Fisher 
et al. 2012).  To address this final potential benefit of BMNC therapy after an AMI 
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a large-scale trial is needed.  The ongoing BAMI trial (BAMI, http://www.bami-
fp7.eu) currently recruiting throughout Europe is the first Phase III trial designed 
to do assess BMNC therapy and all cause mortality by enrolling 3000 participants 
with all-cause mortality at 2 years as the primary endpoint.  
 
6.3. The administration of autologous bone marrow derived 
progenitor cells does not lead to a significant improvement in 
LVEF compared to standard medical therapy alone.  
 
LV function is the most important factor that affects mortality post AMI.  The 
rapid restoration of epicardial flow following a period of coronary occlusion 
results in the preservation of cardiomyocyte integrity and function.  In addition to 
cardiomyocyte damage caused by the period of hypoxia further damage caused 
by reperfusion injury leads to further LV dysfunction (Yellon and Hausenloy 
2007).  The proposed early infusion of BMNC could therefore possibly result in a 
decrease in the damage caused by both hypoxia and reperfusion injury.   In 
Chapter 2, it was shown that the early infusion of BMNC resulted in a greater 
improvement in LVEF compared to patients who received placebo.  After primary 
PCI both groups saw significant improvements in LVEF over time.  There was 
however a signal that BMNC therapy resulted in a greater improvement, as at 1 
year there was a 2.24% greater improvement in LVEF compared to the control 




In addition to the improvement in LVEF there was a signal that the BMNC group 
had a reduction in MVO compared to the control group.  Previous animal studies 
have demonstrated the reduction of MVO with the early allogeneic cardiosphere 
derived cells reducing the amount of MVO and infarct size (Kanazawa, Tseliou et 
al. 2015).  This finding with the improvement in LVEF in REGENERATE-AMI may 
support the benefit of cell therapy however the with not all patients assessed this 
could result in bias.  
 
Previous trials have demonstrated a greater improvement with BMNC post AMI 
in patients with greater LV impairment (Schachinger, Erbs et al. 2006).  In a sub-
group analysis of patients with baseline LVEF less than 45% there was a greater 
trend for improvement in LVEF at 1 year.  These findings are not unsurprising, 
for example if you take a patient who has severely impaired LVEF with an 
ejection fraction of 30%, an improvement in LVEF of 6% represents a 20% 
improvement where as a 6% improvement in a patient with mild LVEF 
impairment (e.g. %) will only represent a 11% improvement in LVEF.  It is highly 
unlikely that patients with mild to preserved LVEF will demonstrate any 
additional benefit with BMNC therapy in comparison to standard medical therapy 
due to the inability to measure these small improvements.   
 
The findings of this thesis are consistent with previous meta-analyses and would 
suggest that the trend seen within the BMNC group is likely to be real but 
underpowered.  This thesis was powered for the primary end point of change in 
LVEF determined by CMR at 1 year compared to baseline.  The sample size was 
calculated using a two-sided unpaired t-test to detect an improvement in LVEF of 
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6%, powered at 90% with a significance of 5% with a standard deviation of 
approximately 8% based on previous studies (Wollert, Meyer et al. 2004, 
Janssens, Dubois et al. 2006).  However as previously described myocardial 
stunning plays a significant role in LVEF impairment after AMI, and therefore in 
the control group you would expect to see an improvement of 1 to 3%(Surder, 
Schwitter et al. 2010).  Therefore this would imply the difference in LVEF 
improvement from baseline to 1 year would have been δ=3%.  Assuming that the 
SD would have been stable at 8% as previously described and using the same 
power calculation with the calculated difference the required study population 
would have been 300 patients.  The original power calculations for this thesis 
would suggest a δ=6%, requiring a near 9% increase in the BMNC therapy arm, 
an improvement which has not been described before.  
 
6.3.1. Highlighting the predictive value of animal models 
 
The lack of benefit of IC BMNC therapy within the first 24 hours after AMI is not 
entirely unexpected.  This thesis is based on previous pre-clinical models that 
assessed the early re-infusion showing beneficial effects of BMNC therapy.  In 
these studies by Orlic et al the animal mice models had coronary ligation and then 
direct myocardial injections (Orlic, Kajstura et al. 2001).  This study induced 
significant myocardial damage and impairment on LV function.  However there 
have been significant short falls in the translation into human clinical trials.  
Although some of these trials are well designed it is difficult for true similarities 
between human and animals to be observed.  Two major drawbacks with the 
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translation between the two is the technique of inducing MI and the methods 
assessing improvement.  The majority of animal models have used the coronary 
ligation technique (Shao, Redfors et al. 2013) resulting in a mechanical occlusion 
of the artery requiring a thoracotomy potentially resulting in other myocardial 
damage that does not occur in AMI. The assessment of LVEF in animals is fraught 
with difficulties especially as the resting heart rate of rats are between 330 and 
480 beats per minute resulting in possible difficulty in true LVEF assessment.  
This is especially true with echocardiography, which was used in early animal 
models. The use of CMR in human models and beta blockade results in a slower 
resting heart rate and better LVEF assessment that makes the methodology of the 
human trials superior to animal models.   
 
All previous studies using stem cell infusions in AMI have performed these 
greater than 24 hours post PCI where LV assessment can be performed with 
greater accuracy, and removes the potential overestimation of LV dysfunction 
secondary to myocardial stunning.   In this thesis the mean baseline LV function 
was 47.51 ± 9.18%, which by definition is only mild LV impairment (Lang, Bierig 
et al. 2005).  The baseline LV function in this thesis was similar in comparison to 
the majority of other studies, in BOOST and REPAIR-AMI where the baseline 
LVEF in the BMNC group were 50.0% ± 10.0% and 46.9% ± 10.4% respectively 
(Wollert, Meyer et al. 2004, Schachinger, Erbs et al. 2006).  In a previous paper by 
Schächinger et al it was demonstrated that with greater LV dysfunction greater 
and more significant improvement is seen (Schächinger, Assmus et al. 2009) 
meaning that the greater the LV dysfunction the greater the need for 
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improvement and consequently with better LV function the less effect the 
therapy is going to be.   
 
In this thesis the CMR imaging time point of 2 to 3 days after stem cell infusion, 
means that a ‘true’ baseline LVEF assessment was never performed using CMR. 
The use of regional wall motion abnormality on LV ventriculography after AMI 
for the inclusion criteria could have resulted in higher than expected LVEF after 
AMI particularly in a LAD cohort of patients.  One of the issues with LV 
ventriculography is that the single view focuses on the anterior and inferior walls 
meaning that when ventricular measurements are performed overestimation of 
dysfunction could be a factor.  In addition post AMI myocardial stunning 
generally shows regional wall motion abnormalities not necessarily be present at 
day 3 (Futterman and Lemberg 2000).   
 
The infusion of progenitor cells into the recently infarcted myocardium also has 
its limitations.  In the ischaemic myocardium there is an increase in free radicals, 
cellular osmolality and local circulating neutrophils factors which all may affect 
stem cell migration. Previous animal studies have demonstrated that stem cell 
transfer has poor survival and cardiac retention with the intra-arterial infusion of 
MSCs found to mainly arrest in the pre-capillary level with only 14% of 
progenitor cells surviving the micro-embolisation induced ischaemia by 72 hours 
(Toma, Wagner et al. 2009).   
 
In a large anterior MI where there is significant LV dysfunction due to the loss of 
nearly 1 billion cardiomyocytes (Robey, Saiget et al. 2008), the role of early 
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BMNC therapy role to replace or repair these cells is the main aspiration.  The 
previously described animal models by Olic et al used transmyocardial injection 
shortly after coronary ligation, this method may not translate into the clinical 
setting.  In addition the majority of the animal models have used small models 
such as rats, rather than large animal models that could represent a better 
predictor in humans than rodents.  
 
 
6.4. Reduction in infarct size with the administration of 
autologous bone marrow derived stem 
 
The results of this thesis showed that the infusion of BMNC resulted in a 
reduction in myocardial infarct size (as assessed by CMR).  The mechanism for 
this is unknown and it could be related to a reduction in I/R injury as previously 
postulated or related to the specific trial population.  This section will consider 
the potential role BMNC therapy has within I/R as well as looking at other 
possible causes. 
 
I/R results in an immune and metabolic cascade resulting in further myocardial 
damage. BMNC therapy has been shown to demonstrate both an anti-
inflammatory, and immunomodulatory effect (Van Linthout, Stamm et al. 2011).  
Previous trials using earlier time points have demonstrated decreased infarct size 
compared to control without significant differences in improvement of LVEF 
(Janssens, Dubois et al. 2006).  In addition to BMNC therapy there have been 
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multiple trials assessing novel therapies in the prevention of I/R.  These trials 
have reflected similar results that were seen in this thesis with improvement in 
infarct size and improved myocardial salvage (Jones, Pellaton et al. 2015).   
 
A challenge with the early infusion time point used in this thesis is that there is a 
potential for significant loss of infused progenitor cells due to free-radicle 
interaction.  It is well recognized that oxidants and free radicals play a significant 
role in I/R (Zweier and Talukder 2006), and the use of progenitor cells in the 
early setting may result in an interaction with the free radicals decreasing the 
potential damage caused and promote repair, which may translate in this thesis 
as a decreased infarct size. 
 
Patients within the BMNC groups had longer symptom to reperfusion times 
compared to the control group, suggesting larger potential infarct sizes with 
reduced potential for myocardial salvage.  This however was not observed in the 
BMNC group compared to the control suggesting a potential effect of the BMNC 
therapy. A key factor that may have played a role in the reduction of infarct size is 
the relationship between reperfusion and reinfusion.  The BMNC group had a 
shorter interval from reperfusion to the reinfusion procedure, suggesting 
possible beneficial effect of early infusion. 
 
Within the BMNC group there was a nearly 50% reduction in the release of serum 
troponin compared to the control group however this did not reach statistical 
significance.  The CMR data supported a potential reduction in infarct size 
however its important to highlight that the troponin values were taken at varied 
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time-points both before and after cell therapy making the data difficult to 
interpret. The relationship between troponin and infarct size is well documented 
and the signal seen within the BMNC group could therefore represent smaller 
infarct size due to other factors such as ischaemia time rather than any direct 
BMNC effect. 
 
The design of the REGENERATE-AMI study however was not to ascertain the true 
mechanism of BMNC therapy rather than its impact on clinical outcomes 
therefore this stands as a hypothesis generating study.  
 
6.4.1. Comparison with other studies using bone marrow derived 
progenitor cells in myocardial infarction 
 
The results in this thesis are consistent with other published studies including 
those most similar to our trial design. Janssens and colleagues also demonstrated 
no benefit of IC infusion of BMNC on LVEF or infarct size and used the closest 
time point of 24 hours of all other studies assessing the IC infusion of BMNC post 
AMI in comparison to this thesis (Janssens, Dubois et al. 2006). There are 
similarities between this thesis and the study by Janssens and colleagues; both 
with respect to patient numbers (n vs n), patient baseline LVEF taken over 2 days 
post infusion and similar baseline LVEF (47.51 ± 9.18% in this study vs 46.9% ± 
8.2 in Janssens et al).  This study also demonstrated significantly smaller infarct 
size coupled with a greater MSI in the BMNC group at baseline compared to the 
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placebo group a finding which is consistent with other early phase I/II studies 
(Janssens, Dubois et al. 2006, Schachinger, Erbs et al. 2006). 
 
There are differences between this study and those that found a significant 
improvement in LVEF (Assmus, Schachinger et al. 2002, Wollert, Meyer et al. 
2004, Schachinger, Erbs et al. 2006).  The largest scale studies assessing the effect 
of BMNC infusion by Schächinger and colleagues assessed a total of 204 patients 
presenting with AMI who received either IC infusion of BMNC (n = 101) or 
matching placebo (n = 103) with a primary endpoint of change in LVEF assessed 
by LV angiography.  Although the improvement seen in LVEF was similar to that 
seen in our study (5.07 ± 7.27% in this study vs 5.5 ± 7.3% in Schächinger et al), 
the use of LV angiography could possible result in over estimation of LV 
improvement compared to the advanced imaging techniques that have been used 
in negative trials (Traverse, Henry et al. 2011, Traverse, Henry et al. 2012). 
 
The majority of trials showing favorable results have used similar BMNC 
preparation methods.  The Ficoll–Hypaque centrifugation method for BMNC 
isolation that was designed by Schächinger et al were used in this study and 
REPAIR-AMI (Schachinger, Assmus et al. 2004).  The use of closed automated 
Ficoll cell processing system (Aktas, Radke et al. 2008) has been used in multiple 
trials that have failed to show any benefit in BMNC therapy (Traverse, Henry et al. 
2011, Traverse, Henry et al. 2012). The similarity in cell preparation between our 
study and positive studies suggests that cell processing is not the factor 




As previously stated this study is the first to assess the safety of IC BMNC infusion 
within 24 hours post AMI.  It is important to note that the safety seen in this study 
is similar to those seen in other studies despite the early re-infusion. These 
results support the safety and feasibility of early reinfusion BMNC with a time 
point under 12 hours (median – within 10 hours).  The concerns over early 
infusions have been a major reason why the majority of BMNC studies have used 
a protracted time point.  In this study we were able to show that patients who 
underwent early BMA had few bleeding complications or arrhythmias during 
reinfusion.  
 
It is possible that the lack of benefit seen in this study reflects the improvement in 
standard medical therapy for AMI.  The majority of the positive trials occurred 
between 2002 to 2006 whereas the development of improved primary PCI 
services and the introduction of new antiplatelet medications/increased use of 
drug eluting stents (DES) could have lead to a potential differences in standard 
care and the reason for different outcomes compared to our study patients 




6.5. Mechanisms of changes in LV function, dimension and scar 
burden in patients treated with early intracoronary infusion of 
BMNC  
 
The second exploratory aim of this thesis was to investigate if changes in LV 
function and infarct size after BMNC infusion were linked to the relase of 
circulating cytokines.  There has been evidence showing that paracrine factors 
released by ASCs particularly MSCs after BMNC infusion play a significant role in 
the regenerative process (Caplan and Dennis 2006).  Pro-inflammatory cytokines 
such as TNF-α and IL-6 are not usually expressed in the normal myocardium and 
are up-regulated during myocardial ischaemia (Kapadia, Lee et al. 1995, Deten, 
Volz et al. 2002).  The up-regulation of cytokines and subsequent return to 
baseline is dependent on the size of infarct. With larger infarcts a sustained up-
regulation can be seen or a prolonged second wave of cytokine expression that 
can correspond to chronic remodeling (Ono, Matsumori et al. 1998).  The 
cytokine up-regulation after MI precedes the increase in MMP and BNP (Deten, 
Volz et al. 2002).  The mechanistic relationship has been demonstrated between 
the expression of myocardial MMP and LV remodeling (Spinale 2007). 
 
In chapter 4, it was demonstrated that baseline cytokine levels were similar 
between treatment groups aside from a significantly lower serum circulating 
MMP-9 level seen in patients who received BMNC therapy.   However this 
difference was seen at baseline prior to cell infusion and therefore should not be 
affected by this therapy.  This difference at baseline although not connected to 
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BMNC therapy could be related to the difference in baseline LVEF seen between 
the groups.   
 
Although categorical evidence that paracrine factors exert direct effects on LVEF 
and infarct size, there were trends seen that could suggest possible relationships 
between certain paracrine factors and the improvements seen.  Elevated levels of 
TNF-α after MI have been associated with increased risk for recurrent coronary 
events (Ridker, Rifai et al. 2000). Smaller increases in TNF-α levels seen over time 
in the BMNC therapy group compared to control suggests that BMNC therapy 
reduced the up-regulation of TNF-α and subsequently reduced negative 
remodeling.   
 
Increased serum circulating VEGF levels have been associated with improved 
angiogenesis (Deuse, Peter et al. 2009).  We showed a trend to a difference in 
VEGF levels over 12 months between groups.  The increase of 87.70 ± 569.4 
pg/ml seen in the BMNC group compared to a large decrease seen in the control 
group of 303.6 ± 661.1 pg/ml.  These results may reflect changes seen in the 
improved LVEF and decreased infarct size at baseline in the BMNC group. VEGF 
has been known to assert a cardioprotective influence by increasing the 
ischaemic tolerance of cardiomyocytes an effect which is reflected by the results 
seen in the BMNC group and would suggest a beneficial effect of BMNC therapy 
within the early infusion window.   
 
G-CSF has been shown to induce myocardial regeneration by promotion of local 
stem cell activation (Orlic, Kajstura et al. 2001).  In both groups there was an 
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increase in circulating G-CSF concentrations although this change was smaller in 
the BMNC group (17.59 ± 70.92 vs. 101.10 ± 288.40 in the control).  A similar 
change was seen in in IL-6 levels, a cytokine known to play an important role in 
the inflammatory process after an ischaemic event with elevated levels 
associated with increased risk of adverse events and LV impairment (Gabriel, 
Martinsson et al. 2004).  The effects of these two paracrine factors on LV 
remodeling and patient outcome are not fully reflected in the results seen in this 
thesis.  Patients with a greater level of G-CSF would be expected to have 
improved LVEF, which was not seen.  This similar pattern was seen with IL-6 
with a smaller decrease seen in the BMNC group (-54.73 ± 221.4 vs -12.94 ± 
195.1, p=0.5531). 
 
The reason for the lack of association seen between cytokines and either LVEF 
improvement or stem cell therapy could be related to the use of peripheral blood 
samples for cytokine analysis.  The proposed mechanism of IC BMNC therapy 
suggests that local increases in paracrine factors after infusion results in positive 
LV remodeling and cardioprotection.  To detect significant difference in cytokine 
concentrations in the peripheral blood would require a monumental local 
increase in cytokine concentration.  The optimum method for measuring the local 
cardiac concentrations of cytokines would have been ideally to use either 
coronary artery or coronary sinus blood sampling.  
 
This sub-study failed to demonstrate any significant relationship between the 
outcomes within the REGENERATE-AMI study and measured cytokines.  The 
minimal signal seen within the population could be related to sample selection 
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rather than a true mechanistic effect.   In future studies the assessment of 
cytokines therapy should be a significant focus to ascertain the mechanistic effect 
of BMNC therapy.  
 
6.6. Optimising Imaging End Points in Clinical Trials  
 
In Chapter 1, it was discussed that the primary endpoint in the majority of BMNC 
trials is the assessment of LVEF and that there are several ways to do this. Early 
clinical trials used a mixture of non-invasive and invasive imaging modalities.  
For the majority of trials the use of simple 2D echocardiography has been an 
essential tool for the assessment of LV function in the acute setting.  One of the 
greatest issues with this imaging modality is the low reproducibility and 
inaccuracy that can result in foreshortened views of the LV.  The development of 
nuclear imaging, CT and CMR has given greater information regarding the effect 
of BMNC therapy after AMI, although these modalities still have drawbacks.   
 
In the majority of early trials, LVEF assessment was performed using either 
echocardiography or LV angiography.  The use of invasive LV angiography has 
been used regularly in AMI patients, as LV assessment can be performed within 
minutes after primary PCI.   The use of LV angiography has been used in 
TOPCARE-AMI (Assmus, Schachinger et al. 2002) and REPAIR-AMI (Schachinger, 
Erbs et al. 2006) and both have demonstrated positive effects of BMNC therapy 
on changes in LVEF over time.  As previously discussed LV angiography uses a 
single 2D image to assess LV function and in patients who have infarction 
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effecting the lateral or septal walls the LVEF maybe underestimated.  In addition 
the requirement for a stable cardiac rate is essential for LV assessment with LV 
angiography, after a premature ventricular contraction the LVEF can be over 
estimated.   
 
In chapter 1.7.2, three different imaging modalities were used to assess LVEF at 
different time points.  Echocardiography and LV angiography were used in the 
first 24 hours and CMR performed 3 days post primary PCI.  The use of these 
different modalities was included to historically compare with previous positive 
trials.  The use of LV angiography is now thought to be outdated and in theory has 
a small but significant risk to the patient. Although LV angiography was not 
performed at 6 months in all patients, the safety data seen is comparable to that 
seen in REPAIR-AMI (Schachinger, Erbs et al. 2006).  Echocardiography was 
performed at multiple time points and was the most non-invasive imaging 
modality used.  As previously stated, the issue with echocardiography is the 
skillset needed to acquire a clear image that can be analysed for LVEF 
assessment.  Since CMR has become more readily available, its use has been 
common within BMNC studies with the added benefit that it can assess more than 
just LVEF.  
 
In chapter 3, it was shown that the three imaging modalities were safe to use and 
well tolerated in most patients.  These imaging modalities demonstrated a very 
strong correlation between the assessment of LVEF with CMR and 
echocardiography, although significantly only a moderate correlation was 
observed between the LVEF assessed with LV angiography and by 
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echocardiography.  Due to the improvement in image quality of CMR and the 
ability to assess more than LVEF it has become the gold standard imaging 
modality in stem cell trials.   
 
Since the development of infarct analysis by positron emission tomography CT or 
late gadolinium enhancement CMR the possibility for a new cardiovascular trial 
endpoint has been assessed.  In addition newer imaging modalities provide the 
ability to give mechanistic insights into the processes occurring with BMNC 
therapy.   Questions have now been raised about the best imaging end point for 
phase II stem cell trials.   
 
The assessment of infarct size is now widely used when CMR is performed, and as 
with this thesis and previous studies (Janssens, Dubois et al. 2006).  The potential 
benefit of using infarct size or myocardial salvage in an investigational medicinal 
product (IMP) AMI study is the reduced requirement for multiple imaging 
assessments.  This potential for decreased follow up times rather than the 
protracted study designs that requires an assessment in changes in LVEF may 
benefit these trials so that they are both cheaper and more product in reaching a 
satisfactory imaging end point.   
 
6.7. To assess the feasibility of 3-slice T2-STIR short axis stack 
imaging compared to conventional 10-slice T2-STIR short axis 




The assessment of myocardial oedema by CMR using T2-STIR has become a 
popular technique for the quantification of AAR.  This study demonstrated that 3-
slice oedema CMR AAR quantification remains accurate for the detection of 
myocardial oedema after AMI when compared to conventional 10-slice oedema 
CMR with similar inter-observer variability, however with quicker acquisition 
and analysis time compared to the conventional 10-slice approach without loss of 
clinical information.   
 
The use of T2-STIR imaging remains popular for assessing myocardial oedema 
(h-Ici, Ridgway et al. 2012) and the AAR after AMI, with studies showing the 
superiority of the clinical use of oedema CMR imaging in both AMI and chronic 
heart disease (Friedrich, Abdel-Aty et al. 2008, Abdel-Aty, Cocker et al. 2009).  
The benefit of oedema CMR assessment over alternative AAR assessment such as 
single-photon emission computed tomography (SPECT) is the lack of ionising 
radiation or the need for tracer administration.  The majority of these previous 
studies have used 10-12 slice short axis stacks covering the whole left ventricle, 
however due to the need for adequate breath holding and the possibility of 
artifact the overall image acquisition time is long for the 10-slice STIR imaging 
technique.  The benefit of the 3-slice T2-STIR sequences in comparison to 10-slice 
T2-STIR sequencing is that it has a quicker acquisition time.  The shorter 
acquisition time of under 2 minutes 30 seconds may have some clinical benefit 
with the use for only 3 breath holds in comparison to the 10 without loss of 
required clinical information is of benefit especially in patients who have issues 




Previous studies have demonstrated the suitability of 3-slice imaging in the 
assessment of myocardial scar as well as LV volumes (Kuoy, Nguyen et al. 2014). 
In Chapter 5, it was tested whether or not AAR can also be assessed using a 3-
slice technique, where it was demonstrated that the technique is comparable to 
the conventional 10-slice approach.  This 3-slice approach is not only beneficial to 
the patient but also to the operator with shorter image interpretation times. 
Additionally shorter scan times and image analysis times can have important cost 
implications for scans performed for research with AAR an increasingly 
important assessment made when testing potential cardioprotective therapies.     
 
6.7.1. To assess the feasibility of 3 slice T2-STIR short axis stack 
imaging for assessing myocardial oedema and the correlation to 
area at risk compared to angiographic risk scores (BARI and 
APPROACH) in patients following AMI. 
 
The assessment of AAR after AMI has become important as it has allowed for 
accurate assessment of myocardial salvage that occurs after reperfusion.  In this 
thesis BARI and APPROACH scores correlated well with each other in their 
assessment of AAR.  Previous animal models have shown that T2-STIR weighted 
imaging is able to delineate the AAR (Aletras, Tilak et al. 2006). Since its early 
development within cardiovascular imaging T2-STIR sequencing has become 
firmly established for the visualisation and quantification of myocardial oedema 
in patients post AMI (Simonetti, Finn et al. 1996, Abdel-Aty, Zagrosek et al. 2004).  
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Since its introduction T2-STIR sequencing quality has improved resulting in 
better image quality and decreased acquisition time.  
 
Angiographic risk scores such as BARI and APPROACH scores were developed for 
prognostic purposes (Graham, Faris et al. 2001).  In this study we over estimated 
the AAR in our patient with the angiographic risk scoring in comparison to T2-
STIR AAR quantifications.  Although there was a significant but low correlation 
between T2-stir imaging and angiographic risk scores.  This is probably in part to 
the short falls in angiographic risk scoring.  The angiographic scoring system 
especially with LAD infarcts rely on TIMI 0 flow, however there was a high 
percentage of patients who had TIMI >0 flow.     
 
6.7.2. The reproducibility of 3-slice T2 STIR imaging is similar to 
10-slice imaging 
 
Over the past decade the use of oedema quantification has increased and is now 
an important part of outcome assessment after AMI (Friedrich 2010).  As 
previously stated the CMR imaging provides both a functional and structural 
assessment of the heart.  With oedema quantification the issues about quality of 
the images secondary to blood pooling has been raised.  The use of semi-
automated quantification process has led to quicker analysis of these images 
without loss of clinical information (Sjogren, Ubachs et al. 2012).  In this thesis, 
there was a low degree of variability in the different image techniques for 
quantitative assessment of oedema.  The oedema quantification from either the 3-
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slice or 10-slice sequences of T2-STIR correlated well with each other and 
different infarct zones.  Of note, the region of infarct correlated better with LAD 
artery territory infarctions.   
 
Inspection of intra-observer performance revealed an overall high degree of 
correlation for both 3-slice technique (r=0.9638, p<0.0001) and 10-slice 
technique (r=0.9734, p<0.0001), with a slightly stronger association seen in the 
10-slice technique.  The exceptionally low intra-observer and inter-observer 
variability for both imaging protocols and the reproducibility was similar to 
previous studies assessing 3-slice techniques for LVEF assessment (Nguyen, Kuoy 
et al. 2015).  
 
 213 
6.7.3. 3-slice T2 STIR imaging technique reduces acquisition time 
and analysis time without loss of clinical information  
 
The introduction of automated and semi-automated techniques for CMR analyses 
has improved the reproducibility and the speed of analysis.  As previously stated 
majority of SAX have used 10-12 slices to cut at 1 cm intervals along the LV.  
When analyzing these sequences the length of analysis time is dependent on the 
number of images that are assessed.  With the 10-12 slice technique some of the 
slices do not fall within the LV or have a mixture of LV and non –LV mass, which 
require close manual exclusions.   
 
It is easy to see how the reduction of SAX slices to 3-slice reduces both acquisition 
and analysis time.  In general it requires approximately 10 seconds per 
acquisition slice, and 14 seconds per analysis slice, with similar timings per slice 
between the two groups.  This study has shown that with this reduction in time 
there is no loss of clinical information.  An issue that is present with 10-12 slice 
techniques is that some segments are cut through the mitral and LV outflow tract 
(LVOT).  These areas can be issues when undergoing analysis; the need for close 
analysis and manual exclusion could result abnormal estimations of oedema 
mass.  
 
A particular issue with T2 STIR imaging is the false signal that occurs in area of 
blood pooling especially in patients with poor LV function (Higgins, Lanzer et al. 
1984).  In the apical segments of the LV there is increased blood pooling causing 
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greater sub-endocardial bright artefact during myocardial quantification.  The 
imaging technique for 10-slice acquisition takes single contiguous 1 cm slices 
from mid atria to true apex, whereas the 3-slice acquisition takes a slice in the 
basal, mid and apical segment of the LV therefore reducing true apical blood 
pooling.  The observer variability was similar in the 3-slice and 10-slice 
acquisition groups.  This implies that the use of 3-slice acquisition imaging may 
not result in the loss of important clinical information and may reduce the issue 
of increased signal from pooled blood in comparison to 10-slice acquisition.  The 
use of 3-slice technique would in theory reduce all these possible artifacts.  The 3-
slice technique removes the LVOT and apical slices due to the SAX acquisition 
process and with this technique as we have shown in this study does not result in 
loss of clinical information.  
 
6.7.4. Translation of 3-slice T2 STIR to clinical practice  
 
The benefit in the clinical setting of the 3-slice T2 STIR technique in comparison 
to the standard 10-slice oedema CMR is a quicker acquisition time.  The average 
shorter acquisition time of just less than 2 minutes 30 seconds may have some 
clinical benefit.   The use of only 3 breath holds in comparison to 10 or 12 without 
the loss of clinical information is of benefit especially in patients who have issues 
including claustrophobia or who are unable to lie flat for extended periods.  
These factors are common in patients who have recently suffered from AMI 




In addition the timing for analysis was significantly shorter within the 3-slice 
approach, which may be of benefit when multiple analysis are required reducing 
analysis times in large quantity analysis.   
 
6.8. The Potential Pitfalls of Cell Therapy 
 
Section 1.6.2. highlights that when considering the most appropriate stem cell 
therapy multiple factors can effect the beneficial effect of this therapy.  Within 
this quandary are three major deciding factors, timing of infusion, route of 
infusion and cell type used. 
 
Despite many positive results in both small non randomised and large 
randomised trials many in vivo animal studies have demonstrated that 90% of 
cells are not viable within hours of infusion (Hill, Dick et al. 2003).  In addition 
Hou et al. were able to demonstrate that within a couple of hours only 2.6%, 
3.2%, and 11% of the intracoronary, interstitial retrograde transvenously, and 
direct intramyocardial injected cells respectively were retained within the 
myocardium (Hou, Youssef et al. 2005).  This poor retention of cells is probably a 
mixture of cell phagocytosis and apoptosis within the myocardium or migration 
of the cells to the peripheral circulation, especially when used with the 
intracoronary route (Freyman, Polin et al. 2006). 
 
As mentioned timing of cell delivery is a significant challenge of stem cell therapy 
and is a fine balance between the safety of cell delivery to occur and the feasibly 
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of the processes.  The optimal time window for stem cell infusion post AMI 
remains unclear, with multiple trials using different time points.  Depending on 
the timing of infusion, stem cells are subjected to a varied environment.  Within 
the first few hours infused stem cells are subjected to an ischaemic and 
inflammatory environment, which would potentially result in cell death but has 
the benefit that may reduce local cardiomyocyte death.  The later time points are 
likely to have less toxic local inflammatory processes occurring but have less 
potential for salvaging viable cardiomyocyte but potentially have a role in 
reduction of late remodeling.   
 
To date the majority of cell types have been bone marrow derived mainly due to 
the ease of harvesting and the relative abundance.  However as previously 
described the environment in which they are infused can potentially be harsh and 
results in rapid cell death.  Therefore a stem cell that can thrive in a diseased 
environment should be considered or introducing an method to prime them to 
withstand the rigors of the post ischaemic environment is required.   
 
Attempts were made to address these 3 variables within the REGENERATE-AMI 
study.  As this study aimed to answer the early infusion time point the methods 
were steered toward a safer application method.  Bone marrow aspiration in 
patients with significant clotting issues has been performed for a long time in 
haematological patients therefore due to its ease and relative safety this cell was 
used, in addition it did not require complicated cell preparation.  The use of 
intracoronary cell infusion was routinely used in the early cell therapy trials 
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within the AMI setting therefore the REGENERATE-AMI study aimed to be similar 
to these trials. 
 
Until a specific delivery route is designed to increase local retention and a 
method to reduce the effects of the local environment on the stem cells it will be 
difficult to truly conclude the beneficial effect of the true optimal time point for 




6.9. The Future of Progenitor cell therapy and Acute Myocardial 
infarction 
 
The original goal of stem cell therapy in heart disease was to discover a way to 
regenerate lost cardiomyocytes and improve LV function.  Many issues have been 
raised regarding the results of previous trials especially with regard to the 
outcomes associated with the improvement in LVEF (Francis, Mielewczik et al. 
2013).  There is now a need to move away from surrogate endpoints to more 
substantial hard clinical outcomes such as mortality, as the relationship between 
markers such as LVEF and mortality is not well defined. 
 
With the results of REGENERATE-AMI trial the final question regarding the 
optimal timing of infusion seems to have been answered.  Previous trials that 
have infused BMNC between time of infarct and day three have failed to 
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demonstrate any significant improvement in LVEF (Janssens, Dubois et al. 2006).  
In addition timing points beyond 1 week post AMI have failed to show any 
significant benefit however trials using a time point between 3-7 days have 
shown significant effects (Wollert, Meyer et al. 2004, Surder, Schwitter et al. 
2010).  These results taken with the results of preclinical trials ultimately show 
that the administration of BMNC result in some beneficial effect after an AMI 
assuming the correct time-point is used.  However there is now a need for larger 
Phase 3 trials to assess clinical outcomes such as the on-going BAMI trial (BAMI - 
http://www.bami-fp7.eu), which aims to enroll 3000 patients assessing all-cause 
mortality at 2 years as the primary endpoint.  
 
Although not specifically addressed in this thesis, the route of stem cell delivery 
in most trials of BMNC delivery for AMI is the IC infusion.  The use of G-CSF or 
peripheral injections of progenitor cells have failed to result in any significant 
value towards the patient (Ince, Petzsch et al. 2005).  With the perceived risk or 
rupture with IM injection post infarct and the benefit of a stented scaffold 
protecting the coronary artery during IC infusion the future method of delivery 
seems to lie with the method used in REGENERATE-AMI.  
 
With the development of other fields within regenerative medicine the 
combination of stem cell therapy with additional therapies remains a potential 
option.  Gene therapy has been suggested but both ethical issues and public 
concerns have been raised with regard to this over the last decade.  One of the 
major concerns is the use of viral vectors for delivery with the potential for 
toxicity or the virus infective property remaining (Sesti and Kloner 2004).  A 
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possible solution for this therapy is the use of progenitor cells as the new vehicle 
for gene transfer into the target area.  In this scenario a group of progenitor cells 
that has been manipulated to express VEGF gene may result in improved local 
angiogenesis, which has been seen similarly in murine models post myocardial 




Important limitations may have affected the results in this study. The first of 
which is the long recruitment period meaning that the advancement of medical 
therapy for AMI including the introduction of new antiplatelet drugs and the 
greater access to primary PCI centers could have resulted in different outcomes 
in patients in the latter stages of the trials.  In addition to this the sample size was 
based on BOOST trials 6% improvement (Wollert, Meyer et al. 2004), which is 
representative of the time when the REGENERATE-AMI study was designed.  
More recent meta analysis have demonstrated an smaller improvement of 3.96% 
(Jeevanantham, Butler et al. 2012), therefore suggesting this thesis was 





In summary the early infusion of BMNC is safe when delivered with 24 hours 
after AMI with no adverse events seen during BMA and BMNC infusion.  Although 
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there was a greater improvement seen in LVEF in the BMNC group this was not 
significant compared to those in the control group.  Infarct size was lower in the 
BMNC group compared to control even with a prolonged ischaemia time and a 
similar AAR, which could suggest a potential beneficial effect of cell therapy 
however as no true baseline CMR was performed this cannot be conclusively 
answered.  
 
The hypothesis generating assessment of the effect of BMNC on certain paracrine 
factors and their functions failed to demonstrate any significant association.  The 
observation that levels of VEGF and TNF-α increased may potentially reflect the 
reason behind the positive outcome in patients who received BMNC therapy as  
these factors are associated with the systemic inflammatory response and 
angiogenesis that are reflected with the trend to improvement in LVEF and 
reductions in infarct size.  
 
A new suitable imaging modality in the form of 3-slice STIR imaging that could 
improve scan times and possible cost benefit without the loss of clinical 
information was shown and can be uses as a surrogate end point in clinical 
studies.  
 
This thesis aimed to answers the final question of the suitable time point for 
BMNC therapy for AMI. With no significant difference seen with the early infusion 
of BMNC, it could be argued that there is little rationale for recruiting patients 
within the first 2 days post AMI and definitely not within the first 24 hours.  This 
early time point, although safe is unlikely to be most beneficial to patients and 
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future studies should aim to infuse between 3-7 days consistent with positive 
study data.  A standard hospital admission post AMI ranges from 2-4 days, the 
time point assessed in this thesis implies that although having some beneficial 
outcome in patients who received BMNC therapy there is currently not enough 
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REGENERATE AMI Trial 
Randomised Controlled Clinical Trial of the use of Autologous Bone 
marrow Derived Progenitor Cells to Salvage Myocardium in Patients with 
Acute Anterior Myocardial Infarction 
 
Protocol number 2.4 
 
 
Summary Information Sheet 
This is a summary of the research study. Please read the attached 
information which explains the study in more detail before making the 
decision whether or not to take part. 
 
 You are invited to join a research study recruiting patients having a heart 
attack and being admitted to the hospital via the Heart Attack Centre, to 
see if their own stem cells help the damaged heart muscle to recover.  
 
 If you agree to take part in the study, following the angioplasty procedure 
to treat your heart attack, we would perform a ‘bone marrow aspiration’. A 
needle is inserted into your hip bone under strong local anaesthetic and 
bone marrow is withdrawn. This should be an uncomfortable but not 
painful procedure. 
 
 On return to the ward, you will be given a full explanation of the study and 
an information sheet to read. You will have some time to decide whether 
or not you want to take part in the study, and will be encouraged to speak 
to your relative(s) about it. The research team will be available to answer 
any questions. 
 
 If you agree to take part, the Stem Cell Lab will have processed your 
bone marrow and will either send back your stem cells or placebo 
(saline). Neither you nor anyone involved in your treatment will know 
which it is. If you do not wish to take part in the study we will ask you 
whether or not we can use your cells for research purposes. If not they 
will be destroyed. 
 
 If you have agreed to the study, as soon as the stem cells or saline is 
ready you will return to the angio lab for infusion into the coronary artery 
which was previously treated to see if this will lead to an improvement in 
heart function. 
 
 Following this, you will return to the ward and receive standard care for all 
patients having had treatment for a heart attack, aiming for discharge as 
usual between 3-5 days. 
 
 Follow up for the study is a visit at 3 months, another angiogram at 6 














REGENERATE AMI Trial 
Randomised Controlled Clinical Trial of the use of Autologous Bone marrow 
Derived Progenitor Cells to Salvage Myocardium in Patients with Acute 
Anterior Myocardial Infarction 
 
Protocol number 2.4 
NORTH EAST LONDON HEALTH AUTHORITY 
Information to Participate in a Research Project 
 
We invite you to take part in a research study, which we think may be important. 
The information, which follows, tells you about it.  It is important that you 
understand what is in this leaflet. It says what will happen if you take part and 
what the risks might be. Try to make sure you know what will happen to you if you 
decide to take part. Whether or not you do take part is entirely your choice. Please 
ask any questions you want to about the research and we will try our best to 
answer them. 
 
What is the purpose of this study? 
This research study involves a new treatment which we hope will help the heart 
muscle to recover following a heart attack.  
 
Why have been invited? 
This study involves 100 patients in centres in the UK and Europe who are 
admitted as an emergency with a heart attack (‘myocardial infarction’). This 
occurs when a blood vessel of the heart (‘coronary artery’) suddenly becomes 
blocked by a clot (thrombus), which usually forms on top of existing area of 
narrowing inside the artery. The resulting impaired blood flow to the heart 
muscle leads to chest pain, indicating that part of the heart muscle is not getting 
enough oxygen. This can lead to damage and loss of function to this part of the 
heart. The treatment is to reopen the artery as soon as possible, to restore blood 
flow and reduce heart muscle damage. This is called Percutaneous Coronary 
Intervention (PCI – the balloon treatment) and is part of the standard care we 
offer to patients like yourself who are having a heart attack. 
 
You are about to have or have recently undergone this PCI procedure which will 
stop the chest pain and prevent further damage to your heart muscle. However, 
not all of your damaged heart muscle may recover. 
 
In this study we aim to inject special cells from your own bone marrow into the 
damaged area of your heart muscle. Bone marrow is a soft material in the middle 
of certain bones in the body. The bone marrow makes and stores red and white 
blood cells and cells called platelets. The cells in the bone marrow which are able 
to make     these blood cells are called ‘stem cells’. These stem cells are unique as 
they can become many types of cells and help to maintain and repair tissue in the 
body It is hoped that these stem cells will have the ability to repair or replace the 




This study will be ‘randomised’. This means that half of the patients will receive 
stem cells and the other half will receive a ‘placebo’ or ‘dummy’. The placebo used 
for this study will be saline. The decision is made in a way similar to ‘flipping a 
coin’ and neither you nor anyone involved in your care will know which 
treatment you have received. All patients are then followed up in the same way. 
This enables us to compare both groups to assess the effectiveness of this new 
treatment.   
 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through the 
information sheet, which we will then give to you. You will then be asked to sign a 
consent form to show that you have agreed to take part. You are free to withdraw 
at any time, without giving a reason. This would not affect the standard of care 
you receive. 
 
What happens if I take part in this study? 
Following a successful PCI procedure we will have decided that you are suitable 
for the study according to the condition and treatment to your coronary arteries. 
We will take regular blood tests which will help monitor the condition of your 
heart (an extra teaspoon of blood will be taken in addition to the routine blood 
samples taken before your treatment and at discharge). We also ask that we can 
test your blood for HIV and hepatitis viruses as part of the protocol (a further 3 
teaspoons of blood). You will receive counselling for these tests. 
 
Following the PCI procedure you will have an echocardiogram. This involves 
putting some jelly onto the chest and placing a small plastic probe over the heart 
that bounces ultrasound waves into the heart following the injection of some dye 
(similar to that used during your PCI). This is a very safe test.  
 
At the end of your PCI you will have 100mls of bone marrow taken from the hip 
bone (bone marrow aspiration). These bone marrow cells are then processed in a 
specialised laboratory,. If you agree to take part in the study the bone marrow is 
processed and either the stem cell infusion or placebo (saline) is returned. This 
means that half the patients will receive stem cells and the other half will receive 
placebo.  We will not be told which it is. 
 
For patients in UK: If you have been chosen to receive a placebo infusion, your 
stem cells will be stored in ice at the laboratory for 10 years after which they will 
be destroyed unless you state differently. If the blood tests which were taken for 
HIV, hepatitis, syphilis and other venereal disease are positive, the Stem Cell Lab 
will be unable to store your stem cells.  
If in the future the study shows that the treatment works and you develop a 
condition in which it will be beneficial to you, e.g. another heart attack, an 
infusion of your stem cells can be given to you.  
In the future we may want to use stem cells which have been stored, for further 
research. We will ask you to sign a separate consent form to allow us to store 
your stem cells if you receive the placebo, but we will contact you again for your 




For patients outside UK: 
If you are randomised to receive placebo, your stem cells will be discarded. 
 
For all patients: 
Following your PCI, as soon as the stem cell or placebo suspension is received 
from the Stem Cell Lab (ideally between 6-8 hours), you will undergo another 
angiogram. At this time the stem cells or placebo will be injected down the 
treated coronary artery. 
 
If you do not wish to participate in the study after you have had bone marrow 
aspirated, you will be asked if the cells can be used for research purposes. If not, 
they will be destroyed.  
 
Some of your blood samples and bone marrow may be used for research 
purposes but will not be tracked back to you. If these samples are to be used for 
future research but will be tracked to you, you will be contacted to obtain your 
consent. 
 
Before discharge from hospital (at least 3 days following your procedure), you 
will undergo an echocardiogram and an MRI scan. An MRI scan uses magnetic 
radio waves to scan the body. This will further assess the pumping ability of your 
heart. If you are not suitable for an MRI scan (e.g. if you have had a pacemaker 
put in), a Cardiac CT scan will be performed. A CT scan uses X-rays and takes lots 
of pictures of your heart the same as an MRI scanner. 
 
Follow-up: 
During your hospital stay and throughout the study, you will be followed up 
closely. This will include ECG’s and blood tests which will help to assess the 
health of your heart and regular assessments by your doctor.  
 
You will be required to attend the hospital for a visit at 3, 6 and 12 months 
following your procedure.  
At 3 months you will need to attend the hospital for a day to have a blood test 
followed by an MRI scan.  
At 6 months you will be asked to return to the hospital for the day to have a left 
ventriculogram to assess the condition of your heart muscle. This is similar to an 
angiogram but looks only at the pumping ability of the heart and not at the 
coronary arteries. At this time you will also have a physical examination, blood 
tests (4 teaspoons of blood), an ECG, and an echocardiogram.  
At 12 months you will attend the hospital to have a physical examination, blood 
tests (4 teaspoons of blood), an ECG, an echocardiogram, and an MRI scan.  
 
In centres in the UK only, you will be asked to complete questionnaires which will 
help us to assess your state of health at discharge, 6months and 12 months. 
 
Following this, you will be contacted by telephone yearly for the next 4 years to 





Risks and side effects 
As always, your health is our priority. If at any time you experience a recurrence 
of symptoms, or your condition requires a different treatment strategy, you will 
receive appropriate treatment regardless of the study. This research is at the 
forefront of our understanding and technology and as such, potential risks apart 
from those mentioned below, are unknown. However, given our current 
understanding of this technology we do not foresee any major problems. 
The risks mentioned below are minimised as procedures are performed by 
experienced staff. 
 
 Left Ventriculogram 
A routine angiogram carries the risk of death 1 patient in 1000. However, we will 
not be looking at the coronary arteries so this risk will be considerably less. The 
catheter is inserted through an artery in the groin, which in a very small number 
of patients may cause a blood blister (aneurysm) or injury to the artery.  
 
 Bone marrow aspiration 
The procedure carries a risk of bleeding, infection and damage to the area where 
the needle is inserted. The skin around the puncture site is cleaned and numbed 
prior to the procedure. The aspiration is performed by inserting a needle into the 
hip bone to obtain the bone marrow. The needle will need to be inserted into the 
hip bone more than once through the same puncture site in the skin. There may 
be some pain during the aspiration of the bone marrow but this only lasts a few 
seconds and is lessened by aspirating more slowly. Any residual pain rarely lasts 
more than a few days and can be relieved by taking pain killers. If it becomes 
difficult to aspirate any bone marrow we will stop the procedure. 
 
There is a risk of infection during the transfusion of the stem cells or placebo. 
However, the infusion is prepared and given in very strict sterile conditions. 
Because the bone marrow is your own there is no risk of rejection as may be seen 
with the injection of cells or organs from a different donor. 
 
 Echocardiogram 
This test carries an extremely small risk of a heart attack or death, (1 in 10,000).  
 
 MRI Scan 
The MRI scan does not use radiation. There are no known side effects or risks 
attached to MRI 
 
 Cardiac CT Scan 
The CT scan uses radiation. Some patients may experience side effects due to 
allergic reactions to the liquid dye injected into the veins during this scan. This 
can be treated easily with medicines. 
In very rare cases, this dye has been known to damage already weakened 
kidneys. The doctors performing this scan will be told if you have weak kidneys 







During this study you will receive more exposure to radiation from X-rays than 
during standard treatment for a heart attack. You will receive a small amount of 
exposure when the stem cells/placebo are injected, at 6 months for the repeat 
angiogram and also if you have been selected to have a CT scan. It is estimated 
that there is a small risk of patients developing cancer in the future but having 
coronary artery disease carries a greater risk. 
 
Benefits 
Although the pilot study performed using this treatment is very promising, there 
is a need for this further research. There may or may not be any benefit to taking 
part in this study. You will however have received the standard optimal 
treatment for your condition. The fact that you are having your blocked artery 
treated by balloon angioplasty leads to a 50% reduction in your chance of a 
future event (e.g. heart attack). 
 
Confidentiality. 
All aspects of this trial are strictly confidential. Your records will be kept at the 
hospital but you will be identified by your initials, a number allocated to you and 
your date of birth. Your identity will be unknown to anybody outside the hospital 
helping to process the information obtained. If you agree to participate, the 
results of your treatment may be published for scientific purposes, however your 
identity will not be revealed. Copies of your tests, including echo, MRI, CT scans 
and angiogram will be sent to a corelab in the UK to be analysed. Every attempt 
will be made to make these copies anonymous but it may not be possible in some 
centres. However all information will be treated in the strictest of confidence 
under the guidance of the 1998 Data Protection Act. 
 
What happens if something goes wrong? 
We would not expect you to suffer any harm or injury because of your 
participation in this study. If you are harmed by taking part in this study, there is 
no special compensation arrangement. If you are harmed due to someone’s 
negligence, then you may have grounds for legal action but you may have to pay 
your legal costs. Regardless of this, if you wish to complain or have any concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints mechanisms 
should be available to you. 
 
Please contact Patient Advisory Liaison service (PALS) if you have concerns 
regarding the care you have received, or as an initial point of contact if you have a 
complaint. Please telephone 020 7377 6335, minicom 020 7943 1350, or email 
pals@bartsandthelondon.nhs.uk. You can also visit PALS by asking at any hospital 
reception. 
 
You don’t have to join the study. You are free to decide not to be in this trial or to 
drop out at any time.  If you decide not to be in the study, or drop out, this will not 





What happens if you get worried or if there is an emergency? 
You will always be able to contact a member of the research team to discuss your 
concerns and/or get help: 
 
Dr Anthony Mathur, Consultant Cardiologist, via Hospital Switchboard 
Dr Steve Hamshere, 0208 983 2475 












CONSENT FORM  (Version 1.6     Dated   06.10.09      ) 
 
Title of project:  REGENERATE - AMI 
 
 
Investigator:  Dr Anthony Mathur 
 
Centre Number:      Study Number:                Patient Identification Number for this trial: 
 




I confirm that I have read and understand the information sheet dated 06.10.09 
(version 1.6) for the above study. I have had the opportunity to consider the 





I understand that my participation is voluntary and that I am free to withdraw at 






I understand that relevant sections of any of my medical notes and data collected 
during the study, may be looked at by responsible individuals from the Barts and 
the London, where it is relevant to my taking part in this research.  I give 





I understand that some of my bone marrow , stem cells and blood samples will  
be used for research purposes as long as they remain anonymous and cannot 
be linked to me. If  there is any research on any of these samples in the future  
which can be linked to me I understand that I will be contacted and asked to  
sign a separate consent form 
 
5. I consent to the storage of my stem cells for 10 years after which they  
will be destroyed (UK sites only) 
 
6. I agree to my GP being informed of my participation in the study. 
 
 







________________________  _______________     __________________ 




________________________  _______________     __________________ 
Name of Person taking consent Date  Signature 
(if different from Investigator) 
 
 
________________________  _______________     __________________ 









APPENDIX IV: REGENERATE-AMI HIV Consent Form 
 
 XIV 
REGENERATE – AMI 
Randomised Controlled Clinical Trial of the use of Autologous Bone Marrow 
Derived Progenitor Cells to Salvage Myocardium in Patients with Acute 
Anterior Myocardial Infarction 
 
Name_________________________  DOB___________  Study no________ 
 
INDICATIONS FOR FURTHER COUNSELLING 
 
 
Gay or bisexual mean 
 
 
Current or ex IDU 
 
Unprotected sex in countries where there is a 
high rate of heterosexual transmission 
 
 






Other possible risk 
 





POINTS TO COVER IN PRE-TEST DISCUSSION 
 




How HIV , hep B&C & syphilis is transmitted 
 
 
Difference between HIV and AIDS 
 
 













Who will they tell about the test and result? 
 
 
Does patient need more time to think? 
 
 




REGENERATE – AMI 
 
Randomised Controlled Clinical Trial of the use of Autologous Bone Marrow 
Derived Progenitor Cells to Salvage Myocardium in Patients with Acute 
Anterior Myocardial Infarction 
 







I agree that I have received adequate information and hereby consent to blood 




Patient signature: ___________________________ Date__________ 
 
Advisors signature: ___________________________ Date__________ 
 
Advisor name (block capitals)  __________________________ 
 
  
                                                        
 
